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ABSTRACT 
 
Silent information regulator human type 2 (SIRT2) enzyme belongs to the class III histone deacetylases 
(HDAC). It is one of the seven human yeast Saccharomyces cerevisiae Sir2 homologues. Sir2 enzyme 
and its homologues are also called sirtuins. Sirtuins need nicotinamide adenine dinucleotide (NAD+) as a 
cofactor to be able to deacetylate histones and non-histone proteins. NAD+ participates in the 
deacetylation reaction, in which the nicotinamide-ribosyl bond cleavage followed by transfer of the acetyl 
group of an acetylated lysine residue to ADP-ribose results; in free nicotinamide, deacetylated lysine and 
2´- and 3´-O-acetyl-ADP-ribose. Nicotinamide is the endogenous inhibitor of sirtuins which regulates the 
sirtuin activity by the nicotinamide exchange reaction.  
A highly potent and selective SIRT2 inhibitor would be useful for the study of the biological function 
of SIRT2. During the recent years, several research groups have been actively developing new SIRT2 
inhibitors. The IC50 values of the most potent inhibitors range between high nanomolar and low 
micromolar levels. There are still a rather limited number of SIRT2 inhibitors. However, the structural 
diversity of the SIRT2 inhibitors and the molecular docking results suggest that SIRT2 inhibitors can 
interact with different binding sites of the enzyme. A couple of the most potent SIRT2 inhibitors have 
been tested on the preliminary disease models. SIRT2 might have a role in glioma tumorigenesis and 
Parkinson’s disease. The inhibition of N-(5-quinolyl)propenamide (AGK2) has been reported to rescue α-
synuclein toxicity and protect against dopaminergic cell death both biological changes caused by 
Parkinson’s disease, thus tenovins-1 and -6 have been claimed to delay the tumour growth without a 
general toxicity.   
The aim of the present study was to design and synthesize new SIRT2 inhibitors. A series of N,N'-
bisbenzylidenebenzene-1,4-diamine and N,N'-bisbenzylidenenaphthalene-1,4-diamine derivatives were 
synthesized based on two earlier reported hits from molecular modelling and virtual screening. The most 
potent compound was N,N'-bis(2-hydroxybenzylidene)benzene-1,4-diamine, which was equipotent with 
the most potent hit compound and well-known SIRT2 inhibitor sirtinol.  
A series of N-(3-(4-hydroxyphenyl)-propenoyl)-amino acid tryptamides was also based on the hit found 
by molecular modelling. The series was designed to study if the molecular size of the compound could be 
reduced. The most potent compounds, N-(3-(4-hydroxyphenyl)-propenoyl)-2-aminoisobutyric acid 
tryptamide and N-(3-(4-hydroxyphenyl)-propenoyl)-L-alanine tryptamide, were equipotent, 30% smaller 
in molecular weight, and slightly more selective (SIRT2/SIRT1) than the parent compound. The research 
of this new interesting backbone was continued and the structure-activity relationships were studied by 
different replacements in the original hit structure. As a result, the N-(3-phenylpropenoyl)-glycine 
tryptamide backbone was also a good backbone for SIRT2 inhibitors, and the series of compounds 
included several potent SIRT2 inhibitors. In addition, the series of compounds gave valuable tools for 
molecular modellers to study the binding interactions with SIRT2. 
The known SIRT2 substrates were utilized to study SIRT2 substrate-based inhibitors. A series of 
thioacetylated tri-, tetra-, and pentapeptides based on the α-tubulin and p53 protein sequences were 
shortest peptide sequences published so far with SIRT1 and SIRT2 inhibitory activity. The most potent 
peptides had the inhibitory activities on high nanomolar (SIRT1) or low micromolar (SIRT2) level. In 
addition, two of the p53–based peptides were more selective SIRT1 inhibitors than well-known EX-527.  
The present study provided new SIRT2 inhibitor backbones and introduced several potent SIRT2 
inhibitors targeting different binding sites of the enzyme. 
 
National Library of Medicine Classification: QU 62, QU 68, QU 136, QU 143, QV 744 
Medical Subject Headings: Histone Deacetylases; Sirtuins; Enzyme Inhibitors; Enzyme Inhibitors / chemical 
synthesis; Amides / chemical synthesis; Peptides / chemical synthesis; Tubulin; Structure-Activity 
Relationship; Drug Design 
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1 INTRODUCTION 
 
Histone proteins are located in nucleosomes packed with the DNA in all eukaryotes. 
The amino termini of the histones are rich in lysines and they stick out of nucleosomes 
(Luger and Richmond 1998). They offer sites of several reversible covalent 
modifications and lead gene expression or silencing fulfil the requirements of the cell 
(Gottschling 2000, Nightingale et al. 2006). Histone deacetylases (HDACs) are 
enzymes, which remove the acetyl groups from acetylated lysine residues. HDACs are 
divided into four classes. The class I, II, IV are similar to each other, for example, in 
their catalytic cores and inhibitors. The class III HDACs, the sirtuins, have no sequence 
similarity to other HDACs and these proteins have their unique requirement for 
nicotinamide adenine dinucleotide (NAD+) to be able to function (Imai et al. 2000, 
Michan and Sinclair 2007, Smith et al. 2000).   
There are seven mammalian sirtuins (SIRTs) (Frye 2000). SIRT2 was reported the 
first time in 1999 (Frye 1999).  SIRTs deacetylate histone and non-histone proteins 
(Buck et al. 2004, North et al. 2003, Wang et al. 2007). SIRT2 is also an α-tubulin 
deacetylase, unlike its evolutionary ancestor the Archeal Sir2 homologue of yeast Hst2 
and other SIRTs (North et al. 2003). SIRT2 has been linked to the regulation of the 
mitotic progression of the cell cycle (Dryden et al. 2003, Inoue et al. 2007, North and 
Verdin 2007b). SIRT2 might have a role in glioma tumorigenesis and Parkinson’s 
disease (Hiratsuka et al. 2003, Outeiro et al. 2007). However, understanding the full 
biological role and the different mechanisms of actions still needs further studies. 
Development of positive and negative regulators of SIRT2 is under intensive 
investigation (Porcu and Chiarugi 2005). There are more and more compounds 
published which show an in vitro inhibitory activity for SIRT2. However, the 
connection of the in vitro activity and the cellular effects needs further clarification.  
When the SIRT2 inhibitor project started in Autumn 2002, the crystal structure of 
SIRT2 and the first two low micromolar inhibitors (sirtinol and A3) had recently been 
published (Finnin et al. 2001, Grozinger et al. 2001). Computational methods were 
employed to search for new inhibitors with different chemical backbones and to study 
the interactions between the inhibitors and the enzyme. News about the preferred 
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substrates of SIRT2 was also published during the first year of the project (North et al. 
2003). Both the computational methods and the substrates of the enzyme were used as 
starting points for the development of new inhibitors.  
15 
 
2 REVIEW OF LITERATURE 
 
2.1 Nomenclature and classification 
The story of silent information regulators (Sirs) started in mid-eighties when four Sir 
genes were found from yeast Saccharomyces cerevisiae (Ivy et al. 1986, Shore et al. 
1984). These genes code for the Sir proteins, which were studied to be part of a system 
of transcriptional inactivation, or silencing, an important and highly conserved 
mechanism of gene regulation. Sir2 enzyme and its homologues, also called the sirtuins, 
are classified as class III histone deacetylases (HDAC). They are unrelated to class I, II,
IV HDACs and have their unique requirement for nicotinamide adenine dinucleotide 
(NAD+) as a substrate (Imai et al. 2000, Smith et al. 2000). SIRTs are Sir2-like human 
homologues and they consists of seven members (SIRT1-SIRT7) (Frye 1999, 2000). 
 
2.2 Distribution of SIRT2 
The Sir2 gene is evolutionarily conserved, and a number of Sir2 enzyme homologues 
are reported from Archeal species, prokaryotes and eukaryotes (Brachmann et al. 1995). 
The Sir2 homologues of mammals share a conserved central deacetylase domain but 
have different N- and C- termini (North and Verdin 2004). They also display distinct 
subcellular localization.  
SIRT1 is nuclear (Frye 1999). SIRT2 was first reported to be a cytoplasmic enzyme, 
which was highly expressed in the heart, brain and skeletal muscles (Afshar and 
Murnane 1999, Perrod et al. 2001). Later, SIRT2 was observed to shuttle between the 
nucleus and cytoplasm and to localize to mitotic structures (Bae et al. 2004, Dryden et 
al. 2003, Hiratsuka et al. 2003, North et al. 2003, North and Verdin 2007a). SIRT3-5 
are localized in mitochondria (Onyango et al. 2002, Schwer et al. 2002), SIRT6 is 
associated with heterochromatic regions, and SIRT7 is concentrated in the nucleolus 
(Michishita et al. 2005).  
Further studies are needed for understanding the mechanism regulating the expression 
of the SIRT2 enzyme. It has been claimed that the SIRT2 enzyme activity could be 
regulated by phosphorylation in the nucleus and ubiquitination in the cytoplasm (Suzuki 
and Koike 2007a). Wilson et al. (2006) reported that the Archeal Sir2 homologue of 
16 
 
yeast Hst2 was exported into the cytoplasm by the chromosomal region maintenance 1 
(Crm1) protein, and assumed, that the same active nuclear export exists also for SIRT2. 
This was confirmed a year later by two research groups (Inoue et al. 2007, North and 
Verdin 2007a). In the brain, the proteolipid protein DM20 provides the same active 
transport of SIRT2 into myelin of the central nervous system (Werner et al. 2007). 
 
2.3 Structure 
SIRT2 contains a catalytic core of 304 amino acids and a so-called N-terminal helical 
extension of 19 amino acids. The crystal structure of SIRT2 has been published in 2001 
(Finnin et al. 2001). The crystal structure revealed that SIRT2 consists of two domains 
that are connected by four conserved loops of the polypeptide chain. The bigger domain 
is an NAD+-binding domain, which is a variant of the Rossmann fold, a structural motif 
found in proteins that bind nucleotides (Bellamacina 1996). The other, smaller domain 
is composed of a helical module and a single zinc-binding module (figure 2.1). At the 
interface of the two domains is a large groove, which includes the NAD+-binding site, 
and contains residues invariant across the Sir2 homologues. A pocket lined with 
hydrophobic residues has been found in the large groove, and it has been suggested to 
be the substrate binding site (Finnin et al. 2001). This hydrophobic region has been 
reported to be unique in the structures of SIRT2 and yeast Hst2 but absent from the 
structures of the archae-bacterium Sir2-Af1 complexed with NAD+ and Sir2-Af2 bound 
to an acetylated p53 peptide (Avalos et al. 2002, Finnin et al. 2001, Min et al. 2001, 
Zhao et al. 2003). 
The reported sequence comparison study with SIRT2 and Sir2-Af1 complexed with 
NAD+ suggested that the large groove contains three sites for NAD+-binding, called A, 
B, and C sites (figure 2.2) (Finnin et al. 2001). In the A site, amino acids of the enzyme 
have been reported to form hydrogen bonds with the 2´- and 3´-hydroxyl groups of the 
adenine ribose and to interact with the adenine base and phosphate oxygens. At the B 
site, two amino acids have been reported to bind by forming hydrogen bonds with the 
3´-hydroxyl of the nicotinamide ribose. However, the large groove of SIRT2 in the B 
site is wider than that of Sir2-Af1 which makes the comparison difficult.  
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Figure 2.1. The structure of SIRT2. The active site of the SIRT2 enzyme is pointed by 
the arrow. Zinc is colored lime, α-helices are colored purple, and β-sheets are colored 
yellow. The picture was kindly created by M.Sc. Heikki Salo. 
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Figure 2.2. NAD+ structure and its binding sites to the enzyme. 
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The flexible C site of SIRT2 has been claimed to be involved in the polarization and 
hydrolysis of the NAD+ glycosidic bond and to show the HDAC activity. The B and C 
sites together are reported to form the active site of the enzyme (Finnin et al. 2001). 
These NAD+-binding sites clarify the progress of the deacetylation reaction described 
later in this literature review. 
 
2.4 Substrates 
Several endogenous SIRT2 substrates have been reported in the literature (table 2.1). 
The study of Borra et al. (2004) have reported that SIRT2 has the strongest substrate 
preference for lysine-8, -12, and -16 of histone H4 tested on in vitro HPLC based assay 
(Borra and Denu 2003, Borra et al. 2002). Several monoacetylated histone H3 and H4 
peptides were employed in the assay based on the knowledge that they are in vivo 
acetylation sites (Csordas 1990, Loidl 1994). The substrate preference of SIRT2 for 
lysine-16 of H4 was also shown in the study of Vaquero et al. (2006). SIRT2 was 
reported to deacetylate lysine-16 of H4 and lysine-9 of H3 in vitro on HDAC based 
assays followed by Western blots, although only lysine-16 of H4 was shown to be a 
valid substrate in 293 cells (Vaquero et al. 2006). However, α-tubulin has been claimed 
to be a preferred substrate of SIRT2 due to SIRT2s predominantly cytoplasmic location 
and co-localization with microtubules (North et al. 2003). Another member of the 
histone deacetylase family, HDAC6, has also been indentified to function as a α-tubulin 
deacetylase (Hubbert et al. 2002).  
Recently, a study with HEK293 cells has been reported where the interaction of 
SIRT2 with the cellular regulatory proteins 14-3-3 β and γ has shown to regulate the 
transcriptional activity of p53 protein by deacetylation (Jin et al. 2008). In addition, 
SIRT2 deacetylation mechanism has been connected to the Forkhead box O (FoxO) 
transcription factors tested on the several cell cultures (Daitoku et al. 2004, Jing et al. 
2007, Wang et al. 2007). It has been speculated, that since Sir2-like proteins have been 
conserved in evolution, they might have been required to perform diverse deacetylation 
reactions on a wide variety of substrates in a manner regulated by cellular energy and 
redox states (Smith et al. 2000). However, it has been suggested that the sirtuins 
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recognize their substrates based on certain amino acid side chains near the Nε-acetyl 
lysine side chain (Cosgrove et al. 2006, Garske and Denu 2006). 
 
Table 2.1. Endogenous substrates of SIRT2 and their reported functions. 
Substrate Type of cells tested Function Reference 
Lys16 of H4 in  293 cells chromatin 
condensation 
(Vaquero et al. 2006) 
Lys40 of α-
tubulin 
in HeLa cells cell cycle (North et al. 2003) 
FoxO1 in HepG2, HEK293 
and HEK293T cells 
transcription (Daitoku et al. 2004) 
in 3T3-L1 
adipocytes 
adipocyte 
differentiation 
(Jing et al. 2007) 
FoxO3a in HEK293T cells oxidative stress 
caloric restriction 
(Wang et al. 2007) 
p53 in HEK293 cells transcription (Jin et al. 2008) 
 
2.5 Deacetylation reaction 
In the beginning of the research of SIRT2, it was unclear if SIRT2, among with the 
other human sirtuins, is an ADP-ribosyl transferase (Frye 1999) or a histone deacetylase 
(Smith et al. 2000). Imai et al. (2000) reported already back then, that the human 
sirtuins catalyze both reactions. Later on, it has been concluded that the histone ADP-
ribosyl transferase activity is a side reaction of the deacetylation reaction (Tanner et al. 
2000) in which the histone deacetylase activity is at least 1000-fold higher than the 
ADP ribosylation activity (Finnin et al. 2001).  
 
2.5.1 Reaction stoichiometry 
In Archeal species, prokaryotes and eukaryotes Sir2 enzyme homologues have been 
reported to have a NAD+-dependent deacetylase activity (Imai et al. 2000, Landry et al. 
2000b, Smith et al. 2000). The identification of the unique reaction product O-acetyl-
ADP-ribose (O-AADPR) resolved the reaction stoichiometry. In the reaction, one 
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molecule of NAD+ is hydrolyzed to nicotinamide and O-AADPR for every molecule of 
acetylated lysine that is deacetylated (Landry et al. 2000a, Tanner et al. 2000, Tanny 
and Moazed 2001). 
 
2.5.2 Reaction mechanism 
The Sir2 deacetylation reaction mechanism has been under wide discussion in the 
literature. Three reaction mechanisms have been; 1) the nucleophilic mechanism (Tanny 
and Moazed 2001), 2) the enzyme nucleophile mechanism (Landry et al. 2000a, Min et 
al. 2001, Tanner et al. 2000) and 3) the ADP-ribose-peptidyl-imidate mechanism 
(Sauve et al. 2001). The ADP-ribose-peptidyl-imidate mechanism explains the best the 
chemistry of sirtuins and the available experimental data (scheme 2.1) (Sauve et al. 
2006).  
The reaction of sirtuins has been reported to start when the carbonyl oxygen of the 
acetyl group of lysine is in the right position relative to NAD+. The electrophilic capture 
of an acetyl oxygen by ADP-ribose (ADPR) is formed and stabilized by the enzyme. 
The proposed capture requires a highly electrophilic ADPR, which gives the weakness 
of the amide as a nucleophile (Sauve et al. 2001). The mechanism of nicotinamide-
ribosyl bond cleavage has been reported to proceed via a SN2-like mechanism 
(I→II→III) (Smith and Denu 2007c). The transition state couple is named as an 
oxacarbenium-ion transition state (complex II) and an ADPR-peptidyl imidate (complex 
III). The reaction has been reported to be written as a reversible step. The step clarifies 
nicotinamide reactivity through a base exchange to reform NAD+. The imidate 
(complex III) has a long enough lifetime to equilibrate nicotinamide in the reaction site 
nicotinamide pocket and reform NAD+ by the reversal reaction (Sauve and Schramm 
2003). This is an important observation since age-related human diseases seem to have 
a connection to the changes in the NAD+ level (Lin and Guarente 2003).  
According to earlier literature, this step of the reaction was suggested to be a reaction 
checkpoint where concentration of nicotinamide in a cell reverses or forwards the 
NAD+-dependent reaction (Sauve et al. 2001). However, it has later been reported that 
the nucleophilic attack of the acetylated lysine oxygen at the 1´-position of the 
nicotinamide ribose of NAD+ forms the covalent intermediate α-1´-O-alkylamidate. 
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According to this mechanism, the final product, 2´- and 3´-O-AADPRs, release would 
be the rate limiting step of the reaction (Borra et al. 2004, Smith and Denu 2006).  
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Scheme 2.1. The ADPR-peptidyl-imidate mechanism (modified from Sauve et al. 
2006). 
 
When the ADPR-peptidyl-imidate mechanism proceeds further, the deacetylation 
reaction is continued by activation of the 2´-hydroxyl group of ribose through the 3´-
hydroxyl group of ribose and the His116 at the reaction site (complex III). The function 
of His116 as a proton acceptor has been confirmed by the His to Ala mutation in which 
the enzymatic activity of Sir2-Af1 was lost (Min et al. 2001). In addition, the activation 
of the 2´-hydroxyl group of ribose has been confirmed by NMR studies (Jackson and 
Denu 2002). The nucleophilic attack of the 2´-hydroxyl group of ribose on the imidate 
forms the intermediate IV. Lysine is eliminated to form an oxonium intermediate 
(complex V). The oxonium intermediate has been reported to capture water to form a 
tetrahedral intermediate VI. The 1´-hydroxyl group is eliminated resulting in an 
equilibrium of the 2´- and 3´-O-acetyl-ADP-ribose isomers as the final product on the 
enzyme (complex VII). The final reaction steps (V→VII) have been studied by 
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reactions conducted in 18O labelled water (Sauve et al. 2001) and by NMR studies 
(Jackson and Denu 2002).     
 
2.6 Regulation of SIRT activity 
It has been reported that NAD+ can bind to the sirtuins in different conformations. 
Studies with both Sir2-Af1 and Sir2-Af2 complexed with NAD+ have suggested that the 
binding site of a nicotinamide of NAD+ is at the conserved C site and the acetyl-lysine 
substrate is bound to its binding tunnel, that intersects the large groove (Avalos et al. 
2004, Min et al. 2001). In this so-called productive conformation of NAD+, the 
nicotinamide ring and ADPR are in correct relative positions with the catalytically 
important residues. The productive binding of NAD+ has been reported to be induced by 
the binding of the acetyl-lysine substrate (Avalos et al. 2004). This has been confirmed 
with the isothermal titration calorimetry study, which was not able to detect the binding 
of NAD+ in SIRT2. Due to the result, the acetyl-lysine substrate seems to bind before 
NAD+. It has also been suggested that NAD+ and the acetyl-lysine substrate must form a 
ternary complex prior to catalysis (Borra et al. 2004).  
However, studies of the so-called non-productive conformations with NAD+ have 
suggested that these conformations are energetically lower when the acetyl-lysine 
substrate is not bound. The binding of the acetyl-lysine substrate to Sir2 causes the 
favourable conformational change for productive NAD+ binding (Avalos et al. 2004). It 
is therefore likely that the large groove of SIRT2 undergoes a conformational change 
upon binding of the acetyl-lysine substrate or NAD+ (Avalos et al. 2002).  
The interactions of nicotinamide with the C site in the productive conformation of 
NAD+ have been reported to induce the destabilization of NAD+ which favours the 
nucleophilic attack of the carbonyl oxygen of the acetyl group on the ribose (I → II, 
scheme 2.1). The reported products are nicotinamide and the α-1´-O-alkylamidate 
intermediate which has been claimed to be located between the acetyl-lysine binding 
tunnel and the A and B sites of the NAD+ binding cleft (figure 2.2). At this point, the 
deacetylation reaction can proceed to the final products or, depending on the 
nicotinamide concentration, to the nicotinamide exchange reaction (Avalos et al. 2004). 
The nicotinamide exchange reaction, which regulates the sirtuin activity by 
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nicotinamide inhibition (Bitterman et al. 2002), is a competing reaction with the 
deacetylation reaction (Sauve and Schramm 2003) described later in this literature 
review.  
The final products of the deacetylation reaction are nicotinamide, the deacetylated 
lysine-enzyme and 2´- and 3´-O-AADPRs (Jackson and Denu 2002, Sauve et al. 2001). 
When the deacetylation reaction was reported, it was suggested that the unique product 
O-AADPR has an important signalling role (Tanner et al. 2000).  It has later been 
reported that O-AADPR has a delay effect on embryo cell division in blastomeres 
(Borra et al. 2002) and an activating effect on the cytoplasmic domain of the transient 
receptor potential melastatin-related channel 2 (TRPM2), which is a nonselective cation 
channel, whose prolonged activation leads to cell death (Grubisha et al. 2006). In 
addition, the regulation by nicotinamide may function on exact opposite ways in 
different species since it has been reported that nicotinamide extends the replicative 
lifespan of primary human fibroblasts (Lim et al. 2006) whereas it shortens the 
replicative lifespan of Saccharomyces cerevisiae (Bitterman et al. 2002).  
 
2.6.1 Inhibition of SIRT 
The nicotinamide exchange reaction is a competing reaction with the deacetylation 
reaction (Sauve and Schramm 2003).  It regulates the sirtuin activity by nicotinamide 
inhibition (Bitterman et al. 2002), which was also confirmed for SIRT2 (Jackson et al. 
2003). Concentrations of nicotinamide 1 in mammalian tissues have been reported to 
vary between 11–400 µM (Bitterman et al. 2002). The reported observation with mouse 
Sir2 has claimed that the mammalian enzymes might be subjected to stronger regulation 
by nicotinamide 1 than yeast and bacterial Sir2s (Sauve and Schramm 2003). Reported 
IC50 value of nicotinamide 1 is 100.5 µM for SIRT2 tested in the [3H]-substrate based 
assay (Tervo et al. 2004). Nicotinamide has been reported to function as a 
noncompetative inhibitor against NAD+ (Bitterman et al. 2002, Landry et al. 2000a) and 
the acetylated substrate for Sir2-like enzymes (Borra et al. 2004).  
It has been claimed that the great flexibility of the Sir2 structure facilitates the 
nicotinamide exchange in and out the enzyme. Nicotinamide might reform β-NAD+ by 
doing a reverse attack on the β-face of the α-1´-O-alkylamidate intermediate (Avalos et 
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al. 2004). The site of the nicotinamide inhibition was confirmed by the single point 
mutation study with Sir2Af2 and Sir2 homologue of thermophilic bacterium Sir2Tm 
which directed a dual role for the C site of the groove in both the nicotinamide exchange 
and the deacetylation reaction (Avalos et al. 2005).  
 
 
It has been reported that compounds that can interact with the C site and prevent 
NAD+ from adopting its productive conformation could act as competitive inhibitors. 
Thus, compounds which are able to participate in the possible flipping mechanism and 
react with the α-1´-O-alkylamidate intermediate, could act as noncompetative inhibitors 
(Avalos et al. 2005). It has also been suggested that compounds that could mimic the 
binding of the acetyl-lysine substrate might be potent and selective inhibitors of Sir2 
deacetylases over other NAD+-metabolizing enzymes (Smith and Denu 2007c). In 
addition, it has been suggested that small molecule regulation of sirtuins involves the 
cellular balance of NAD+ to nicotinamide (Grubisha et al. 2005), and this would be 
controlled by enzymes involved in NAD+ synthesis or salvage (Denu 2003, Lin and 
Guarente 2003). 
 
2.6.2 Activation of SIRT 
The positive regulator could enhance the deacetylation reaction of SIRTs. The function 
of Sir2 activators has been postulated to occur by blocking the binding site of free 
nicotinamide (Marmorstein 2004). It has been reported that the yeast life span can be 
extended through the action of calorie restriction by increasing the activity of Sir2 (Lin 
et al. 2000). The most potent small molecule activator called resveratrol 2 has been 
reported to mimic the calorie restriction and assist the life span extension in yeast and 
increase cell survival by stimulating SIRT1-dependent deacetylation of p53 (Howitz et 
al. 2003). However, it has later been reported that the activation was caused by a 
specific substrate containing a non-physiological, fluorescent Fluor de Lys moiety 
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(Kaeberlein et al. 2005a). More accurately, it was the fluorophore of that substrate, 
which posed the substrate bind more tightly to SIRT1 in the presence of resveratrol 2 
(Borra et al. 2005).  
SIRT2 activation by resveratrol 2 has not been observed in a fluorescence based Fluor 
de Lys kit (Borra et al. 2005). However, the study of slow Wallerian degeneration mice 
has later suggested that resveratrol 2 abolishes the resistance to axonal degeneration by 
enhancing SIRT2-mediated tubulin deacetylation. An activation mechanism of 
resveratrol 2 was reported to be unknown (Suzuki and Koike 2007b). 
 
 
2.7 Biological relevance of SIRT2 
The biological function of SIRT2 appears to be largely unknown. Although, the yeast 
Sir2 gene is related to the human SIRT2 gene and its functions are widely studied, the 
functions of these two homologues do not seem to be related (Afshar and Murnane 
1999, Guarente 2000). However, the aim of this chapter is to give an overview of the 
reported biological functions of the SIRT2 enzyme and the relevant prospects on cell 
cycle regulation and some human diseases. 
 
2.7.1 Tubulin deacetylation 
North et al. (2003) have published a highly cited article where they showed that the 
SIRT2 enzyme deacetylates lysine-40 of α-tubulin both in vitro and in vivo. This has not 
been reported for other human sirtuins or yeast Hst2. SIRT2 has been claimed to 
function together as a complex with HDAC6, another HDAC with α-tubulin deacetylase 
activity, in cytoplasm (Hubbert et al. 2002, North et al. 2003). The microtubule network 
is formed from α- and β-tubulin heterodimers and play a crucial role in the regulation of 
cell shape, intracellular transport, cell mobility and cell division (Nogales 2000). 
Recently, the suggested complex was confirmed by the report that tubulin binds only to 
the HDAC6-SIRT2 complex, not either of HDACs individually. The study was done 
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with the human osteoplastic cells (SAOS2) (Nahhas et al. 2007). However, SIRT2 and 
HDAC6 are expressed in several cell types and it has been suggested that in the nervous 
system they are localized to different cell types and are unlikely form the complex in 
vivo (Southwood et al. 2006).  
 
2.7.2 Histone deacetylation 
SIRT2 has been reported to deacetylate lysines-8, -12, and -16 of histone H4 in vitro 
(Borra et al. 2004). Earlier, it was postulated that SIRT2 may influence silencing 
without being targeted to the site of repression (Perrod et al. 2001). Later, it has been 
reported that there is a correlation between SIRT2 and the level of acetylated lysine-16 
of histone H4 in the nucleus during the G2 to M transition and mitosis of the cell cycle. 
This means that mainly cytoplasmic SIRT2 can move to the nucleus and is associated 
there with chromatin (Vaquero et al. 2006).  
 
2.7.3 Cell cycle regulation 
The cell cycle involves four phases: the cell grows (G1), the DNA is replicated (S), the 
cell prepares to divide (G2) and the cell divides (M) (figure 2.3) (Alberts et al. 2002). 
Many studies have reported that SIRT2 participates in these phases of the cell cycle in 
several types of cells. However, the targets for SIRT2 are so far largely unknown. The 
understanding of the involvement of SIRT2 in the cell cycle regulation processes can 
lead to the new therapeutic possibilities. 
 
 
Figure 2.3. The cell cycle (modified from Alberts et al. 2002). 
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It seems to be clear that SIRT2 regulates mitotic progression (M) (Dryden et al. 2003, 
Inoue et al. 2007, North and Verdin 2007b). SIRT2 is phosphorylated both in vitro and 
in vivo on Ser368 by a mitotic cell cycle regulator, a cyclin-dependent kinase 1 (Cdk1). 
SIRT2 phosphorylation mediates a delay in mitosis (North and Verdin 2007b). 
Furthermore, the study in glioma cell lines provided evidence for that SIRT2 may 
function as a novel mitotic checkpoint enzyme in the early metaphase (M) to prevent 
chromosomal instability (Inoue et al. 2007). SIRT2 phosphorylation and expression has 
also been reported to increase during the G2 and M phases and to have a role in the 
control of the G2 to M transition in SAOS2 cells (Dryden et al. 2003). SIRT2 may 
directly influence chromatin condensation during the G2 to M transition by regulating 
deacetylation of lysine-16 of histone H4 (Vaquero et al. 2006). It was recently reported 
that SIRT2 decreases the transcriptional activity of p53 through the interaction with 14-
3-3 β and γ proteins (Jin et al. 2008). In addition, SIRT2 has also been reported to 
interact with several transcription factors Homeobox A10 (Hoxa10), FoxO1 and 
FoxO3a in different mammalian cells (Bae et al. 2004, Jing et al. 2007, Wang et al. 
2007). SIRT2 has even been connected to cell death in response to various stress stimuli 
including DNA damage (Matsushita et al. 2005).  
 
2.7.4 Aging and aging related diseases 
The important factors in the control of the aging process are calorie restriction, insulin-
like signalling pathway and oxidative stress resistance. The connection between these 
factors and SIRT2 has been under intense research (Michishita et al. 2005, Wang et al. 
2007). It has been reported that the life span of yeast can be extended through the action 
of calorie restriction (CR) which has been linked to Sir2 by decreasing NADH levels. 
NADH (the reduced form of NAD+) is a competitive inhibitor of Sir2 (Guarente and 
Picard 2005, Lin et al. 2004). It has also been reported that the levels of SIRT1 are 
increased under CR conditions in rats (Cohen et al. 2004), although further studies have 
postulated that CR-induced lifespan might occur independently of the mammalian 
SIRTs (Kaeberlein et al. 2005b, Longo 2008, Tsuchiya et al. 2006). These controversial 
issues on the connection between the effect of CR on longevity in mammals and SIRTs 
should be studied further.  
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SIRT2 has been reported to be the most abundant sirtuin in adipocytes. SIRT2 
deacetylation has been claimed to regulate adipocyte differentiation through FoxO1 
transcription factor (Jing et al. 2007) and oxidative stress and CR through FoxO3a 
transcription factor in the cytoplasm (Wang et al. 2007). Hence, regulators of SIRT2 
could provide potent drugs for obesity and its complications (Jing et al. 2007).  
There are a few early studies, which have reported the role of SIRT2 in 
neurodegenerative diseases. Li et al. (2007) and Tang and Chua (2008) have presented 
the possible connection between SIRT2 and brain aging and related diseases. SIRT2 has 
been reported to regulate oligodendroglial differentiation and maturation through its 
tubulin deacetylation activity. The main function of oligodendroglia is the insulation of 
the axons in the central nervous system. Selective, small-molecule inhibitor of SIRT2 
has been reported to protect against α-synuclein-mediated toxicity in cellular models of 
Parkinson’s disease (Outeiro et al. 2007). The suggested inhibition mechanism claimed 
that SIRT inhibition could reduce the formation of abnormal protein aggregates inside 
nerve cells. These aggregates are called Lewy bodies and they contain α-synuclein 
(Outeiro et al. 2007). This study together with other recent publications suggest that 
SIRT2 might function as a negative regulator of biological stress (Grubisha et al. 2006, 
Lynn et al. 2008, Outeiro et al. 2007). In addition, a study with wild-type granule cells 
suggested that SIRT2 inhibition might enhance microtubule acetylation and resistance 
to axonal degeneration (Suzuki and Koike 2007a). 
The anticancer activity of class I and II HDAC inhibitors is well known. One of the 
latest accepted compounds called SAHA (Zolinda®) is used for treatment of cutaneous 
T-cell lymphoma (Mann et al. 2007). Thus, the interest of the anticancer activity of 
SIRT2 inhibitors has been under intense research. However, one should bear in mind, 
that compounds able to inhibit class I and II HDACs are ineffective in inhibiting the 
sirtuins (Mai 2007) due to the different type of catalytic mechanism (Imai et al. 2000, 
Smith et al. 2000). It has been reported that the human SIRT2 gene is located at the 
region of the genome, 19q13.1 (Voelter-Mahlknecht et al. 2005), that is frequently 
deleted in human gliomas and gastric carcinomas, supporting its potential role as a gene 
that protects cells from excessive proliferation and, further, cancer (Hiratsuka et al. 
2003, Inoue et al. 2007). SIRT2 down-regulation in tumors has also been reported with 
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human brain tumor cell lines and chicken DNA-damaged cells (Matsushita et al. 2005, 
Voelter-Mahlknecht et al. 2005). This may offer a novel tumor marker (Wang et al. 
2007). In addition, SIRT2 has been reported to interfere with cell adhesion in the 
cervical cancer cell line (Pandithage et al. 2008). 
SIRT2 has also been reported to have a role in mediating cell survival in cardiac 
myocytes (Alcendor et al. 2004) and to have a reduced expression in diabetic hearts 
(Turdi et al. 2007). It has also been suggested to interact with HoxA10 that may have a 
role in the development of adult reproductive tissues (Bae et al. 2004). 
 
2.8 SIRT2 inhibitors 
The aim of this section is to give an overview of published SIRT2 inhibitors and their 
structure-activity relationships. The inhibitory activities against other human SIRTs are 
also discussed if reported. Direct comparisons will be made only between inhibitors that 
have been tested in the same test system.  
 
2.8.1 Small molecule inhibitors 
The first reported cell permeable SIRT2 inhibitor was sirtinol 3 found by a high 
throughput, phenotypic screen in cells (table 2.2). The inhibitory activity has been 
reported to be 38 µM tested in vitro in a radioactivity based HDAC assay (Grozinger et 
al. 2001). However, sirtinol has been reported to be poorly soluble and to precipitate in 
buffer and protein-containing solutions and during a crude enzyme preparation 
(Heltweg et al. 2003, Neugebauer et al. 2008).  
The imine derived from 2-hydroxy-1-naphthaldehyde in the structure of sirtinol 3 was 
expected to be important for the inhibitory activity. However, it has been reported that 
2-hydroxy-1-naphthaldehyde inhibits the SIRT2 activity alone only moderately 
(Grozinger et al. 2001). Removal of the 2-hydroxy group of sirtinol decreases the 
inhibitory activity of SIRT1 (Mai et al. 2005). The tested 2-hydroxy-1-naphthaldehyde 
derivatives have been reported to give IC50 values in the range 50–70 µM for SIRT2. 
However, the structures of the derivatives were not published (Grozinger et al. 2001).  
Sirtinol 3 has also been tested in a fluorescence based HDAC assay, together with its 
derivatives 4–7 (table 2.2). The IC50 value of sirtinol 3 was 57.7 µM and 131 µM for 
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SIRT2 and SIRT1, respectively. The meta- and para-isomers of sirtinol (4 and 5) were 
twice to ten-times more potent for both SIRT2 and SIRT1. (R)- and (S)-sirtinols (6 and 
7) were equipotent and they could not bring out an enantioselective inhibitory effect 
(Mai et al. 2005). Sirtinol 3 has also been reported to have an in vivo effect on the 
acetylation status of p53 through SIRT1 in human endothelial cells (Ota et al. 2007).   
 
Table 2.2. β-Naphthol analogues and their inhibitory activities for SIRT2 and SIRT1. 
Compd Name Structure IC50 (µM) 
SIRT2 
IC50 (µM) 
SIRT1 
Reference 
rac-3 sirtinol 38 ± 2 a 
 
60 a  
 
(Grozinger et al. 
2001) 
57.7 ± 9 b 131 ± 11 b (Mai et al. 2005) 
rac-4 meta-sirtinol 35.7 ± 2 59 ± 2 (Mai et al. 2005) 
rac-5 para-sirtinol 25.9 ± 6 13 ± 2 (Mai et al. 2005) 
(R)-6 (R)-sirtinol 49.3 ± 6 55 ± 5 (Mai et al. 2005) 
(S)-7 (S)-sirtinol 
OH
N
H
N
O
39.4 ± 5 67 ± 4 (Mai et al. 2005) 
8 cambinol 59 ± 4 56 ± 2 (Heltweg et al. 
2006) 
a Tested in a radioactivity based HDAC assay. b Tested in a fluorescence based HDAC assay. 
 
The structurally similar β-naphthol analogue, cambinol 8 has been reported to be an 
equipotent SIRT2 and SIRT1 inhibitor with IC50 values of 59 µM and 56 µM, 
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respectively, tested in a radioactive based HDAC assay (table 2.2). Cambinol 8 is also 
inhibiting SIRT2 in vivo. The reported competition studies of SIRT2 with NAD+ and 
histone H4-peptide substrates revealed that cambinol 8 is noncompetitive with NAD+ 
but competitive with the substrate. Cambinol 8 is the first SIRT inhibitor, which has 
been reported to show an antitumor activity in vitro tested in a mouse xenograft model. 
This has suggested that SIRT inhibitors could be used as novel anticancer agents 
(Heltweg et al. 2006).  
Splitomicin 9, a β-naphthol analogue and a by-product in the synthesis of cambinol 
(Heltweg et al. 2006), has been reported to inhibit yeast Sir2 with an IC50 value of 60 
µM in a yeast cell-based screen (Bedalov et al. 2001). Hydrolysis of the lactone ring of 
splitomicin and its analogues at neutral pH have complicated their studies in 
mammalian cells (Posakony et al. 2004a). However, several splitomicin analogues, such 
as compounds 10–13 in table 2.3, have been reported to be potent SIRT2 inhibitors 
(Neugebauer et al. 2008).  
 
 
 
The series of compounds was tested in a homogenous deacetylase assay using a 
fluorescent lysine derivative, that was developed in the group of Heltweg et al. (2005). 
The results claimed that the bromo or methyl substituent in the 8-position of the 
naphthalene ring (10–13) had a positive effect on the inhibitory activity. In addition, 
replacing the lactone ring by a lactam ring resulted in compound 13 which had a similar 
inhibitory activity and an increased stability (Neugebauer et al. 2008).  
The importance of the naphthalene ring has not been studied although it has not been 
required for the inhibitory activity in yeasts (Posakony et al. 2004b). Selected 
compounds were also tested for inhibition of proliferation of MCF-7 breast cancer cells, 
which confirmed the antitumor activity of SIRT2 inhibitors. Generally, these 
compounds were not potent cytotoxic agents on those cells which might due to the high 
lipophilicity of splitomicin derivatives. But compounds (11–13), which inhibited SIRT2 
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in the low micromolar region, were also the most potent antiproliferative agents 
(Neugebauer et al. 2008).   
 
Table 2.3. Splitomicin derivatives and their inhibitory  
activities for SIRT2 (Neugebauer et al. 2008). 
Compd Structure IC50 (µM) SIRT2 
rac-10 
 
1.5 ± 0.5 
rac-11 
 
1.5 ± 0.6 
(R)-12 
 
1.0 ± 0.3 
rac-13 
 
6.4 ± 0.3 
 
A series of indoles are one of the most potent SIRT inhibitors reported so far (table 
2.4). Compounds 14–16 were found by high-throughput screening for recombinant 
human SIRT1 and tested in a fluorescence based assay. Compound 17, the seven-
membered-ring analogue, has been synthesized as a ring modification of 14 (table 2.4). 
All compounds showed better inhibitory activity for SIRT1 than SIRT2. Compound 14 
was 200-times more potent for SIRT1 than SIRT2. The inhibitory activity of 14 was 
19.6 µM and 0.098 µM for SIRT2 and SIRT1, respectively. Thus, 14 is one of the most 
selective inhibitors (SIRT1/ SIRT2) reported. Small nonpolar groups at the 6-position in 
14, 15, and 16 have not been claimed to have a significant effect on the inhibitory 
activity of SIRT2. Compound 16 was an equipotent SIRT1 inhibitor as compared to 14, 
whereas 17 was seven times more potent for SIRT2 as compared to 14. The enantiomers 
of 14 and 17 were separated but their inhibitory activities of SIRT2 have not been 
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reported. Overall, the series of indoles have been reported to be low molecular weight, 
cell-permeable, orally bioavailable, and metabolically stable (Napper et al. 2005). 
 
Table 2.4. Indoles 14–17 and their inhibitory activities for SIRT2 and  
SIRT1 (Napper et al. 2005). 
Compd Structure IC50 (µM) SIRT2a IC50 (µM) SIRT1a 
rac-14 
 
19.6 0.098 
rac-15 
 
11.5 0.205 
rac-16 
 
24.8 1.47 
rac-17 
 
2.77 0.124 
a IC50 data are reported as the mean of at least three independent determinations,  
standard error of the mean ≤ 30%.  
 
Reported 2-anilinobenzamides are indole analogues from which the best SIRT1 
inhibitor 18 has also been tested in a fluorescence based assay for SIRT2 with an IC50 
value of 74 µM for SIRT2 and 17 µM for SIRT1. Although the structures of 18 and 14 
have structural similarities (the same distance between amine and amide groups), 
compound 14 is more rigid, and they have different aromatic ring systems. It has been 
reported that the structure activity relationships differ. The enzyme kinetic assay 
claimed that compound 18 exhibited a noncompetitive inhibition with NAD+ but a 
competitive inhibition with the acetylated lysine substrate (Suzuki et al. 2006). 
Compound 14 has not been reported to have competitive inhibition with the acetylated 
lysine substrate (Napper et al. 2005).  However, the analysis of the X-ray structure of 
SIRT2 and preliminary docking simulations using cambinol 8, 12, and 17 have 
suggested that compounds interact with the nicotinamide site C of SIRT2 (Neugebauer 
et al. 2008) and that they are the noncompetitive inhibitors with NAD+ (Heltweg et al. 
2006, Napper et al. 2005, Neugebauer et al. 2008). 
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A systematic study for identification of lead structures for sirtuins from drugs that 
target enzymes or receptors that bind adenosine-containing cofactors or ligands has 
been conducted (Trapp et al. 2006). Bis(indolyl)maleimides were originally discovered 
as ATP-competitive protein kinase C inhibitors (table 2.5). The plain compound 19 
without any substituent had an IC50 value of 4.7 µM for SIRT2. Compounds 20 and 21 
having a bulky substituent on one of the indole nitrogen have slightly increased 
inhibitory activities. The IC50 values of 20 and 21 were 2.8 µM and 2.5 µM for SIRT2, 
respectively. Compounds 19–21 had roughly five-fold inhibitory activities against 
SIRT1. However, the best compound of the series, 22 had the IC50 value of 0.8 µM for 
SIRT2 and 3.5 µM for SIRT1, respectively (Trapp et al. 2006). The series of 
compounds was tested on a homogenous deacetylase assay using a fluorescent lysine 
derivative that was developed in the group of Heltweg et al. (2005). In addition, 22 was 
also tested in the scintillation assay, which gave the IC50 values of 1.1 µM and 5.1 µM 
for SIRT2 and SIRT1, respectively (Trapp et al. 2006). 
Furthermore, 22 exhibited also an in vivo inhibitory activity as it induced 
hyperacetylation of tubulin tested on A549 human lung adenocarcinoma cells. 
Competition analysis for 22 suggested that the inhibition is competitive with NAD+ and 
noncompetitive with the acetylated lysine substrate. In addition, the docking results 
suggested that 22 interacts with the adenine binding pocket (figure 2.2). The results of 
the competition and the docking analysis supported to each other (Trapp et al. 2006). 
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Table 2.5. Bis(indolyl)maleimides and their inhibitory activities for SIRT2 and SIRT1 
(Trapp et al. 2006). 
Compd R1 R2 R3 R4 IC50 ± SE 
(µM)a 
SIRT2 
Inhibition at 
50 µM, % a 
SIRT1  
IC50 ± SE 
(µM)a 
SIRT1 
19 H H H H 4.7 ± 1.1 52.7% - 
20 
 
H H H 2.8 ± 1.2 77.5% - 
21 
 
H H F 2.5 ± 0.6 71.9% - 
22 
 
CH3 H H 0.8 ± 0.2 - 3.5 ± 0.4 
a Values are means ± SE of duplicate experiments. 
 
Compound 23 (A3) (table 2.6) was published at the same time with sirtinol 3 (table 
2.2). It was found by a high throughput, phenotypic screening in cells by Grozinger et 
al. (2001). Compound 23 has been reported to have an IC50 value of 45 µM for SIRT2. 
The molecular structures of 23 and 3 are planar and aromatic, similar to the adenine and 
nicotinamide moieties of NAD+. However, the imine derived from 2-hydroxy-1-
naphthaldehyde in the structure of sirtinol 3 was claimed to be essential for the 
inhibitory activity and analogues of 23 have not been published thereafter (Grozinger et 
al. 2001). 
 Molecular modelling and virtual screening has been employed to find novel structural 
scaffolds for SIRT2 inhibitors. Compounds 24 and 25 are commercial compounds 
discovered from the Maybridge database (Maybridge Chemical Company Ltd) and 
tested using a radioactive [3H]-substrate based assay (table 2.6). The determined IC50 
values were 74.3 µM and 56.7 µM, respectively. Phenol groups of compounds 24 (CD 
04097) and 25 (JFD 00244) were suggested to be capable of acting as hydrogen-bond 
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donors and, together with a hydrophobic moiety, to form an active SIRT2 
pharmacophore (Tervo et al. 2004). According to Tervo et al. (2004), the naphthol 
moiety of sirtinol 3 can be replaced by a phenolic moiety without the loss of the 
inhibitory activity.  
Successful virtual screening methods have also been used to discover structurally 
diverse inhibitors of SIRT2. One of the potent compounds ordered from LeadQuest 
Compound Library (Tripos Associates) 26 (Tripos 360702) had an indole moiety (table 
2.6). Compound 26 had an IC50 value of 51 µM for SIRT2 (Tervo et al. 2006). 
 
Table 2.6. Compounds 23–26 and their IC50 values for SIRT2.  
Compd Structure IC50 (µM) SIRT2 Reference 
23 (A3) 
 
45 ± 3a (Grozinger et al. 
2001) 
24 (CD 04097) 74.3 ± 1.5a (Tervo et al. 
2004) 
25 (JFD 00244) 56.7 ± 4.2a (Tervo et al. 
2004) 
26 (Tripos 360702) 
 
51 (27-75)b (Tervo et al. 
2006) 
a Average and standard deviation values were obtained from the IC50 determination performed in 
triplicate. b 95% confidence intervals given in parentheses. 
 
Suramin 27, originally used for the treatment of trypanosomiasis and onchocerciasis, 
is a symmetric polyanionic naphthylurea, which was first reported to inhibit SIRT1 
(Howitz et al. 2003). The approach of previously identified adenosine mimics from the 
same group (Trapp et al. 2006) had led to assume a similar structure-activity 
relationship for suramin than for the bis(indolyl)maleimides (table 2.5). However, it has 
been reported that suramin interacts with the nicotinamide binding site, the C site of 
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SIRT2 and, hence, would function as SIRT inhibitor. The binding of suramin has been 
claimed to be noncompetitive (Trapp et al. 2007).  
Suramin and several of its analogues were tested in a fluorescence based assay using 
ZMAL as the acetylated peptide substrate (table 2.7) (Heltweg and Jung 2003). The IC50 
values of suramin 27 were 1.150 µM and 0.297 µM for SIRT2 and SIRT1, respectively. 
The best suramin analogue for SIRT2 was 34, where the methyl substituents on the 
benzene rings of suramin had been replaced by chlorine atoms. This compound had an 
IC50 value of 0.407 µM. Thus the best suramin analogue for SIRT1 was 28, where the 
methyl substituents on the benzene rings of suramin had been replaced by hydrogen 
atoms. This compound had IC50 values of 0.585 µM and 0.165 µM for SIRT2 and 
SIRT1, respectively. Compounds 29, 30, 31, and 35 with ethyl, isopropyl, fluoro, and 
methoxy groups as replacements of the methyl substituents on the benzene rings had 
similar inhibitory activities for SIRT2 than 28 ranging from 0.449 µM to 0.612 µM. The 
same compounds 29–31 and 35 had slightly better IC50 values for SIRT1, between 
0.223 µM and 0.308 µM.  Compounds 32 and 33 with larger substituents at these 
positions were reported to have a decreased inhibitory activity compared to suramin 27 
for SIRT1. Compound 32 had slightly better IC50 value for SIRT2 than suramin 27 
(Trapp et al. 2007).  
In addition, the structure of compounds 28–35 was simplified by replacing the central 
symmetric bis(meta-carboxyphenyl)urea moiety by an isophthalic acid. The central 
benzene ring was substituted with an amino group resulting in 36. This is one of the 
most potent SIRT1 inhibitors published. The inhibitory activity of 36 was about 24-
times lower for SIRT2. The IC50 values of 36 were 2.261 µM 0.093 µM for SIRT2 and 
SIRT1, respectively. Moreover, compound 37, which was a truncated compound 31 
(one half of it) had IC50 values of 15.534 µM and 0.525 µM for SIRT2 and SIRT1, 
respectively (Trapp et al. 2007).  
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Table 2.7. Suramin and its analogues and their inhibitory activities for SIRT2 
and SIRT1 (Trapp et al. 2007). 
Compd R IC50 (µM) ± SEa SIRT2 IC50 (µM) ± SEa SIRT1 
27 suramin CH3 1.150 ± 0.123 0.297 ± 0.010 
28 H 0.585 ± 0.053 0.165 ± 0.019 
29  0.612 ± 0.124 0.223 ± 0.014 
30 
 
0.449 ± 0.025 0.308 ± 0.009 
31 F 0.467 ± 0.175 0.283 ± 0.012 
32  0.929 ± 0.055 1.713 ± 0.131 
33  1.725 ± 0.140 0.662 ± 0.028 
34 Cl 0.407 ± 0.099 0.339 ± 0.011 
35  0.510 ± 0.031 0.233 ± 0.012 
a Values are means ± SE of duplicate experiments. 
 
 
The molecular weight of the most potent SIRT2 inhibitor 34 of the series is 1491.5 
g/mol. It has been reported that the cellular uptake and the bioavailability of the 
compounds are generally limited considering the high molecular weight of the 
compounds and highly polar sulfonic acids in the chemical structures (Trapp et al. 
2007). 
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Compound 38 has been reported to be a SIRT2 inhibitor both in vitro and in vivo 
(table 2.8) (Outeiro et al. 2007). Compound 39 (AGK2) was revealed from the library 
search of designed 200 structural analogues of 38. Compound 39 inhibited SIRT2 with 
an IC50 value of 3.5 µM and SIRT1 with an IC50 value of over 50 µM tested in vitro in a 
fluorescence based assay. N-(5-Quinolyl)propenamide 39 has been reported to link 
SIRT2 inhibition and neurodegeration. The cellular inhibition by 39 rescued α-synuclein 
toxicity and protected against dopaminergic cell death, both biological changes caused 
by Parkinson disease (Outeiro et al. 2007).  
 
Table 2.8. AGK lead structures and their IC50 values for SIRT2 and SIRT1  
(Outeiro et al. 2007). 
Compd Structure IC50 (µM) SIRT2a IC50 (µM) SIRT1a 
38 
 
35 > 50 
39 
(AGK2) 
 
3.5 > 50 
40  
 
5.5 > 50 
41 N
NH N
O
H
O
H
CF3
 
6 > 50 
42 
 
> 50 > 50 
a The standard error not reported. 
 
Compound 40 with one chloro-substituent and compound 41 with a trifluoromethyl-
substituent at the 3-position gave the IC50 values 5.5 µM and 6 µM for SIRT2, 
respectively. As a reference, N-(2-quinolyl)propenamide 42 gave an over 50 µM 
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inhibitory activity for SIRT2. Compound 39 has been claimed to interact with the C site 
of SIRT2 by mimicking nicotinamide. So far, the mechanism for the effect of SIRT2 
inhibition remains unclear. However, microtubule stabilization itself resulting from 
SIRT2 inhibition could be an important factor in neuroprotection (Outeiro et al. 2007).   
In the fluorescence based assay at University of Kuopio compound 39 gave IC50 
values of 42.5 µM and 63.2 µM for SIRT2 and SIRT1, respectively (unpublished 
results).  
Also a few natural products have been tested as sirtuin inhibitors (Gey et al. 2007). 
Guttiferone G 43, hyperforin 44 and 45 (a synthetic derivative of 44) have been tested in 
a radioactive [3H]-substrate based assay for SIRT2 and SIRT1 (table 2.9). Aristoforin 
45 was the most potent compound of the series with IC50 values of 21 µM and 7 µM for 
SIRT2 and SIRT1, respectively. However, guttiferone 43 was almost equipotent. The 
IC50 values were slightly better for SIRT1 than for SIRT2. The cytotoxicity of 43–45 
and the effect on cell proliferation were also tested. It has been reported that 43 and 45 
were less toxic than 44 and they were stronger inhibitors of the cell proliferation. The 
results indicated the value of the phloroglucinol scaffold for the design of SIRT2 and 
SIRT1 inhibitors (Gey et al. 2007).       
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Table 2.9. Phloroglucinol derivatives and their IC50 values for SIRT2 and SIRT1.  
Compd Name Structure IC50 (µM) 
SIRT2 
IC50 (µM) 
SIRT1 
43 (+)-guttiferone G 22 ± 0.5 9 ± 0.2 
44 hyperforin 28 ± 0.2 15 ± 0.5 
45  aristoforin 21 ± 1 7 ± 0.2 
 
There are several post-transitional modifications of core histones, from which lysine 
acetylation and deacetylation are just one that lead gene expression or silencing to fulfil 
the requirements of the cell (Nightingale et al. 2006). These modifications in gene 
expression are also called epigenetics and they form a complex network where the 
effect of one modification will most probably change next one. There are certain 
diseases, such as cancer and central nervous system disorders, which take advantage of 
the complex network of cellular pathways and signals (Biel et al. 2005, Egger et al. 
2004). A multitarget-directed drug design strategy has been proposed which aim at the 
design of a single compound for several targets in a disease is to enhance an efficacy 
and to improve a safety of a therapy. The series of epigenetic multiple ligands have also 
been tested for SIRT2 and SIRT1. Compound 46 has been reported to inhibit SIRT2 
activity 100% at 25 µM and SIRT1 activity 61% at 25 µM tested in the fluorescence 
based assay (Mai et al. 2008). Compound 46 is symmetric and it has the 4-
hydroxyphenyl-propenoyl structure, one or both qualities which are reported also to be 
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found from several other SIRT2 inhibitors (Tervo et al. 2004, Tervo et al. 2006, Trapp 
et al. 2006, Trapp et al. 2007).    
 
 
Small active compounds for SIRT2 and SIRT1 have also been discovered using a 
mammalian cell-based screening assay (Lain et al. 2008). The advantage of the assay is 
that potent compounds that are found are already acceptable for further experiments (not 
toxic to cells). Compounds called tenovins have recently been found by cell-based 
screening and they have been reported to inhibit SIRT2 and SIRT1. The IC50 values of 
tenovin-6 47 are 10 µM and 21 µM for SIRT2 and SIRT1, respectively, tested in vitro 
in a fluorescence based assay. In addition, tenovins-1 and -6 have also been claimed to 
delay growth of tumors without general toxicity. Hence, Lain et al. (2008) suggested 
that tenovins should be considered as valuable leads in medicinal chemistry.     
 
 
 
Oxadiazole-carbonylaminothiourea has been reported to be a potent structural scaffold 
for SIRT2 and SIRT1 inhibitors. It has been found by virtual database screening tested 
in vitro in microplate filtration based assay (Huhtiniemi et al. 2008). The assay was 
based on the release of a radioactively labelled nicotinamide from NAD+ and its 
detection by thin layer chromatography (McDonagh et al. 2005, Tanny and Moazed 
2001). Compound 48 was the reported hit compound and a series of analogues were 
synthesized and tested for SIRT2 and SIRT1 (table 2.10). The inhibitory activity of 48 
was 57 µM and 192 µM for SIRT2 and SIRT1, respectively. The inhibitory activity of 
SIRT2 could not be improved.  However, compound 50 was almost equipotent with an 
IC50 value of 74 µM for SIRT2. Compound 49 was the most potent SIRT1 inhibitor 
with an IC50 value of 13 µM. The inhibitory activity of 49 for SIRT2 was almost nine-
times lower with a IC50 value of 113 µM (Huhtiniemi et al. 2008). 
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Huhtiniemi et al. (2006) have published a comparative model of SIRT1 and studied 
the binding modes of compound 14. Compound 48 was found by virtual database 
screening of novel inhibitors which share a similar binding site with 14 (table 2.4). This 
binding site is also known as the C site. Thus it has been reported that the inhibition 
mechanism of oxadiazole-carbonylaminothioureas is most likely the preventation of the 
productive conformation of NAD+  (Huhtiniemi et al. 2008).  
  
Table 2.10. Oxadiazole-carbonylaminothioureas and their IC50 values SIRT2 and 
SIRT1 (Huhtiniemi et al. 2008). 
Compd R1 R2 IC50 (µM) SIRT2a IC50 (µM) SIRT1a 
48 4-t-Bu-Ph 3-CF3-Ph 57 (26-125) 192 (104-354) 
49 1-naphthyl 3-CF3-Ph 113 (64-200) 13 (5-37) 
50  1-naphthyl 4-CF3-Ph 74 (47-115) 318 (140-723) 
a 95% confidence intervals for IC50 given in parentheses. 
 
2.8.2 Substrate-based inhibitors 
Substrate analogues have also been used as SIRT2 inhibitors. Initially, the Nε- 
thioacetylated lysine was considered as a functional mimic for the N-acetylated lysine. 
However, the Nε-thioacetylated Lys382 of human p53 sequence (amino acid residue 
372-389) 51 inhibited the deacetylation reaction (Fatkins et al. 2006). The peptide 51 
had IC50 values of 1.8 µM and 1.7 µM for SIRT2 and SIRT1, respectively (table 2.11) 
(Fatkins and Zheng 2008). On the other hand, Nα-Fmoc-Nε-thioacetyl-lysine 52 and Nα-
acetyl-Nε-thioacetyl-lysine 53 were only inhibiting SIRT1 at high concentrations 
(Fatkins et al. 2006). 
The research was continued with the SIRT2 substrate human α-tubulin sequence 36-
44 54 and the SIRT3 substrate human acetyl-coenzyme A synthetase 2 (AceCS2) 
sequence 633-652 55 (Fatkins and Zheng 2008). The sequence of α-tubulin had an IC50 
value of 11.4 µM and had a weak selectivity for SIRT2 over SIRT1 and SIRT3. The 
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sequence from AceCS2 55 had an IC50 value of 0.9 µM for SIRT1 and it had a weak 
selectivity for SIRT1 over SIRT2 and SIRT3 (table 2.11) (Fatkins and Zheng 2008).   
Several pentapeptides, which had an Nε-acetylated lysine in the middle of the 
sequence, were identified from a combinatorial peptide library to mimic SIRT1 
substrates (Garske and Denu 2006). Due to the results, the short peptide 56 based on 
human p53 sequence has been determined to have about six-times lower inhibitory 
activity than the longer peptide 51 (table 2.11) (Fatkins and Zheng 2008). The HPLC 
based assay was used to determine the inhibitory activities of the peptides 51–56 
(Fatkins et al. 2006). 
These results have given a starting point for mechanism-based inhibitors of Sir2 
deacetylases. The reported mechanism of Nε-thioacetylated lysine of human histone H3 
sequence (11 amino acid residues) 57 has indicated that the dethioacetylation reaction 
proceeds with the same mechanism as the deacetylation reaction, the only difference is 
that it is extremely slow. The dethioacetylation reaction has been claimed to stall at the 
1´-S-alkylamidate intermediate after nicotinamide formation.  As a reference, Nε-
trifluoroacetyl-lysine peptide was reported to exhibit a competitive inhibition with the 
acetyl lysine substrate in contrary to 57. The IC50 value of 57 was reported to be 5.6 µM 
and 2.0 µM for SIRT2 and SIRT1, respectively (table 2.11) (Smith and Denu 2007b).  
Binding studies of several acetyl-lysine analog peptides have suggested that the 
hydrophobicity of the analogs has better correlation to binding than the electronic and 
steric effects. The propionyl-lysine peptide was found to bind tighter to Hst2 compared 
with the acetyl-lysine peptide. The depropionylation reaction was measurable 
suggesting that the propionyl-lysine proteins may function as sirtuin substrates in vivo. 
The result was suggested to be applicable towards the development of substrate-based 
inhibitors (Smith and Denu 2007a). 
 45 
  T
ab
le
 2
.1
1.
 S
ub
st
ra
te
-li
ke
 in
hi
bi
to
rs
 a
nd
 th
ei
r I
C
50
 v
al
ue
s f
or
 S
IR
T2
 a
nd
 S
IR
T1
. 
C
om
pd
 
So
ur
ce
 
Se
qu
en
ce
 
IC
50
 (µ
M
) 
SI
R
T2
 
IC
50
 (µ
M
) 
SI
R
T1
 
IC
50
 (µ
M
) 
SI
R
T3
 
R
ef
er
en
ce
 
51
 
hu
m
an
 p
53
  
(3
72
-3
89
) 
H
2N
-K
K
G
Q
ST
SR
H
K
K
(N
ε -T
hi
oA
c)
LM
FK
TE
G
-O
H
 
1.
8 
± 
0.
3 
1.
7 
± 
0.
4 
67
.3
 ±
 2
.4
 
(F
at
ki
ns
 a
nd
 
Zh
en
g 
20
08
) 
52
 
- 
N
α -
Fm
oc
-N
ε -t
hi
oa
ce
ty
l-l
ys
in
e 
N
D
 a
 
20
00
 (I
C
25
) 
N
D
a  
(F
at
ki
ns
 e
t 
al
. 2
00
6)
 
53
 
- 
N
α -
A
ce
ty
l-N
ε -t
hi
oa
ce
ty
l-l
ys
in
e 
N
D
 a
 
N
Ib  
at
 2
 m
M
 
N
D
a  
(F
at
ki
ns
 e
t 
al
. 2
00
6)
 
54
 
hu
m
an
 α
-
tu
bu
lin
  
(3
6-
44
) 
H
2N
-M
PS
D
K
(N
ε -T
hi
oA
c)
TI
G
G
-O
H
 
11
.4
 ±
 1
.1
 
11
6.
8 
± 
12
.0
 
44
9.
4 
± 
18
.4
 
(F
at
ki
ns
 a
nd
 
Zh
en
g 
20
08
) 
55
 
hu
m
an
 
A
ce
C
S2
  
(6
33
-6
52
) 
H
2N
-K
R
LP
K
TR
SG
K
(N
ε -T
hi
oA
c)
V
M
R
R
LL
R
K
II
-O
H
 
4.
3 
± 
0.
3 
0.
9 
± 
0.
2 
4.
5 
± 
2.
0 
(F
at
ki
ns
 a
nd
 
Zh
en
g 
20
08
) 
56
 
hu
m
an
 p
53
  
(3
80
-3
84
) 
H
2N
-H
K
K
(N
ε -T
hi
oA
c)
LM
-O
H
 
N
D
 a
 
A
bo
ut
 1
0 
c  
N
D
a  
(F
at
ki
ns
 a
nd
 
Zh
en
g 
20
08
) 
57
 
hu
m
an
 
hi
st
on
e 
H
3 
H
2N
-K
ST
G
G
K
(N
ε -T
hi
oA
c)
A
PR
K
Q
-O
H
 
5.
6 
± 
0.
8 
2.
0 
± 
0.
2 
2.
3 
± 
0.
3 
(S
m
ith
 a
nd
 
D
en
u 
20
07
b)
 
a  N
ot
 d
et
er
m
in
ed
. b
 N
o 
in
hi
bi
tio
n.
 c 
Th
e 
ex
ac
t v
al
ue
 w
as
 n
ot
 re
po
rte
d.
 
 
46 
 
2.9 References 
Afshar, G.; Murnane, J. P., Characterization of a human gene with sequence homology to Saccharomyces 
cerevisiae SIR2. Gene 234: 161-8, 1999. 
 
Alberts, B.; Johnson, A.; Lewis, J.; Raff, M.; Roberts, K.; Walter, P., The cell cycle and programmed cell 
death. In Molecular Biology of the Cell, 4 Ed.; Garland Science: New York, 2002; p 985. 
 
Alcendor, R. R.; Kirshenbaum, L. A.; Imai, S.; Vatner, S. F.; Sadoshima, J., Silent information regulator 
2alpha, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor 
in cardiac myocytes. Circ Res 95: 971-80, 2004. 
 
Avalos, J. L.; Bever, K. M.; Wolberger, C., Mechanism of sirtuin inhibition by nicotinamide: altering the 
NAD(+) cosubstrate specificity of a Sir2 enzyme. Mol Cell 17: 855-68, 2005. 
 
Avalos, J. L.; Boeke, J. D.; Wolberger, C., Structural basis for the mechanism and regulation of Sir2 
enzymes. Mol Cell 13: 639-48, 2004. 
 
Avalos, J. L.; Celic, I.; Muhammad, S.; Cosgrove, M. S.; Boeke, J. D.; Wolberger, C., Structure of a Sir2 
enzyme bound to an acetylated p53 peptide. Mol Cell 10: 523-35, 2002. 
 
Bae, N. S.; Swanson, M. J.; Vassilev, A.; Howard, B. H., Human histone deacetylase SIRT2 interacts 
with the homeobox transcription factor HOXA10. J Biochem (Tokyo) 135: 695-700, 2004. 
 
Bedalov, A.; Gatbonton, T.; Irvine, W. P.; Gottschling, D. E.; Simon, J. A., Identification of a small 
molecule inhibitor of Sir2p. Proc Natl Acad Sci U S A 98: 15113-8, 2001. 
 
Bellamacina, C. R., The nicotinamide dinucleotide binding motif: a comparison of nucleotide binding 
proteins. Faseb J 10: 1257-69, 1996. 
 
Biel, M.; Wascholowski, V.; Giannis, A., Epigenetics--an epicenter of gene regulation: histones and 
histone-modifying enzymes. Angew Chem Int Ed Engl 44: 3186-216, 2005. 
 
Bitterman, K. J.; Anderson, R. M.; Cohen, H. Y.; Latorre-Esteves, M.; Sinclair, D. A., Inhibition of 
silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human 
SIRT1. J Biol Chem 277: 45099-107, 2002. 
 
Borra, M. T.; Denu, J. M., Quantative assays for characterization of the Sir2 family of NAD+-dependent 
deacetylase. Methods Enzymol 376: 171-187, 2003. 
 
Borra, M. T.; Langer, M. R.; Slama, J. T.; Denu, J. M., Substrate specificity and kinetic mechanism of the 
Sir2 family of NAD+-dependent histone/protein deacetylases. Biochemistry 43: 9877-87, 2004. 
 
Borra, M. T.; O'Neill, F. J.; Jackson, M. D.; Marshall, B.; Verdin, E.; Foltz, K. R.; Denu, J. M., 
Conserved enzymatic production and biological effect of O-acetyl-ADP-ribose by silent information 
regulator 2-like NAD+-dependent deacetylases. J Biol Chem 277: 12632-41, 2002. 
 
Borra, M. T.; Smith, B. C.; Denu, J. M., Mechanism of human SIRT1 activation by resveratrol. J Biol 
Chem 280: 17187-95, 2005. 
 
Brachmann, C. B.; Sherman, J. M.; Devine, S. E.; Cameron, E. E.; Pillus, L.; Boeke, J. D., The SIR2 gene 
family, conserved from bacteria to humans, functions in silencing, cell cycle progression, and 
chromosome stability. Genes Dev 9: 2888-902, 1995. 
47 
 
Buck, S. W.; Gallo, C. M.; Smith, J. S., Diversity in the Sir2 family of protein deacetylases. J Leukoc 
Biol 75: 939-50, 2004. 
 
Cohen, H. Y.; Miller, C.; Bitterman, K. J.; Wall, N. R.; Hekking, B.; Kessler, B.; Howitz, K. T.; Gorospe, 
M.; de Cabo, R.; Sinclair, D. A., Calorie restriction promotes mammalian cell survival by inducing the 
SIRT1 deacetylase. Science 305: 390-2, 2004. 
 
Cosgrove, M. S.; Bever, K.; Avalos, J. L.; Muhammad, S.; Zhang, X.; Wolberger, C., The structural basis 
of sirtuin substrate affinity. Biochemistry 45: 7511-21, 2006. 
 
Csordas, A., On the biological role of histone acetylation. Biochem J 265: 23-38, 1990. 
 
Daitoku, H.; Hatta, M.; Matsuzaki, H.; Aratani, S.; Ohshima, T.; Miyagishi, M.; Nakajima, T.; Fukamizu, 
A., Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase 
activity. Proc Natl Acad Sci U S A 101: 10042-7, 2004. 
 
Denu, J. M., Linking chromatin function with metabolic networks: Sir2 family of NAD(+)-dependent 
deacetylases. Trends Biochem Sci 28: 41-8, 2003. 
 
Dryden, S. C.; Nahhas, F. A.; Nowak, J. E.; Goustin, A. S.; Tainsky, M. A., Role for human SIRT2 NAD-
dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol Cell Biol 23: 3173-85, 
2003. 
 
Egger, G.; Liang, G.; Aparicio, A.; Jones, P. A., Epigenetics in human disease and prospects for 
epigenetic therapy. Nature 429: 457-63, 2004. 
 
Fatkins, D. G.; Monnot, A. D.; Zheng, W., Nepsilon-thioacetyl-lysine: a multi-facet functional probe for 
enzymatic protein lysine Nepsilon-deacetylation. Bioorg Med Chem Lett 16: 3651-6, 2006. 
 
Fatkins, D. G.; Zheng, W., Substituting Nε-thioacetyl-lysine for Nε-acetyl-lysine in Peptide Substrates as a 
General Approarch to Inhibiting Human NAD+-dependent Protein Deacetylases. Int J Mol Sci 9: 1-11, 
2008. 
 
Finnin, M. S.; Donigian, J. R.; Pavletich, N. P., Structure of the histone deacetylase SIRT2. Nat Struct 
Biol 8: 621-5, 2001. 
 
Frye, R. A., Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like 
proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem 
Biophys Res Commun 260: 273-9, 1999. 
 
Frye, R. A., Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem 
Biophys Res Commun 273: 793-8, 2000. 
 
Garske, A. L.; Denu, J. M., SIRT1 top 40 hits: use of one-bead, one-compound acetyl-peptide libraries 
and quantum dots to probe deacetylase specificity. Biochemistry 45: 94-101, 2006. 
 
Gey, C.; Kyrylenko, S.; Hennig, L.; Nguyen, L. H.; Buttner, A.; Pham, H. D.; Giannis, A., Phloroglucinol 
derivatives guttiferone G, aristoforin, and hyperforin: inhibitors of human sirtuins SIRT1 and SIRT2. 
Angew Chem Int Ed Engl 46: 5219-22, 2007. 
 
Gottschling, D. E., Gene silencing: two faces of SIR2. Curr Biol 10: R708-11, 2000. 
 
48 
 
Grozinger, C. M.; Chao, E. D.; Blackwell, H. E.; Moazed, D.; Schreiber, S. L., Identification of a class of 
small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J 
Biol Chem 276: 38837-43, 2001. 
 
Grubisha, O.; Rafty, L. A.; Takanishi, C. L.; Xu, X.; Tong, L.; Perraud, A. L.; Scharenberg, A. M.; Denu, 
J. M., Metabolite of SIR2 reaction modulates TRPM2 ion channel. J Biol Chem 281: 14057-65, 2006. 
 
Grubisha, O.; Smith, B. C.; Denu, J. M., Small molecule regulation of Sir2 protein deacetylases. Febs J 
272: 4607-16, 2005. 
 
Guarente, L., Sir2 links chromatin silencing, metabolism, and aging. Genes Dev 14: 1021-6, 2000. 
 
Guarente, L.; Picard, F., Calorie restriction--the SIR2 connection. Cell 120: 473-82, 2005. 
 
Heltweg, B.; Dequiedt, F.; Verdin, E.; Jung, M., Nonisotopic substrate for assaying both human zinc and 
NAD+-dependent histone deacetylases. Anal Biochem 319: 42-8, 2003. 
 
Heltweg, B.; Gatbonton, T.; Schuler, A. D.; Posakony, J.; Li, H.; Goehle, S.; Kollipara, R.; DePinho, R. 
A.; Gu, Y.; Simon, J. A.; Bedalov, A., Antitumor activity of a small-molecule inhibitor of human silent 
information regulator 2 enzymes. Cancer Res 66: 4368-77, 2006. 
 
Heltweg, B.; Jung, M., A homogeneous nonisotopic histone deacetylase activity assay. J Biomol Screen 
8: 89-95, 2003. 
 
Heltweg, B.; Trapp, J.; Jung, M., In vitro assays for the determination of histone deacetylase activity. 
Methods 36: 332-7, 2005. 
 
Hiratsuka, M.; Inoue, T.; Toda, T.; Kimura, N.; Shirayoshi, Y.; Kamitani, H.; Watanabe, T.; Ohama, E.; 
Tahimic, C. G.; Kurimasa, A.; Oshimura, M., Proteomics-based identification of differentially expressed 
genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun 309: 558-66, 
2003. 
 
Howitz, K. T.; Bitterman, K. J.; Cohen, H. Y.; Lamming, D. W.; Lavu, S.; Wood, J. G.; Zipkin, R. E.; 
Chung, P.; Kisielewski, A.; Zhang, L. L.; Scherer, B.; Sinclair, D. A., Small molecule activators of 
sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-6, 2003. 
 
Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; Yoshida, M.; Wang, X. F.; Yao, 
T. P., HDAC6 is a microtubule-associated deacetylase. Nature 417: 455-8, 2002. 
 
Huhtiniemi, T.; Suuronen, T.; Rinne, V. M.; Wittekindt, C.; Lahtela-Kakkonen, M.; Jarho, E.; Wallen, E. 
A.; Salminen, A.; Poso, A.; Leppanen, J., Oxadiazole-carbonylaminothioureas as SIRT1 and SIRT2 
Inhibitors. J Med Chem: 2008. 
 
Huhtiniemi, T.; Wittekindt, C.; Laitinen, T.; Leppanen, J.; Salminen, A.; Poso, A.; Lahtela-Kakkonen, 
M., Comparative and pharmacophore model for deacetylase SIRT1. J Comput Aided Mol Des 20: 589-
99, 2006. 
 
Imai, S.; Armstrong, C. M.; Kaeberlein, M.; Guarente, L., Transcriptional silencing and longevity protein 
Sir2 is an NAD-dependent histone deacetylase. Nature 403: 795-800, 2000. 
 
Inoue, T.; Hiratsuka, M.; Osaki, M.; Yamada, H.; Kishimoto, I.; Yamaguchi, S.; Nakano, S.; Katoh, M.; 
Ito, H.; Oshimura, M., SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation 
in response to mitotic stress. Oncogene 26: 945-57, 2007. 
49 
 
Ivy, J. M.; Klar, A. J.; Hicks, J. B., Cloning and characterization of four SIR genes of Saccharomyces 
cerevisiae. Mol Cell Biol 6: 688-702, 1986. 
 
Jackson, M. D.; Denu, J. M., Structural identification of 2'- and 3'-O-acetyl-ADP-ribose as novel 
metabolites derived from the Sir2 family of beta -NAD+-dependent histone/protein deacetylases. J Biol 
Chem 277: 18535-44, 2002. 
 
Jackson, M. D.; Schmidt, M. T.; Oppenheimer, N. J.; Denu, J. M., Mechanism of nicotinamide inhibition 
and transglycosidation by Sir2 histone/protein deacetylases. J Biol Chem 278: 50985-98, 2003. 
 
Jin, Y. H.; Kim, Y. J.; Kim, D. W.; Baek, K. H.; Kang, B. Y.; Yeo, C. Y.; Lee, K. Y., Sirt2 interacts with 
14-3-3 beta/gamma and down-regulates the activity of p53. Biochem Biophys Res Commun 368: 690-5, 
2008. 
 
Jing, E.; Gesta, S.; Kahn, C. R., SIRT2 regulates adipocyte differentiation through FoxO1 
acetylation/deacetylation. Cell Metab 6: 105-14, 2007. 
 
Kaeberlein, M.; McDonagh, T.; Heltweg, B.; Hixon, J.; Westman, E. A.; Caldwell, S. D.; Napper, A.; 
Curtis, R.; DiStefano, P. S.; Fields, S.; Bedalov, A.; Kennedy, B. K., Substrate-specific activation of 
sirtuins by resveratrol. J Biol Chem 280: 17038-45, 2005a. 
 
Kaeberlein, M.; Powers, R. W., 3rd; Steffen, K. K.; Westman, E. A.; Hu, D.; Dang, N.; Kerr, E. O.; 
Kirkland, K. T.; Fields, S.; Kennedy, B. K., Regulation of yeast replicative life span by TOR and Sch9 in 
response to nutrients. Science 310: 1193-6, 2005b. 
 
Lain, S.; Hollick, J. J.; Campbell, J.; Staples, O. D.; Higgins, M.; Aoubala, M.; McCarthy, A.; Appleyard, 
V.; Murray, K. E.; Baker, L.; Thompson, A.; Mathers, J.; Holland, S. J.; Stark, M. J.; Pass, G.; Woods, J.; 
Lane, D. P.; Westwood, N. J., Discovery, in vivo activity, and mechanism of action of a small-molecule 
p53 activator. Cancer Cell 13: 454-63, 2008. 
 
Landry, J.; Slama, J. T.; Sternglanz, R., Role of NAD(+) in the deacetylase activity of the SIR2-like 
proteins. Biochem Biophys Res Commun 278: 685-90, 2000a. 
 
Landry, J.; Sutton, A.; Tafrov, S. T.; Heller, R. C.; Stebbins, J.; Pillus, L.; Sternglanz, R., The silencing 
protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc Natl Acad Sci U S A 97: 
5807-11, 2000b. 
 
Li, W.; Zhang, B.; Tang, J.; Cao, Q.; Wu, Y.; Wu, C.; Guo, J.; Ling, E. A.; Liang, F., Sirtuin 2, a 
mammalian homolog of yeast silent information regulator-2 longevity regulator, is an oligodendroglial 
protein that decelerates cell differentiation through deacetylating alpha-tubulin. J Neurosci 27: 2606-16, 
2007. 
 
Lim, C. S.; Potts, M.; Helm, R. F., Nicotinamide extends the replicative life span of primary human cells. 
Mech Ageing Dev 127: 511-4, 2006. 
 
Lin, S. J.; Defossez, P. A.; Guarente, L., Requirement of NAD and SIR2 for life-span extension by calorie 
restriction in Saccharomyces cerevisiae. Science 289: 2126-8, 2000. 
 
Lin, S. J.; Ford, E.; Haigis, M.; Liszt, G.; Guarente, L., Calorie restriction extends yeast life span by 
lowering the level of NADH. Genes Dev 18: 12-6, 2004. 
 
Lin, S. J.; Guarente, L., Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, 
longevity and disease. Curr Opin Cell Biol 15: 241-6, 2003. 
50 
 
Loidl, P., Histone acetylation: facts and questions. Chromosoma 103: 441-9, 1994. 
 
Longo, V. D., Linking sirtuins, IGF-I signaling, and starvation. Exp Gerontol: 2008. 
 
Luger, K.; Richmond, T. J., The histone tails of the nucleosome. Curr Opin Genet Dev 8: 140-6, 1998. 
 
Lynn, E. G.; McLeod, C. J.; Gordon, J. P.; Bao, J.; Sack, M. N., SIRT2 is a negative regulator of anoxia-
reoxygenation tolerance via regulation of 14-3-3 zeta and BAD in H9c2 cells. FEBS Lett 582: 2857-62, 
2008. 
 
Mai, A., The therapeutic uses of chromatin-modifying agents. Expert Opin Ther Targets 11: 835-51, 
2007. 
 
Mai, A.; Cheng, D.; Bedford, M. T.; Valente, S.; Nebbioso, A.; Perrone, A.; Brosch, G.; Sbardella, G.; De 
Bellis, F.; Miceli, M.; Altucci, L., epigenetic multiple ligands: mixed histone/protein methyltransferase, 
acetyltransferase, and class III deacetylase (sirtuin) inhibitors. J Med Chem 51: 2279-90, 2008. 
 
Mai, A.; Massa, S.; Lavu, S.; Pezzi, R.; Simeoni, S.; Ragno, R.; Mariotti, F. R.; Chiani, F.; Camilloni, G.; 
Sinclair, D. A., Design, synthesis, and biological evaluation of sirtinol analogues as class III 
histone/protein deacetylase (sirtuin) inhibitors. J Med Chem 48: 7789-95, 2005. 
 
Mann, B. S.; Johnson, J. R.; Cohen, M. H.; Justice, R.; Pazdur, R., FDA approval summary: vorinostat for 
treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12: 1247-52, 2007. 
 
Marmorstein, R., Structure and chemistry of the Sir2 family of NAD+-dependent histone/protein 
deactylases. Biochem Soc Trans 32: 904-9, 2004. 
 
Matsushita, N.; Takami, Y.; Kimura, M.; Tachiiri, S.; Ishiai, M.; Nakayama, T.; Takata, M., Role of 
NAD-dependent deacetylases SIRT1 and SIRT2 in radiation and cisplatin-induced cell death in vertebrate 
cells. Genes Cells 10: 321-32, 2005. 
 
Maybridge Chemical Company Ltd, Maybridge Chemicals Database; Trevillet, Tintangel, Cornwall 
PL34 OHW, England. http//www.maybridge.com/. 
 
McDonagh, T.; Hixon, J.; DiStefano, P. S.; Curtis, R.; Napper, A. D., Microplate filtration assay for 
nicotinamide release from NAD using a boronic acid resin. Methods 36: 346-50, 2005. 
 
Michan, S.; Sinclair, D., Sirtuins in mammals: insights into their biological function. Biochem J 404: 1-
13, 2007. 
 
Michishita, E.; Park, J. Y.; Burneskis, J. M.; Barrett, J. C.; Horikawa, I., Evolutionarily conserved and 
nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 16: 4623-35, 
2005. 
 
Min, J.; Landry, J.; Sternglanz, R.; Xu, R. M., Crystal structure of a SIR2 homolog-NAD complex. Cell 
105: 269-79, 2001. 
 
Nahhas, F.; Dryden, S. C.; Abrams, J.; Tainsky, M. A., Mutations in SIRT2 deacetylase which regulate 
enzymatic activity but not its interaction with HDAC6 and tubulin. Mol Cell Biochem 303: 221-30, 2007. 
 
Napper, A. D.; Hixon, J.; McDonagh, T.; Keavey, K.; Pons, J. F.; Barker, J.; Yau, W. T.; Amouzegh, P.; 
Flegg, A.; Hamelin, E.; Thomas, R. J.; Kates, M.; Jones, S.; Navia, M. A.; Saunders, J. O.; DiStefano, P. 
51 
 
S.; Curtis, R., Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med 
Chem 48: 8045-54, 2005. 
 
Neugebauer, R. C.; Uchiechowska, U.; Meier, R.; Hruby, H.; Valkov, V.; Verdin, E.; Sippl, W.; Jung, M., 
Structure-Activity Studies on Splitomicin Derivatives as Sirtuin Inhibitors and Computational Prediction 
of Binding Mode. J Med Chem 51: 1203-1213, 2008. 
 
Nightingale, K. P.; O'Neill, L. P.; Turner, B. M., Histone modifications: signalling receptors and potential 
elements of a heritable epigenetic code. Curr Opin Genet Dev 16: 125-36, 2006. 
 
Nogales, E., Structural insights into microtubule function. Annu Rev Biochem 69: 277-302, 2000. 
 
North, B. J.; Marshall, B. L.; Borra, M. T.; Denu, J. M.; Verdin, E., The human Sir2 ortholog, SIRT2, is 
an NAD+-dependent tubulin deacetylase. Mol Cell 11: 437-44, 2003. 
 
North, B. J.; Verdin, E., Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol 5: 224, 
2004. 
 
North, B. J.; Verdin, E., Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during 
mitosis. PLoS ONE 2: e784, 2007a. 
 
North, B. J.; Verdin, E., Mitotic regulation of SIRT2 by cyclin-dependent kinase 1-dependent 
phosphorylation. J Biol Chem 282: 19546-55, 2007b. 
 
Onyango, P.; Celic, I.; McCaffery, J. M.; Boeke, J. D.; Feinberg, A. P., SIRT3, a human SIR2 
homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc Natl Acad Sci U S A 99: 
13653-8, 2002. 
 
Ota, H.; Akishita, M.; Eto, M.; Iijima, K.; Kaneki, M.; Ouchi, Y., Sirt1 modulates premature senescence-
like phenotype in human endothelial cells. J Mol Cell Cardiol 43: 571-9, 2007. 
 
Outeiro, T. F.; Kontopoulos, E.; Altmann, S. M.; Kufareva, I.; Strathearn, K. E.; Amore, A. M.; Volk, C. 
B.; Maxwell, M. M.; Rochet, J. C.; McLean, P. J.; Young, A. B.; Abagyan, R.; Feany, M. B.; Hyman, B. 
T.; Kazantsev, A. G., Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of 
Parkinson's disease. Science 317: 516-9, 2007. 
 
Pandithage, R.; Lilischkis, R.; Harting, K.; Wolf, A.; Jedamzik, B.; Luscher-Firzlaff, J.; Vervoorts, J.; 
Lasonder, E.; Kremmer, E.; Knoll, B.; Luscher, B., The regulation of SIRT2 function by cyclin-dependent 
kinases affects cell motility. J Cell Biol 180: 915-29, 2008. 
 
Perrod, S.; Cockell, M. M.; Laroche, T.; Renauld, H.; Ducrest, A. L.; Bonnard, C.; Gasser, S. M., A 
cytosolic NAD-dependent deacetylase, Hst2p, can modulate nucleolar and telomeric silencing in yeast. 
Embo J 20: 197-209, 2001. 
 
Porcu, M.; Chiarugi, A., The emerging therapeutic potential of sirtuin-interacting drugs: from cell death 
to lifespan extension. Trends Pharmacol Sci 26: 94-103, 2005. 
 
Posakony, J.; Hirao, M.; Bedalov, A., Identification and characterization of Sir2 inhibitors through 
phenotypic assays in yeast. Comb Chem High Throughput Screen 7: 661-8, 2004a. 
 
Posakony, J.; Hirao, M.; Stevens, S.; Simon, J. A.; Bedalov, A., Inhibitors of Sir2: evaluation of 
splitomicin analogues. J Med Chem 47: 2635-44, 2004b. 
 
52 
 
Sauve, A. A.; Celic, I.; Avalos, J.; Deng, H.; Boeke, J. D.; Schramm, V. L., Chemistry of gene silencing: 
the mechanism of NAD+-dependent deacetylation reactions. Biochemistry 40: 15456-63, 2001. 
 
Sauve, A. A.; Schramm, V. L., Sir 2 regulation by nicotinamide results from switching between base 
exchange and deacetylation chemistry. Biochemistry 42: 9249-9256, 2003. 
 
Sauve, A. A.; Wolberger, C.; Schramm, V. L.; Boeke, J. D., The biochemistry of sirtuins. Annu Rev 
Biochem 75: 435-65, 2006. 
 
Schwer, B.; North, B. J.; Frye, R. A.; Ott, M.; Verdin, E., The human silent information regulator (Sir)2 
homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J Cell 
Biol 158: 647-57, 2002. 
 
Shore, D.; Squire, M.; Nasmyth, K. A., Characterization of two genes required for the position-effect 
control of yeast mating-type genes. Embo J 3: 2817-23, 1984. 
 
Smith, B. C.; Denu, J. M., Sir2 protein deacetylases: evidence for chemical intermediates and functions of 
a conserved histidine. Biochemistry 45: 272-82, 2006. 
 
Smith, B. C.; Denu, J. M., Acetyl-lysine analog peptides as mechanistic probes of protein deacetylases. J 
Biol Chem 282: 37256-65, 2007a. 
 
Smith, B. C.; Denu, J. M., Mechanism-based inhibition of sir2 deacetylases by thioacetyl-lysine Peptide. 
Biochemistry 46: 14478-86, 2007b. 
 
Smith, B. C.; Denu, J. M., Sir2 deacetylases exhibit nucleophilic participation of acetyl-lysine in NAD+ 
cleavage. J Am Chem Soc 129: 5802-3, 2007c. 
 
Smith, J. S.; Brachmann, C. B.; Celic, I.; Kenna, M. A.; Muhammad, S.; Starai, V. J.; Avalos, J. L.; 
Escalante-Semerena, J. C.; Grubmeyer, C.; Wolberger, C.; Boeke, J. D., A phylogenetically conserved 
NAD+-dependent protein deacetylase activity in the Sir2 protein family. Proc Natl Acad Sci U S A 97: 
6658-63, 2000. 
 
Southwood, C. M.; Peppi, M.; Dryden, S.; Tainsky, M. A.; Gow, A., Microtubule deacetylases, SirT2 and 
HDAC6, in the nervous system. Neurochem Res: 2006. 
 
Suzuki, K.; Koike, T., Mammalian Sir2-related protein (SIRT) 2-mediated modulation of resistance to 
axonal degeneration in slow Wallerian degeneration mice: a crucial role of tubulin deacetylation. 
Neuroscience 147: 599-612, 2007a. 
 
Suzuki, K.; Koike, T., Resveratrol abolishes resistance to axonal degeneration in slow Wallerian 
degeneration (WldS) mice: activation of SIRT2, an NAD-dependent tubulin deacetylase. Biochem 
Biophys Res Commun 359: 665-71, 2007b. 
 
Suzuki, T.; Imai, K.; Nakagawa, H.; Miyata, N., 2-Anilinobenzamides as SIRT inhibitors. 
ChemMedChem 1: 1059-62, 2006. 
 
Tang, B. L.; Chua, C. E., SIRT2, tubulin deacetylation, and oligodendroglia differentiation. Cell Motil 
Cytoskeleton 65: 179-82, 2008. 
 
Tanner, K. G.; Landry, J.; Sternglanz, R.; Denu, J. M., Silent information regulator 2 family of NAD- 
dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose. Proc Natl 
Acad Sci U S A 97: 14178-82, 2000. 
53 
 
Tanny, J. C.; Moazed, D., Coupling of histone deacetylation to NAD breakdown by the yeast silencing 
protein Sir2: Evidence for acetyl transfer from substrate to an NAD breakdown product. Proc Natl Acad 
Sci U S A 98: 415-20, 2001. 
 
Tervo, A. J.; Kyrylenko, S.; Niskanen, P.; Salminen, A.; Leppanen, J.; Nyronen, T. H.; Jarvinen, T.; Poso, 
A., An in silico approach to discovering novel inhibitors of human sirtuin type 2. J Med Chem 47: 6292-
8, 2004. 
 
Tervo, A. J.; Suuronen, T.; Kyrylenko, S.; Kuusisto, E.; Kiviranta, P. H.; Salminen, A.; Leppanen, J.; 
Poso, A., Discovering inhibitors of human sirtuin type 2: novel structural scaffolds. J Med Chem 49: 
7239-7241, 2006. 
 
Trapp, J.; Jochum, A.; Meier, R.; Saunders, L.; Marshall, B.; Kunick, C.; Verdin, E.; Goekjian, P.; Sippl, 
W.; Jung, M., Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to 
sirtuin inhibition. J Med Chem 49: 7307-16, 2006. 
 
Trapp, J.; Meier, R.; Hongwiset, D.; Kassack, M. U.; Sippl, W.; Jung, M., Structure-Activity Studies on 
Suramin Analogues as Inhibitors of NAD(+)-Dependent Histone Deacetylases (Sirtuins). ChemMedChem 
2: 1419-1431, 2007. 
 
Tripos Associates, Inc. LeadQuest Compound Library; 1699 South Hanley Road, St. Louis, MO. 
http//www.tripos.com/. 
 
Tsuchiya, M.; Dang, N.; Kerr, E. O.; Hu, D.; Steffen, K. K.; Oakes, J. A.; Kennedy, B. K.; Kaeberlein, 
M., Sirtuin-independent effects of nicotinamide on lifespan extension from calorie restriction in yeast. 
Aging Cell 5: 505-14, 2006. 
 
Turdi, S.; Li, Q.; Lopez, F. L.; Ren, J., Catalase alleviates cardiomyocyte dysfunction in diabetes: role of 
Akt, Forkhead transcriptional factor and silent information regulator 2. Life Sci 81: 895-905, 2007. 
 
Vaquero, A.; Scher, M. B.; Lee, D. H.; Sutton, A.; Cheng, H. L.; Alt, F. W.; Serrano, L.; Sternglanz, R.; 
Reinberg, D., SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes 
Dev 20: 1256-61, 2006. 
 
Voelter-Mahlknecht, S.; Ho, A. D.; Mahlknecht, U., FISH-mapping and genomic organization of the 
NAD-dependent histone deacetylase gene, Sirtuin 2 (Sirt2). Int J Oncol 27: 1187-96, 2005. 
 
Wang, F.; Nguyen, M.; Qin, F. X.; Tong, Q., SIRT2 deacetylates FOXO3a in response to oxidative stress 
and caloric restriction. Aging Cell 6: 505-14, 2007. 
 
Werner, H. B.; Kuhlmann, K.; Shen, S.; Uecker, M.; Schardt, A.; Dimova, K.; Orfaniotou, F.; 
Dhaunchak, A.; Brinkmann, B. G.; Mobius, W.; Guarente, L.; Casaccia-Bonnefil, P.; Jahn, O.; Nave, K. 
A., Proteolipid protein is required for transport of sirtuin 2 into CNS myelin. J Neurosci 27: 7717-30, 
2007. 
 
Wilson, J. M.; Le, V. Q.; Zimmerman, C.; Marmorstein, R.; Pillus, L., Nuclear export modulates the 
cytoplasmic Sir2 homologue Hst2. EMBO Rep 7: 1247-51, 2006. 
 
Zhao, K.; Chai, X.; Clements, A.; Marmorstein, R., Structure and autoregulation of the yeast Hst2 
homolog of Sir2. Nat Struct Biol 10: 864-71, 2003. 
 
 
 
54 
 
3 AIMS OF THE STUDY 
 
The aim of the study was to design and synthesize new SIRT2 inhibitors, which would 
be suitable for further studies of the biological function of SIRT2. The more specific 
aims were:       
 
1. To develop new SIRT2 inhibiting compounds with improved inhibitory activity, 
increased solubility and decreased toxicity as compared to the earlier known 
SIRT2 inhibitors. 
 
2. To search for new molecular backbones for SIRT2 inhibitors based on the 
results from molecular modelling and virtual screening. 
 
3. To study the structure-activity relationships by different replacements on the 
new SIRT2 inhibitors in collaboration with molecular modellers. 
 
4. To develop new SIRT2 inhibitors based on the peptide sequences of known 
SIRT2 substrates. 
 
5. To study the selectivity (between SIRT1 and SIRT2) of the new inhibitors in 
order to determine possible differences in their binding interactions.  
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4 GENERAL EXPERIMENTAL PROCEDURES 
 
4.1 General synthetic procedures  
This chapter describes the general synthetic procedures in this thesis. Detailed synthetic 
procedures are given in Chapters 5-8.  
All reagents and solvents obtained from commercial suppliers were used without 
further purification. When needed, the solvents were dried over 3 Å or 4 Å molecular 
sieves. Anhydrous tetrahydrofuran (THF) was prepared by drying over sodium followed 
by distillation under argon. The glassware for anhydrous conditions was dried at 140 oC 
and cooled in a desicator or under argon and the reactions were performed under argon or 
nitrogen. The light sensitive reactions were protected by aluminium foil. 
When possible, the described reactions and work-up were first monitored by thin layer 
chromatography using aluminum sheets precoated with Merck silica gel 60 F254. Samples 
were visualized by UV light, heating, or staining using potassium permanganate or 
ninhydrine in combination with heating. Purifications by flash chromatography were 
performed on J. T. Bakers silica gel for chromatography (pore size 60 Å, particle size 50 
mm), or by CombiFlash® chromatography on a commercial silica column, or by 
Chromatotron® on silica gel plates made of Merck silica gel 60 PF254-containing gypsum 
(particle size 5-40 µM).  
Peptides were synthesized on a solid phase manually or on a peptide synthesizer an 
Apex 396 DC multiple peptide synthesizer (Advanced ChemTech, Louisville, KY). 
 
4.2 Analytical procedures 
Nuclear magnetic resonance (NMR) spectroscopy. 1H and decoupled 13C NMR spectra 
were recorded on a Bruker Avance 500 spectrometer (500.1 MHz for 1H and 125.8 MHz 
for 13C, respectively) at 25 oC. The FID files were processed with TopSpin software 
(version 2.1 or older, Bruker Biospin) to obtain NMR spectra. The chemical shifts (δ) are 
expressed in ppm relative to tetrametylsilane (δ 0.00) as an internal standard.  
The N-amide bond of proline has energetically similar cis and trans isomers (rotamers). 
These rotamers have slightly different chemical shifts as described in Chapter 7. The 
minor rotamer has an integral corresponding to 30% of the integral of the major rotamer.  
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The chemical shifts of the proton resonances (1H and COSY) for the described peptides 
in Chapter 8 are presented on tables and were determined at 500.1 MHz in D2O with 
DMSO-d6 (δ 2.71) as an internal standard or in DMSO-d6 with tetrametylsilane (δ 0.00) 
as an internal standard. 13C- and attached proton test (APT)-spectra were determined at 
125.8 MHz in D2O with DMSO-d6 (δ 39.39) as an internal standard or in DMSO-d6 with 
CDCl3 (δ 79.16) as an internal standard. 
Electrospray ionization mass spectroscopy (ESI-MS). Electronspray ionization mass 
spectra were acquired by an LCQ quadrupole ion trap (Finnigan MAT, San Jose, CA), or 
LTQ linear ion trap (Thermo Fisher Scientific), or 6410 Triple Quad MS (Agilent 
Technologies) mass spectrometers with an electron spray ionization source.  
Elemental analysis. Elemental analyses were carried out on a ThermoQuest CE 
Instruments EA 1110-CHNS-O elemental analyzer. 
High pressure liquid chromatography (HPLC) purification. Peptides described in 
Chapter 8 were purified by preparative HPLC (Shimadzu LC-10Avp (Fennolab, Fenno 
Medical Oy)) on a reverse-phase C18 column (Supelcogel ODP-50, 25 cm * 21.2 mm, 5 
μm) with a linear gradient of 5-90% solvent B (0.05% acetic acid/ acetonitrile) in solvent 
A (0.05% acetic acid/ H2O) in 30 min with the flow rate 10mL/min. The peptide was 
detected by UV at λ = 215 nm. The purity of each peptide was verified by NMR.  
 
4.3 Expression of human SIRT1 and SIRT2 recombinant proteins 
Human SIRT1 cDNA (as in RefSeq NM_012238) and SIRT2 cDNA (transcript variant 
1 as in RefSeq NM_012237) were amplified by polymerase chain reaction (PCR) with 
the Advantage cDNA Polymerase Mix (Takara/Clontech for SIRT1 and BD/Clontech 
for SIRT2) using a sense primer 5'-GCGGATCCAAGATGGCGGACGAGG and an 
antisense primer 5'-GAACTATCCATCAAACAAATCATAG for SIRT1 and a sense 
primer 5´-CCGGATCCATGGCAGAGCCAGAC and an antisense primer 5´-
CAGAATTCACTGGGGTTTCTCCC for SIRT2. The primers contained recognition 
sites for BamHI and EcoRI (only SIRT2) restriction endonucleases, respectively 
(underlined). cDNA synthesized on total RNA from the WI-38 normal human lung 
fibroblast cell line (ATCC) by M-MLV Reverse Transcriptase (Promega) was used as a 
template for PCR. The PCR fragment was digested with the appropriate restriction 
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endonucleases and cloned into the BamHI-SmaI (SIRT1) or the BamHI-EcoRI (SIRT2) 
digested pGEX-2T bacterial expression vector (GE Healthcare or Amersham 
Biosciences) under the control of a Ptaq inducible promoter. The identity of inserts in 
the resulting plasmid pTe34 (pGEX2T-SIRT1) and pTe25 (pGEX2T-SIRT2) were 
verified by sequencing. The cultures of E. coli strain DH5α bearing either pTe34 or 
pTe25 were induced by 0.2 mM isopropyl-β-D-1-thiogalactopyranoside at 23°C for 4-6 
h in terrific broth rich medium with vigorous shaking in baffled Erlenmeyer flasks, and 
the soluble overexpressed recombinant proteins were affinity purified on Glutatione 
Sepharose 4B medium or GSTrapp FF colums (GE Healthcare or Amersham 
Biosciences). The size and the identity of the proteins obtained were further verified by 
SDS-PAGE analysis and protein mass spectrometry, respectively. The purified 
recombinant GST-SIRT1 and GST-SIRT2 fusion proteins showed robust protein 
deacetylase activity. Their activity was dependent on NAD+ and could be inhibited by 
nicotinamide, both of which are characteristic features attributed to mammalian SIRT1 
and SIRT2. In contrast, the control GST protein preparations obtained from unmodified 
pGEX-2T vector showed no deacetylase activity. The purified recombinant GST-SIRT1 
and GST-SIRT2 fusion proteins were stored at -80oC in 20% glycerol. 
 
4.4 In vitro assays for SIRT1 and SIRT2 activities 
The SIRT2 inhibitory activity of the synthesized compounds described in Chapter 5 were 
tested on in vitro radioactive [3H]-substrate based deacetylation assay according to the 
histone deacetylase assay kit protocol (Upstate Biotechnology). Whereas, the SIRT1 and 
SIRT2 inhibitory activities of the synthesized compounds described in Chapter 6-8 were 
tested on in vitro Fluor de Lys assay modified from the BioMol product sheet. The proper 
test system for the inhibitory activity measurements was chosen depending on the 
properties of the compounds. The optic properties of compounds described in Chapter 5 
disturbed the use of the fluorescence based assay. 
Radioactive [3H]-substrate based deacetylation assay. The α-tubulin peptide 
MPSDKTIGG was chemically acetylated with [3H]-acetic acid and a benzotriazol-1-
yloxytris-(dimethylamino)-phosphonium hexafluorophosphate (BOP) reagent. The 
labeled peptide was purified with HPLC on C18 reverse phase column. The SIRT2 
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deacetylation reaction was performed in 100 µl of HDAC buffer (15 mM Tris/HCl, pH 
7.9, 0.25 mM EDTA, 10 mM NaCl, 10% glycerol (v/v), 10 mM mercaptoethanol; 
Upstate Biotechnology) with 40 000 cpm [3H]-peptide substrate and 500 µM NAD+ 
(Sigma) as cosubstrate. The SIRT2 inhibitors were diluted in DMSO. The concentration 
of DMSO was always kept equal in every test tube at 5%. The reaction was started by 
adding 1 µg of recombinant GST-SIRT2 and incubated at 37oC overnight. The released 
[3H]-acetyl product was extracted with ethyl acetate and quantified with a liquid 
scintillation counter (Wallac WinSpectral 1414 or Wallac 1450 MicroBeta). Radioactive 
[3H]-substrate based deacetylation assay has been tested beforehand to be linear up to 
12 h. Each experiment was repeated at least three times. The IC50 values were based on 
a 6-point dose-response determination (200 µM, 100 µM, 50 µM, 25 µM, 10 µM, and 0 
µM) where more necessary dose points were added between the critical concentrations 
depending on the inhibitor and calculated using Origin graphic program version 6.0 
(MicroCal Software, Inc.).  
Fluor de Lys fluorescence based assay. Fluor de Lys-SIRT1 peptide substrate is 
based on residues 379-382 of p53 (Arg-His-Lys-Lys(Ac)) and Fluor de Lys-SIRT2 
peptide substrate is based on residues 317-320 of p53 (Gln-Pro-Lys-Lys(Ac)) (BioMol 
KI-177 for SIRT1 and KI-179 for SIRT2). The assays were carried out using Fluor de 
Lys-acetylated peptide substrate (50 µM for SIRT1 and 125 µM for SIRT2), 500 µM 
NAD+ (N6522, Sigma), recombinant GST-SIRT1/2-enzyme and SIRT1/2-assay buffer 
(HDAC assay buffer, KI-143, supplemented with 1 mg/ml BSA, A3803, Sigma). The 
buffer, SIRT1/2-enzyme, NAD+ and DMSO/compounds in DMSO (2.5 µl in 50 µl total 
volume of reaction mixture; DMSO from Sigma, D2650) for testing were preincubated 
for 5 min at room temperature (rt). The reaction was started by adding the substrate, and 
the reaction mixture was incubated for 1 h (SIRT1) or 3 h (SIRT2) at 37°C. After that 
Fluor de Lys-developer (KI-176) plus 2 mM nicotinamide in 50 µl were added and 
incubation was continued for 45 min at 37°C. Fluorescence readings were obtained 
using the VictorTM 1420 Multilabel Counter (Wallac, Finland) with excitation 
wavelength 360 nm and emission 460 nm. The fluorescent signal indicated 
deacetylation of Lys382 (SIRT1) or Lys320 (SIRT2). 
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The IC50 values of the fluorescence based assay were based on a 8-point dose-
response determination (1000 µM, 100 µM, 10 µM, 1 µM, 0.1 µM, 0.01 µM, 0.001 µM, 
and 0.0001 µM) where more necessary dose points were added between the critical 
concentrations depending on the inhibitor. Each experiment was repeated at least three 
times and calculated using GraphPad Prism Software version 4.03 (© 1992-2005 
GraphPad Software, Inc.).  
60 
 
5 N,N'-BISBENZYLIDENEBENZENE-1,4-DIAMINES AND N,N'-
BISBENZYLIDENENAPHTHALENE-1,4-DIAMINES AS SIRT2 INHIBITORS* 
 
 
Abstract: A series of N,N'-bisbenzylidenebenzene-1,4-diamine and N,N'-
bisbenzylidenenaphthalene-1,4-diamine derivatives were synthesized as inhibitors for 
SIRT2. The design of the new compounds was based on two earlier reported hits from 
molecular modelling and virtual screening. The most potent compound was N,N'-bis(2-
hydroxybenzylidene)benzene-1,4-diamine, which was equipotent with the most potent 
hit compound and well-known SIRT2 inhibitor sirtinol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Adapted with permission from: Kiviranta PH, Leppänen J, Kyrylenko S, Salo HS, 
Lahtela-Kakkonen M, Tervo AJ, Wittekindt C, Suuronen T, Kuusisto E, Järvinen T, 
Salminen A, Poso A, Wallén EAA. N,N'-Bisbenzylidenebenzene-1,4-diamines and 
N,N'-Bisbenzylidenenaphthalene-1,4-diamines as Sirtuin Type 2 (SIRT2) Inhibitors. 
Journal of Medicinal Chemistry 49: 7907-11, 2006. Copyright 2008 American 
Chemical Society. 
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5.1 Introduction 
The starting point for the design and synthesis of the novel SIRT2 inhibitors described 
in this chapter was the Maybridge database search done by Tervo et al. (2004). The 
crystal structure of SIRT2 was utilized in molecular modelling and virtual screening 
(Finnin et al. 2001). A search in the Maybridge database resulted in five compounds 
that showed inhibitory activity for SIRT2. The IC50 values of the two most potent 
compounds 1,4-bis[2-(4-hydroxyphenyl)ethylamino]anthraquinone 1 (Maybridge 
JFD00244) and 5-(2-{[1-(3,5-dichloro-2-hydroxyphenyl)meth-(E)-ylidene]amino} 
phenylsulfanylmethyl)-4-hydroxymethyl-2-methylpyridin-3-ol 2 (Maybridge CD04097) 
were 56.7 and 74.3 µM, respectively (figure 5.1) (Tervo et al. 2004). 
  
 
Figure 5.1. Two most potent compounds found by molecular modelling and virtual 
screening (Tervo et al. 2004). 
 
The two compounds in figure 5.1 have structural backbones that are new for SIRT2 
inhibitors. The common structural features in the two compounds in figure 5.1 are that 
both have a central aromatic group, which is disubstituted with two tethered hydroxy 
substituted aromatic groups. The phenolic hydroxyl groups of sirtinol and its analogues 
have been reported to be important for inhibitory activity (Grozinger et al. 2001, Mai et 
al. 2005). The symmetrical 1 is 1,4-disubstituted. The length of the tether is three atoms, 
and the tether is connected via a nitrogen atom with an amine function. The 
unsymmetrical 2 is 1,2-disubstituted. The lengths of the tethers are two atoms, and the 
tethers are connected via a nitrogen atom with an imine function or via a sulfur atom 
with a sulfide function. 
A new series of SIRT2 inhibitors with the general structure in figure 5.2 was designed 
based on 1 and 2. In the new series of compounds the central aromatic group is a 1,4-
disubstituted benzene or naphthalene, the tether length is two atoms, it is connected via 
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a nitrogen atom with an amine or an imine function, and the tethered aromatic group is a 
phenyl group. The choice of a naphthalene group as the central aromatic group was also 
supported by the fact that naphthalene derivatives have been reported to inhibit yeast 
Sir2 inhibitors (Posakony et al. 2004). 
  
 
Figure 5.2. General structures of the new series of compounds. 
 
5.2 Synthetic chemistry  
The compounds were synthesized via imine formation from benzene-1,4-diamine (or 
naphthalene-1,4-diamine) and the appropriate aldehyde (scheme 5.1). The imine groups 
of the compounds from benzene-1,4-diamine were reduced with sodium borohydride. 
 
 
Scheme 5.1. Synthetic route for 3 and 4. Reagents: (a) EtOH; (b) NaBH4, 1,2-
dimethoxyethane. 
 
5.3 Results and discussion 
The structures of the compounds and their SIRT2 inhibitory activities at 200 µM are 
presented in tables 5.1, 5.2, and 5.3, respectively. The IC50 values are presented for the 
most potent compounds in table 5.4. The unsubstituted N,N'-bisbenzylidenebenzene-
1,4-diamine (3a) gave an inhibition of 35% at 200 µM (table 5.1). This shows that the 
new backbone is a moderate inhibitor of SIRT2, even when it is unsubstituted. N,N'-
Bis(2-hydroxybenzylidene)benzene-1,4-diamine (3b) was the most potent inhibitor in 
the series with hydroxy substituted derivatives 3b–e. Compound 3b had an inhibition of 
56% at 200 µM and an IC50 of 58.4 µM (table 5.4). The methoxy substituted derivatives 
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3f–g had lower inhibitory activities than the unsubstituted compound 3a. The inhibitory 
activity of the para-substituted methoxy derivative 3h was not determined because of 
an extremely low solubility. 
The reduction of the imine function of 3a–d resulted in 4a–d (table 5.2). Compounds 
4a–d are more flexible than 3a–d because of deletion of the conjugated double bond 
between the aromatic rings. Compounds 4a–d had a slightly lower inhibitory activity 
compared to compounds 3a–d, the ortho-hydroxy substituted 4b being again the most 
potent with an inhibition of 27% at 200 µM.  
The unsubstituted N,N'-bisbenzylidenenaphthalene-1,4-diamine (5a) resulted in an 
inhibition of 18% at 200 µM (table 5.3). This showed that the replacement of the central 
benzene group by a naphthalene group lowered the inhibitory activity slightly. 
However, all hydroxy substituted derivatives 5b–d show improved inhibitory activities 
compared to the unsubstituted 5a. Interestingly, the meta- and para-substituted 5c and 
5d are the most potent compounds in this series with inhibitions of 53% and 64% at 200 
µM, respectively, and IC50 of 195.9 and 137.4 µM, respectively. The methoxy 
substituted 5e–g are equipotent with the unsubstituted 5a, but slightly less potent than 
the most potent hydroxy substituted 5c–d.  
When the compounds from tables 5.1, 5.2, and 5.3 are compared, it can be seen that 
the most potent compounds 3b, 5c, and 5d have almost equal percentages of inhibition 
at 200 µM (56%, 53%, and 64%, respectively). Since these are only three compounds 
that have over 50% inhibition at 200 µM, their IC50 values were determined. In the in 
vitro assay for SIRT2 activity, poor solubility of several compounds was observed when 
determining the inhibition at higher concentrations. This was an additional reason not to 
determine the IC50 of compounds with less than 50% inhibition at 200 µM.  The most 
potent compound 3b has an IC50 of 58.4 µM which is equipotent with the most potent 
hit compound 1 and sirtinol (table 5.4). N,N'-Bis(3-hydroxybenzylidene)naphthalene-
1,4-diamine (5c) and N,N'-bis(4-hydroxybenzylidene)naphthalene-1,4-diamine (5d) 
gave slightly higher IC50 values of 195.9 µM and 137.4 µM, respectively. The 
difference can be explained by the relatively large standard deviation of the percent 
inhibition of 3b (56% ± 8.2%) at 200 µM. The Hill slopes of the inhibition curves did 
not deviate significantly from unity. 
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An interesting observation regarding the conformation of the compounds is that the 
most potent compound 3b has hydroxyl groups in the ortho-positions, which create 
strong intramolecular hydrogen bonds with the electronegative nitrogen atoms. The 
hydrogen bonds have an effect on the NMR spectra of 3b, giving a more downfield 
chemical shift of the hydroxyl groups (in DMSO-d6). The same chemical shift cannot be 
observed for N,N'-bis(2-hydroxybenzyl)benzene-1,4-diamine (4b) but can again be 
observed for N,N'-bis(2-hydroxybenzylidene)naphthalene-1,4-diamine (5b).  
 
Table 5.1. Structures of 3 and their % inhibition at 200 µM.  
3  
Compd R1 R2 R3 Inhibition at 200 µM ± SD,a % 
3a H H H 35 ± 1.4 
3b OH H H 56 ± 8.2 
3c H OH H 12 ± 0.9 
3d H H OH 22 ± 1.6 
3e H OH OH 13 ± 0.2 
3f OCH3 H H 13 ± 0.5 
3g H OCH3 H 20 ± 1.2 
3h H H OCH3 ND b 
a SD = standard deviation. b The product did not dissolve. 
 
Table 5.2. Structures of 4 and their % inhibition at 200 µM.  
4  
Compd R1 R2 R3 Inhibition at 200 µM ± SD,a % 
4a H H H 21 ± 1.7 
4b OH H H 27 ± 2.4 
4c H OH H  8 ± 0.4 
4d H H OH 14 ± 0.5 
a SD = standard deviation.  
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Table 5.3. Structures of 5 and their % inhibition at 200 µM.  
5  
Compd R1 R2 R3 Inhibition at 200 µM ± SD,a % 
5a H H H 18 ± 0.5 
5b OH H H 38 ± 1.2 
5c H OH H 53 ± 1.9  
5d H H OH 64 ± 1.9 
5e OCH3 H H 34 ± 1.2 
5f H OCH3 H 20 ± 0.2 
5g H H OCH3 17 ± 1.1 
a SD = standard deviation.  
 
Table 5.4. IC50 values of the most potent compounds.  
Compd IC50 ± SD,a µmol/L 
sirtinol 45.1 ± 1.6 
1 56.7 ± 4.2 
2 74.3 ± 1.5 
3b 58.4 ± 14.8 
5c 195.9 ± 10.9 
5d 137.4 ± 8.8 
a SD = standard deviation  
 
To elucidate the binding possibilities of the SIRT2 inhibitors, compounds 3b, 5c, 5d, 
sirtinol, 1, and 2 were docked to the crystal structure of SIRT2 (figure 5.3) (Finnin et al. 
2001). Compounds 3b, 5c, and 5d were able to adopt binding modes that shared 
similarities with the best ranked binding conformation of sirtinol. Compound 2 was also 
able to bind in the same area of the cavity. However, a similar binding pose for 1 could 
not be found in these dockings. 
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Figure 5.3. Compounds 3b (iceblue), 5c (blue), 5d (purple), and sirtinol (orange) 
docked into the putative binding site of SIRT2 (Humphrey et al. 1996).  
 
5.4 Conclusions 
A series of N,N'-bisbenzylidenebenzene-1,4-diamine and N,N'-bisbenzylidene-
naphthalene-1,4-diamine derivatives were synthesized and tested in vitro against SIRT2.  
The most potent compounds were 3b, 5c, and 5d with IC50 of 58.4 µM, 195.9 µM, and 
137.4 µM, respectively. Compound 3b was equipotent with the well-known SIRT2 
inhibitor sirtinol. These compounds have a new type of backbone for SIRT2 inhibitors. 
The new compounds were able to adopt binding modes that shared similarities with the 
best ranked binding conformation of sirtinol. The synthesized compounds are 
symmetrical, but there is no requirement of symmetry in the binding site of the SIRT2 
inhibitor, and therefore, the next study will involve the synthesis of unsymmetrical 
compounds.  
 
5.5 Synthetic procedures and analytical data 
General method for synthesis of imines 3a–3h and 5a–5g. The reactions were 
performed in 1–7 mmol scale. The appropriate aldehyde (2.0–2.5 eq) was added to a 
solution 1,4-phenylenediamine (1.0 eq) in anhydrous ethanol (20 mL) or naphthalene-
1,4-diamine (1.0 eq) in anhydrous tetrahydrofuran (except 5c in anhydrous acetonitrile) 
(20 mL). The reaction was performed under an argon or nitrogen atmosphere and 
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protected from light. Benzene-1,4-diamine reactions were stirred at rt or refluxed if 
necessary. The product precipitated out of the reaction mixture. Naphthalene-1,4-
diamine reactions were stirred overnight at rt. Afterwards, the solvent was evaporated 
and the residue was washed with methanol.  
N,N'-Bisbenzylidenebenzene-1,4-diamine (3a). Benzaldehyde (2.1 eq), rt for 1 h 
(77%). 1H NMR: δ = 7.33 (s, 4 H), 7.48–7.51 (m, 6 H), 7.93–7.95 (m, 4 H), 8.63 (s, 
2H). 13C NMR: δ = 121.62, 128.39, 128.42, 131.00, 135.91, 149.16, 159.39. ESI-MS 
(m/z): 285 [M + H]+. Anal. (C20H16N2) C, H, N. 
N,N'-Bis(2-hydroxybenzylidene)benzene-1,4-diamine (3b). 2-Hydroxybenz-
aldehyde (2.0 eq),  reflux for 3.5 h (99%). The 1H NMR parameters were solved 
precisely with the PERCHit iterator (Laatikainen et al. 1996) using PERCH software 
version 2004 (Pearch Solutions Ltd, Kuopio, Finland). 1H NMR: δ = 6.977 (d, 3J = 8.28 
Hz, 4J = 1.06 Hz, 2 H), 6.995 (t, 3J = 7.70, 7.27 Hz, 4J = 1.06 Hz, 2 H), 7.426 (td, 3J = 
8.28, 7.27 Hz, 4J = 1.72 Hz, 2 H), 7.545 (s, 4 H), 7.673 (dd, 3J = 7.70 Hz, 4J= 1.72 Hz, 2 
H), 9.030 (s, 2 H), 13.068 (s, 2 OH). 13C NMR: δ = 116.51, 119.08, 119.27, 122.44, 
132.47, 133.22, 146.58, 160.23, 163.05. ESI-MS (m/z): 317 [M + H]+. Anal. 
(C20H16N2O2) C, H, N. 
N,N'-Bis(3-Hydroxybenzylidene)benzene-1,4-diamine (3c). 3-Hydroxybenz-
aldehyde (2.0 eq), rt for 3 days (80%). 1H NMR: δ = 6.92–6.94 (m, 2 H), 7.30–7.38 (m, 
10 H), 8.58 (s, 2 H), 9.66 (s, 2 OH). 13C NMR: δ = 114.18, 118.62, 120.20, 121.88, 
129.70, 137.39, 149.18, 157.62, 159.89. ESI-MS (m/z): 317 [M + H]+. Anal. 
(C20H16N2O2·0.2H2O) C, H, N. 
N,N'-Bis(4-Hydroxybenzylidene)benzene-1,4-diamine (3d). 4-Hydroxybenz-
aldehyde (2.0 eq), reflux for 3.0 h (56%). 1H NMR: δ = 6.89 (d, 3J = 8.5 Hz, 4 H), 7.26 
(s, 4 H), 7.78 (d, 3J = 8.5 Hz, 4 H), 8.51 (s, 2 H), 10.08 (s, 2 OH). 13C NMR: δ = 115.56, 
121.66, 127.56, 130.50, 149.22, 158.98, 160.48. ESI-MS (m/z): 317 [M + H]+. Anal. 
(C20H16N2O2·0.5H2O) C, H, N. 
N,N'-Bis(3,4-Dihydroxybenzylidene)benzene-1,4-diamine (3e). 3,4-Dihydroxy-
benzaldehyde (2.1 eq), rt overnight (63%). 1H NMR (DMSO-d6:CD3OD): δ = 6.87 (d, 
3J = 8.1 Hz, 2 H), 7.21 (dd, 3J = 8.1 Hz, 4J = 1.8 Hz, 2 H), 7.25 (s, 4 H), 7.44–7.45 (m, 2 
H), 8.42 (s, 2 H). 13C NMR (DMSO-d6:CD3OD): δ = 114.33, 115.63, 121.94, 122.88, 
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128.50, 145.76, 149.34, 149.56, 159.51. ESI-MS (m/z): 349 [M + H]+. Anal. 
(C20H16N2O4·0.3H2O) C, H, N. 
N,N'-Bis(2-Methoxybenzylidene)benzene-1,4-diamine (3f). 2-Methoxybenz-
aldehyde (2.0 eq), rt for 2 h (95%). 1H NMR: δ = 3.92 (s, 6 H), 7.03–7.06 (m, 2 H), 
7.08–7.10 (m, 2 H), 7.26 (s, 4 H), 7.46–7.50 (m, 2 H), 8.06–8.08 (m, 2 H), 8.92 (s, 2 H). 
13C NMR: δ = 55.57, 111.53, 120.51, 121.73, 124.12, 126.86, 132.78, 149.93, 154.75, 
159.23. ESI-MS (m/z): 345 [M + H]+. Anal. (C22H20N2O2·0.1H2O) C, H, N. 
N,N'-Bis(3-Methoxybenzylidene)benzene-1,4-diamine (3g). 3-Methoxybenz-
aldehyde (2.5 eq), reflux 2 h (65%). 1H NMR: δ = 3.84 (s, 6H), 7.10–7.12 (m, 2 H), 
7.36 (s, 4 H), 7.43–7.46 (m, 2 H), 7.52–7.53 (m, 4 H) 8.66 (s, 2 H). 13C NMR: δ = 
55.14, 112.48, 117.58, 121.54, 121.94, 129.80, 137.47, 149.16, 159.49, 159.82. ESI-MS 
(m/z): 345 [M + H]+. Anal. (C22H20N2O2·0.1H2O) C, H, N. 
N,N'-Bis(4-Methoxybenzylidene)benzene-1,4-diamine (3h). 4-Methoxybenz-
aldehyde (3.7 eq), rt for 3 h (97%). 1H NMR: δ = 3.89 (s, 6 H), 7.00 (d, 3J = 8.5 Hz, 4 
H), 7.25 (s, 4 H), 7.86 (d, 3J = 8.5 Hz, 4 H), 8.47 (s, 2 H). 13C NMR: δ = 55.69, 114.72, 
122.32, 129.97, 130.92, 150.20, 159.32, 162.70. ESI-MS (m/z): 345 [M + H]+. Anal. 
(C22H20N2O2·0.1H2O) C, H, N. 
N,N'-Bisbenzylidenenaphthalene-1,4-diamine (5a). Benzaldehyde (2.1 eq), rt 
overnight (64%). 1H NMR: δ = 7.31 (s, 2 H), 7.57–7.62 (m, 8 H), 8.08–8.10 (m, 4 H), 
8.37–8.39 (m, 2 H), 8.76 (s, 2 H). 13C NMR: δ = 113.18, 123.45, 126.21, 128.76, 
128.76, 128.92, 131.42, 136.21, 146.18, 159.97. ESI-MS (m/z): 335 [M + H]+. Anal. 
(C24H18N2·0.2H2O) C, H, N. 
N,N'-Bis(2-Hydroxybenzylidene)naphthalene-1,4-diamine (5b). 2-Hydroxybenz-
aldehyde (2.1 eq), rt overnight (51%). 1H NMR: δ = 7.03–7.06 (m, 4 H), 7.46–7.50 (s, 2 
H), 7.55 (s, 2 H), 7.70–7.72 (m, 2 H), 7.77–7.79 (m, 2 H), 8.25–8.27 (m, 2 H), 9.07 (s, 2 
H), 13.06 (s, 2 OH). 13C NMR: δ = 114.73, 116.57, 119.24, 119.73, 122.79, 127.14, 
128.23, 132.37, 133.47, 144.16, 160.22, 163.46. ESI-MS (m/z): 367 [M + H]+. Anal. 
(C24H18N2O2) C, H, N. 
N,N'-Bis(3-Hydroxybenzylidene) naphthalene-1,4-diamine (5c). 3-Hydroxybenz-
aldehyde (2.5 eq), rt for 2.5 h (27%).1H NMR: δ = 6.98–6.99 (m, 2 H), 7.26–7.62 (m, 10 
H), 8.36 (m, 2 H), 8.68 (s, 2 H), 9.76 (s, 2 OH). 13C NMR: δ =113.32, 114.41, 118.87, 
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120.46, 123.48, 126.30, 128.96, 129.90, 137.62, 146.16, 157.79, 160.15. ESI-MS (m/z): 
367 [M + H]+. Anal. (C24H18N2O2·1.1H2O) C, H, N. 
N,N'-Bis(4-Hydroxybenzylidene)naphthalene-1,4-diamine (5d). 4-Hydroxybenz-
aldehyde (2.1 eq), rt for 3 days (47%). 1H NMR: δ = 6.94 (d, 3J = 8.2 Hz, 4 H), 7.21 (s, 
2 H), 7.56–7.58 (m, 2 H), 7.92 (d, 3J = 8.2 Hz, 4 H), 8.35–8.37 (m, 2 H), 8.60 (s, 2 H), 
10.16 (s, 2 OH). 13C NMR: δ = 113.10, 115.74, 123.57, 126.03, 127.87, 129.08, 130.83, 
146.23, 159.25, 160.72. ESI-MS (m/z): 367 [M + H]+. Anal. (C24H18N2O2·1.7CH3OH) 
C, H, N. CH3OH was observed in the NMR spectra. 
N,N'-Bis(2-Methoxybenzylidene)naphthalene-1,4-diamine (5e). 2-Methoxybenz-
aldehyde (2.0 eq), rt overnight (18%). 1H NMR: δ = 3.93 (s, 6 H), 7.12–7.15 (m, 2 H), 
7.19–7.21 (m, 4 H), 7.55–7.60 (m, 4 H), 8.23–8.25 (m, 2 H), 8.33–8.35 (m, 2 H), 9.00 
(s, 2 H). 13C NMR: δ = 55.74, 111.98, 113.20, 120.70, 123.45, 124.07, 126.19, 127.10, 
128.88, 133.16, 146.79, 154.85, 159.25. ESI-MS (m/z): 395 [M + H]+. Anal. 
(C26H22N2O2·0.1H2O) C, H, N.  
N,N'-Bis(3-Methoxybenzylidene)naphthalene-1,4-diamine (5f). 3-Methoxybenz-
aldehyde (2.4 eq), rt for 2 days (60%). 1H NMR (CDCl3): δ = 3.92 (s, 6 H), 7.07–7.09 
(m, 4 H), 7.40–7.44 (m, 2 H), 7.52–7.53 (m, 2 H), 7.56–7.58 (m, 2 H), 7.67–7.67 (m, 2 
H), 8.38–8.40 (m, 2 H), 8.56 (s, 2 H). 13C NMR (CDCl3): δ = 55.46, 112.17, 112.84, 
118.16, 122.40, 123.86, 126.30, 129.27, 129.78, 137.92, 147.27, 159.52, 160.05. ESI-
MS (m/z): 395 [M + H]+. Anal. (C26H22N2O2·0.3H2O) C, H, N. 
N,N'-Bis(4-Methoxybenzylidene)naphthalene-1,4-diamine (5g). 4-Methoxybenz-
aldehyde (2.0 eq), rt for 2 days (66%). 1H NMR: δ = 3.89 (s, 6 H), 7.07 (d, 3J = 8.4 Hz, 
4 H), 7.19 (s, 2 H), 7.54–7.56 (m, 2 H), 8.00 (d, 3J = 8.4 Hz, 4 H), 8.36–8.38 (m, 2 H), 
8.62 (s, 2 H). 13C NMR: δ = 55.30, 112.86, 114.16, 123.58, 125.90, 129.11, 129.27, 
130.50, 146.37, 158.72, 161.99. ESI-MS (m/z): 395 [M + H]+. Anal. 
(C26H22N2O2·0.1H2O) C, H, N. 
General method for reduction of imines for amines. The reactions were performed 
in 1–7 mmol scale. NaBH4 (2.8–3.6 eq) was added carefully in small portions to a 
solution of 3 (1.0 eq) in 1,2-dimethoxyethane. After the mixture was stirred at rt for 1.5 
h to 3 days, a catalytic amount of glacial acetic acid was added according to Krebs and 
Jørgensen (2002). The mixture was stirred at rt overnight. The solution was acidified to 
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pH 1–2 using concentrated HCl and stirred for another 10 min. Then the solution was 
brought to pH 7 using a 2 M NaOH (Lubben and Feringa 1994). The mixture was 
diluted with water and extracted with CH2Cl2. The organic layer was washed once with 
water, dried over Na2SO4 and evaporated. The product was purified by flash 
chromatography.       
N,N'-Bisbenzylbenzene-1,4-diamine (4a). 3a and NaBH4 (2.8 eq), 2 h (43%). 1H 
NMR: δ = 4.13 (d, 3J = 5.3 Hz, 4 H), 5.31 (t, 3J = 5.3 Hz, 2 NH), 6.40 (s, 4 H), 7.17–
7.20 (m, 2 H), 7.26–7.29 (m, 4 H), 7.32-7.33 (m, 4 H). 13C NMR: δ = 47.68, 113.71, 
126.30, 127.15, 128.01, 140.03, 140.85. ESI-MS (m/z): 289 [M + H]+. Anal. 
(C20H20N2·0.1H2O) C, H, N. 
N,N'-Bis(2-Hydroxybenzyl)benzene-1,4-diamine (4b). 3b and NaBH4 (2.8 eq), 1.5 
h (30%). 1H NMR: δ = 4.08 (s, 4 H), 5.18 (s, 2 NH), 6.44 (s, 4 H), 6.69–6.72 (m, 2 H), 
6.76–6.78 (m, 2 H), 6.99–7.03 (m, 2 H), 7.17–7.18 (m, 2 H), 9.47 (s, 2 OH). 13C NMR: 
δ = 43.10, 114.00, 114.70, 118.59, 126.01, 127.20, 128.28, 140.15, 155.03. ESI-MS 
(m/z): 321 [M + H]+. Anal. (C20H20N2O2·0.3H2O) C, H, N. 
N,N'-Bis(3-Hydroxybenzyl)benzene-1,4-diamine (4c). 3c and NaBH4 (2.8 eq), 3 
days (36%). 1H NMR: δ = 4.04–4.05 (m, 4 H), 5.26 (s, 2 NH), 6.38 (s, 4 H), 6.57–6.58 
(m, 2 H), 6.73–6.74 (m, 4 H), 7.04–7.07 (m, 2 H), 9.18–9.20 (m, 2 OH). 13C NMR: δ = 
47.70, 113.32, 113.67, 113.93, 117.73, 128.97, 140.10, 142.46, 157.29. ESI-MS (m/z): 
321 [M + H]+. Anal. (C20H20N2O2·0.1H2O) C, H, N. 
N,N'-Bis(4-Hydroxybenzyl)benzene-1,4-diamine (4d). 3d and NaBH4 (3.6 eq), 3 h 
(71%). 1H NMR (D2O): δ = 4.04 (s, 4 H), 6.60 (d, 3J = 8.4 Hz, 4 H), 6.80 (s, 4H), 7.12 
(d, 3J = 8.4 Hz, 4 H). 13C NMR (D2O): δ = 51.97, 119.97, 121.52, 127.67, 132.58, 
144.12, 168.03. ESI-MS (m/z): 321 [M + H]+. Anal. (C20H16N2O2·2.2H2O) C, H, N.   
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6 N-(3-(4-HYDROXYPHENYL)-PROPENOYL)-AMINO ACID TRYPTAMIDES 
AS SIRT2 INHIBITORS* 
 
 
Abstract: A series of N-(3-(4-hydroxyphenyl)-propenoyl)-amino acid tryptamides was 
based on a previously reported new SIRT2 inhibitor from our group, and it was 
designed to study if the molecular size of the compound could be reduced. The most 
potent compounds, N-(3-(4-hydroxyphenyl)-propenoyl)-2-aminoisobutyric acid 
tryptamide and N-(3-(4-hydroxyphenyl)-propenoyl)-L-alanine tryptamide, were 
equipotent, 30% smaller in molecular weight, and slightly more selective 
(SIRT2/SIRT1) than the parent compound. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Adapted with permission from: Kiviranta PH, Leppänen J, Rinne VM, Suuronen T, 
Kyrylenko O, Kyrylenko S, Kuusisto E, Tervo AJ, Järvinen T, Salminen A, Poso A, 
Wallén EAA.  N-(3-(4-Hydroxyphenyl)-propenoyl)-amino acid tryptamides as SIRT2 
inhibitors. Bioorganic & Medicinal Chemistry Letters 17: 2448-51, 2007. Copyright 
2008 Elsevier Ltd. 
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6.1 Introduction 
Second virtual screening by Tervo et al. (2006) was based on our previous results 
(Kiviranta et al. 2006, Tervo et al. 2004) and examinations of favorable interactions 
between the known SIRT2 inhibitors and the putative binding site. Compound 1 (Tripos 
360702) was the most potent compound that was found in the study and it had an IC50 
value of 51 µM (figure 6.1) (Tervo et al. 2006). Compound 1 had a structural scaffold 
that was new for SIRT2 inhibitors. The desire to reduce the molecular size of compound 
1 was the main focus for this study. The design of the new series of compounds was 
based on simplifying the structure and finding the essential parts of 1 for the inhibitory 
activity.  
 
 
Figure 6.1. Compound 1 found by modelling and virtual screening (Tervo et al. 2006).  
 
6.2 Synthetic chemistry 
The synthetic routes are presented in scheme 6.1. The starting material 4-amino-1-Boc-
piperidine-4-carboxylic acid was synthesized as described in the literature (Wysong et 
al. 1996). The amino groups of the amino acids 2a, 2b, and 2f were protected with 
benzyl chloroformate. The carboxylic acid was activated with ethyl chloroformate (Sam 
et al. 1959) or DCC (Jung and Gervay 1991) and reacted with tryptamine. N-Cbz-L-
alanine N-hydroxysuccinimide ester and N-Cbz-D-alanine N-hydroxysuccinimide ester 
was reacted with tryptamine in THF (Garcia-Lopez et al. 1987). The Cbz group was 
removed with palladium (10%) on activated charcoal and either ammoniumformate or 
hydrogen gas in methanol. 3-(4-Benzyloxyphenyl)-propenoic acid (5) was synthesized 
from 3-(4-hydroxyphenyl)-propenoic acid and benzyl bromide. 3-(4-Acetoxyphenyl)-
propenoic acid (6) was synthesized by protecting the phenolic hydroxyl group with 
acetic anhydride. Compound 7a was synthesized from 5 with ethyl chloroformate 
activation followed by reaction with 4a (Sam et al. 1959). The removal of the Boc 
group yielded compound 7a. To form compound 7b, compound 5 was reacted with 
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oxalyl chloride to form the acid chloride which was reacted with 2-amino-isobutyric 
acid tryptamide (4b) in DCM. Compounds 7d, (S)-7e, (R)-7e, and 7g were also 
synthesized from 6 with ethyl chloroformate activation followed by reaction with the 
appropriate amino acid tryptamide (Sam et al. 1959). Compound 7f was synthesized 
from compound 6 with DCC activation followed by reaction with glycine tryptamide 
(4f). The acetyl protection group was hydrolyzed with K2CO3 in water and methanol or 
CH3ONa in methanol, yielding compounds 7d–7g. In most amide formation reactions 
ethyl chloroformate activation was found to be the most successful method. The yields 
of the amide bond formations varied between 14–93%.  
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Scheme 6.1.  Reagents a) tryptamine, THF or 1—Et3N, ethyl chloroformate, DCM or THF, -20–0oC, 2—
Et3N, tryptamine or DMAP, tryptamine, DCC, CHCl3; (b) ammoniumformate, 10% Pd/C, MeOH or H2, 
10% Pd/C, MeOH; (c) 1—Et3N, ethyl chloroformate, THF or DCM, -20–0oC, 2—Et3N, 4a, or 4b, or (S)-, 
or (R)-4e, or 4g; or DMAP, 4f, DCC, DCM and 1,4-dioxane, 0oC; (d) TFA, anisole, sodium 
thiophenolate; (e) 1—5, oxalyl chloride, DMF, DCM; 2—4b, Et3N, DCM; (f) K2CO3, H2O/ MeOH, 0oC 
or 1M CH3ONa in MeOH, DCM, 0oC; (g) 1—Et3N, pivaloylchloride, DCM, 0–25oC, 2—Et3N, 2-amino-
2-methyl-propionic acid methyl ester; (h) LiOH·H2O, H2O/MeOH; (i) 1—Et3N, ethyl chloroformate, 
DCM, -20oC, 2—Et3N, tryptamine. 
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Another synthetic procedure was used for compound 7c. 3-(4-Methoxyphenyl)-
propenoic acid (8) was synthesized as described in the literature (Furniss et al. 1989). 
Compound 8 was activated with pivaloyl chloride and reacted with 2-amino-isobutyric 
acid methyl ester. The methyl ester of the obtained product 9 was hydrolyzed with 
LiOH·H2O in water and methanol. The obtained free carboxylic acid was activated with 
ethyl chloroformate and reacted with tryptamine to yield compound 7c. This synthetic 
procedure was not useful when 3-(4-hydroxyphenyl)-propenoic acid was used because 
the removal of the methyl ester would also have removed the acetyl protection group of 
the phenolic hydroxyl group. EX-527 was used as a reference compound. EX-527 was 
synthesized as described in the literature (Napper et al. 2005). 
 
6.3 Results and discussion 
The compounds and their inhibitory activities are presented in table 6.1. The inhibitory 
activities were tested in a Fluor de Lys fluorescence based assay described in Chapter 
4.4. Poor water solubility of some compounds was observed when determining the 
inhibition at higher concentrations. This was the main reason not to determine the IC50 
values of the compounds with less than 50% inhibition at 200 µM. The importance of 
the fluorine atoms for the inhibitory activity of 1 was investigated with 7a. Removal of 
the fluorine atoms did not have a significant effect on the inhibitory activity. Opening 
the piperidine ring and removing the amine functionality in the side chain by using a 2-
aminoisobutyric acid group in the middle of the structure resulted in 7b, with a 
significantly lower inhibitory activity, inhibition of 32.6% at 200 µM. Furthermore, 
removal of the phenyl group resulted in 7c, which was slightly more potent, with an 
inhibition of 55.4% at 200 µM and an IC50 of 99 µM. The structure was further 
simplified by removing the methyl group from the methoxy group, resulting in 7d. 
Compound 7d was equipotent with 1 and it showed that the chemical structure could be 
reduced in size without affecting the inhibitory activity for SIRT2. The molecular 
weight of 1 was reduced about 30%. Replacing the aminoisobutyric acid group by an L-
alanine group gave (S)-7e, which had an inhibition of 88.6% at 200 µM and an IC50 of 
47 µM. Compound (S)-7e showed also selectivity for SIRT2. However, replacing the 
aminoisobutyric acid group by a D-alanine group gave (R)-7e, with an inhibition of 
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8.5% at 200 µM. The structure was further simplified by replacing the alanine group by 
a glycine group resulting in 7f, which was less potent than a L-alanine group but more 
potent than a D-alanine group. Finally, the effect of the fluorine atom on the indole ring 
was studied with 7g. Compound 7g showed that the fluorine atom does not have a 
positive effect on the inhibitory activity since 7g had a slightly lower inhibitory activity 
compared to 7d.  
In addition, the selectivity for SIRT2 was studied (table 6.1). As earlier reported, 
SIRT2 inhibitors are also good SIRT1 inhibitors. Interestingly, compound 7d showed a 
slightly higher selectivity for SIRT2 than 1. At the concentration of 200 µM compound 
1 inhibits SIRT1 94.1% but 7d only 6.6%. Compound (S)-7e is almost as selective as 
7d.  
 
6.4 Conclusions 
In conclusion, the essential parts of compound 1 for the inhibitory activity were 
identified, and the study showed that the molecular weight of compound 1 could be 
reduced 30% while maintaining the inhibitory activity. In addition, the most potent 
compounds 7d and (S)-7e were slightly more selective for SIRT2 (SIRT2/SIRT1) than 
compound 1. 
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6.5 Synthetic procedures and analytical data 
Synthesis of 7a  
4-Amino-1-Boc-piperidine-4-carboxylic acid. The reaction had three steps and they 
were done according to Wysong et al. (1996).  
Step 1: 4-Piperidone monohydrate hydrochloride 53.55 g (348.6 mmol) and 
(NH4)2CO3 69.0 g (718.5 mmol) were dissolved in the mixture of H2O (180 mL) and 
MeOH (220 mL). NaCN 34.0 g (693.7 mmol) was dissolved in H2O (100 mL) and 
added to the well stirred mixture during 5 min. A light precipitate started to form 
immediately. The mixture was protected with a light plastic cap and stirred at rt for 3 d. 
The precipitated product was filtered and washed with H2O. After the vacuum, the 
product still contained some (NH4)2CO3. It was stirred in H2O for a couple of hours, 
filtered and dried well in the vacuum (75%).  
Step 2: Piperidine-4-spriro-5'-hydantoin 41.3 g (244.1 mmol) was dissolved in 1,2-
dimethoxyethane. The suspension was formed. Di-tert-butyl dicarbonate 275.3 g (1.26 
mol), DMAP 0.53 g (4.32 mmol) and Et3N 34.6 mL (247.9 mmol) were added. The 
mixture was stirred at rt for 3.5 h. Carbon dioxide was freed. The second portion of 
DMAP 0.53 g (4.32 mmol) was added and the mixture was stirred at rt for 6 d. The third 
portion of DMAP 0.53 g (4.32 mmol) was added and the mixture was stirred at rt 
overnight. The solvent was evaporated and the residue was dissolved in 800 mL of 
DCM. The organic phase was washed twice with 1 M HCl, once with sat. Na2CO3 aq. 
and once with sat. NaCl aq. The organic phase was dried, filtered and evaporated. The 
residue was yet first stirred in 200 mL of EtOH and evaporated until dryness. Then, it 
was stirred in the mixture of EtOH (250 mL) and H2O (750 mL). The crystals were 
filtered and washed with 200 mL of the 25% EtOH:H2O mixture and, finally, with 500 
mL of H2O. The product was dried in the vacuum for several days (86%). 1H NMR 
(CDCl3): δ = 1.47 (s, 9 H), 1.55 (s, 9 H), 1.59 (s, 9 H), 1.73–1.76 (m, 2 H), 2.64–2.70 
(m, 2 H), 3.37–3.47 (m, 2 H), 4.04–4.19 (m, 2 H). 
Step 3: 1-Boc-piperidine-4-spiro-5'-(1',3'-bis-Boc)hydantoin 34.0 g (72.4 mmol) was 
dissolved in 450 mL of 1,2-dimethoxyethane. The suspension was formed. NaOH 26.0 
g (650 mmol) was dissolved in 650 mL of H2O and added. The mixture was stirred at rt 
for 2 d. Diethyl ether 200 mL was added and the mixture was stirred for 0.5 h. The 
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phases were separated and the procedure was repeated once. The H2O phase was 
neutralized by adding first sat. HCl aq. and, then 2 M HCl until the pH was about 7–8. 
The product was crystallized during 4 d at 4 oC. The crystals were filtered, washed with 
small amount of H2O and dried in the vacuum (76%). 
4-(Cbz-amino)-1-Boc-piperidine-4-carboxylic acid (2a). 4-Amino-1-Boc-
piperidine-4-carboxylic acid 8.3 g (34.0 mmol) was dissolved in the mixture of 1,4-
dioxane:water (1:2) where 5% K2CO3 (0.36 M) was added. Benzyl chloroformate 9.7 
mL (68.0 mmol) was dissolved in a small amount of 1,4-dioxane and added to the 
mixture. The mixture was stirred at rt overnight. Afterward, diethyl ether and sat. 
NaHCO3 aq. were added. Phases were separated and the organic phase was yet 
extracted once with sat. NaHCO3 aq. The water phases were combined and made acidic 
with 2 M HCl. The product was extracted with DCM, dried and evaporated (78%). 1H 
NMR (DMSO-d6): δ = 1.39 (s, 9 H), 1.72–1.78 (m, 2 H), 1.93–1.96 (m, 2 H), 3.02 (s, 2 
H), 3.65–3.68 (m, 2 H), 5.02 (s, 2 H), 7.30–7.36 (m, 5 H), 12.51 (s, OH).  
4-(Cbz-amino)-1-Boc-piperidine-4-carboxylic acid tryptamide (3a). Compound 2a 
3.78 g (10.0 mmol) and Et3N 1.53 mL (11.0 mmol) were dissolved in dry DCM and 
ethyl chloroformate 0.95 mL (10.0 mmol) was added to active the carboxylic acid 
during 1 h at -20oC under argon. Another portion of Et3N 1.53 mL (11.0 mmol) and 
tryptamine 1.76 g (11.0 mmol) were added and then the mixture was stirred under argon 
at rt overnight (Sam et al. 1959). The mixture was washed twice with 30% citric acid, 
once with sat. NaCl aq. and once with sat. NaHCO3 aq. The organic phase was dried 
and evaporated. The product was purified by chromatography on silica gel using manual 
gradient of ethyl acetate:petrol ether (50:50→66:33→100:0) (67%). 1H NMR (CDCl3): 
δ = 1.44 (s, 9 H), 1.90 (s, 2 H), 2.00–2.04 (m, 2 H), 2.92 (s, 2 H), 2.98–3.03 (m, 2 H), 
3.56–3.57 (m, 2 H), 3.77–3.80 (m, 2 H), 5.01 (s, 2 H), 6.95 (s, 1 H), 7.09–7.12 (m, 1 H), 
7.17–7.20 (m, 1 H), 7.30–7.37 (m, 6 H), 7.57–7.59 (m, 1 H). 
4-Amino-1-Boc-piperidine-4-carbocylic acid tryptamide (4a). Compound 3a 6.63 
g (12.7 mmol) was dissolved in dry MeOH and ammoniumformate 2.45 g (38.8 mmol) 
and 10% Pd/C 0.47 g (4.37 mmol) were added. The mixture was stirred under argon at 
the rt for 3 h and, then, it was filtered through Celite and the solvent was evaporated. 
The residue was dissolved in DCM and washed with sat. Na2CO3 aq. The organic phase 
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was dried and evaporated (89%). 1H NMR (CD3OD): δ = 1.28–1.31 (m, 2 H), 1.45 (s, 9 
H), 1.90–1.96 (m, 2 H), 2.96 (t, 3J = 7.1 Hz, 2 H), 3.15 (s, 2 H), 3.50 (t, 3J = 7.1 Hz, 2 
H), 3.73–3.77 (m, 2 H), 6.98–7.01 (m, 1 H), 7.07–7.09 (m, 2 H), 7.32–7.33 (m, 1 H), 
7.56–7.57 (m, 1 H). 
3-(4-Benzyloxyphenyl)-propenoic acid (5). 3-(4-Hydroxyphenyl)-propenoic acid 4.0 
g (24.4 mmol) was dissolved in EtOH 120 mL and KOH 6.83 g (121.8 mmol) was 
dissolved in water 80 mL. These mixtures were combined. Benzyl bromide 5.79 mL 
(48.7 mmol) was dissolved in EtOH 40.0 mL and added slowly to the mixture through 
the dropping funnel. The mixture was stirred at rt for 3 d. The mixture was poured into 
ice-water and acidified with 3 M HCl. The product precipitated out the solution. The 
product was filtered, washed with water and recrystallized from hot toluene (41%). 1H 
NMR (DMSO-d6): δ =  5.15 (s, 2 H), 6.37 (d, 3J = 16.0 Hz, 1 H), 7.04 (d, 3J = 8.8 Hz, 2 
H), 7.32–7.35 (m, 1 H), 7.38–7.41 (m, 2 H), 7.44–7.46 (m, 2 H), 7.54 (d, 3J = 16.0 Hz, 1 
H), 7.62 (d, 3J = 8.7 Hz, 2 H), 12.19 (s, OH). 
4-(3-(4-Benzyloxyphenyl)-propenoyl-amino)-1-Boc-piperidine-4-carboxylic acid 
tryptamide. Compound 5 0.50 g (1.96 mmol) and Et3N 0.30 mL (2.16 mmol) were 
dissolved in dry THF. Ethyl chloroformate 0.21 mL (2.16 mmol) was added to active 
the carboxylic acid during 1 h at -20oC under argon. Another portion of Et3N 0.30 mL 
(2.16 mmol) and 4a 0.76 g (1.96 mmol) were added and then the mixture was stirred 
under argon at the rt for 3 d (Sam et al. 1959). The solvents were evaporated and the 
residue was dissolved in DCM and washed twice with 30% citric acid, once with sat. 
NaCl aq. and twice with sat. NaHCO3 aq. The organic phase was dried and evaporated. 
The product was recrystallized from MeOH (41%). 1H NMR (CD3OD): δ = 1.46 (s, 9 
H), 1.94–1.98 (m, 2 H), 2.04–2.07 (m, 2 H), 2.94 (t, 3J = 7.1 Hz, 2 H), 3.07–3.12 (m, 2 
H), 3.50 (t, 3J = 7.2 Hz, 2 H), 3.79–3.82 (m, 2 H), 6.55–6.58 (m, 1 H), 6.96–6.99 (m, 1 
H), 7.02–7.07 (m, 4 H), 7.26–7.28 (m, 1 H), 7.31–7.33 (m, 1 H), 7.36–7.39 (m, 2 H), 
7.43–7.46 (m, 3 H), 7.50–7.52 (m, 2 H), 7.55–7.57 (m, 1 H). 
4-(3-(4-Benzyloxyphenyl)-propenoyl-amino)-piperidine-4-carboxylic acid 
tryptamide (7a). 4-(3-(4-Benzyloxyphenyl)-propenoyl-amino)-1-Boc-piperidine-4-
carboxylic acid tryptamide 0.45 g (0.72 mmol) was dissolved in DCM (10 mL). 
Methoxybenzol 0.20 mL (1.84 mmol) and sodium thiophenolate 0.02 g (0.11 mmol) 
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were added to the solution (Guerlavais et al. 2003). Trifluoroacetic acid 2 ml (0.03 
mmol) was added at -20oC. Because the reaction did not proceed, the -20oC bath was 
changed to the 0oC bath. The reaction was completed in 1 h. The solvents were 
evaporated and the residue was dissolved in diethyl ether. The product precipitated out 
of the solution. The product was yet dissolved in ethyl acetate and washed twice with 
NaHCO3 (5%), dried and evaporated. The product was purified by Chromatotron® on 
silica gel using MeOH:NH4OH (98:2) and recrystallized from acetone (8%). 1H NMR 
(CD3OD): δ = 1.96–2.01 (m, 2 H), 2.05–2.07 (m, 2 H), 2.75–2.81 (m, 2 H), 2.86–2.90 
(m, 2 H), 2.94 (t, 3J = 7.2 Hz, 2 H), 3.51 (t, 3J = 7.2 Hz, 2 H), 5.12 (s, 2 H), 6.56–6.59 
(m, 1 H), 6.96–7.06 (m, 5 H), 7.26–7.32 (m, 2 H), 7.36–7.38 (m, 2 H), 7.42–7.45 (m, 3 
H), 7.50–7.51 (m, 2 H), 7.55–7.57 (m, 1 H). 13C NMR (CD3OD): δ = 26.12, 33.40, 
41.44, 42.37, 59.72, 71.10, 112.22, 113.51, 116.35, 119.32, 119.41, 119.59, 122.29, 
123.62, 128.59, 128.74, 129.00, 129.16, 129.56, 130.57, 138.16, 138.37, 141.91, 
161.75, 168.64, 176.25. ESI-MS (m/z): 523 [M + H]+. Anal. (C32H34N4O3·0.1H2O) C, 
H, N. 
Synthesis of 7b  
2-(Cbz-amino)-isobutyric acid (2b) was prepared from 2-amino-2-methyl-propionic 
acid 3.0 g (29 mmol) and benzyl chloroformate 8.3 mL (58 mmol) according to the 
syntheses of 2a. The product was used directly for the following coupling reaction. 1H 
NMR ((CD3)2CO): δ = 1.52 (s, 6 H), 5.04 (s, 2 H), 6.54 (s, NH), 7.27–7.37 (m, 5 H), 
10.91 (s, OH).  
2-(Cbz-amino)-isobutyric acid tryptamide (3b) was prepared from acid 2b 1.5 g 
(6.32 mmol) and tryptamine 1.11 g (6.95 mmol) using  ethyl chloroformate 0.60 mL 
(6.32 mmol) and two portions of Et3N 1.9 mL (13 mmol) in dry DCM according to the 
syntheses of 3a (Sam et al. 1959). The mixture was washed twice with 30% citric acid, 
once with sat. NaCl aq. and twice with sat. NaHCO3 aq. Some of the product was 
already crystallized during citric acid wash. The organic phase was dried and 
evaporated. The product was recrystallized from ethyl acetate and hexane (49%). 1H 
NMR (CDCl3): δ = 1.46 (s, 6 H), 2.93–2.96 (m, 2 H), 3.56–3.60 (m, 2 H), 5.04 (s, 2 H), 
6.97 (s, 1 H), 7.10–7.13 (m, 1 H), 7.18–7.21 (m, 1 H), 7.32–7.37 (m, 5 H), 7.59–7.61 
(m, 1 H), 7.88 (s, 1 H).  
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2-Amino-isobutyric acid tryptamide (4b) was prepared from compound 3b 1.2 g 
(3.1 mmol) using ammoniumformate 0.58 g (9.3 mmol) and 10% Pd/C 0.10 g (1.0 
mmol) according to the syntheses of 4a. The mixture was stirred overnight (98%). 1H 
NMR (CD3OD): δ = 1.25 (s, 6 H), 2.96 (t, 3J = 7.2 Hz, 2 H), 3.49 (t, 3J = 7.2 Hz, 2 H), 
6.98–7.01 (m, 1 H), 7.06–7.10 (m, 2 H), 7.32–7.33 (m, 1 H), 7.57–7.58 (m, 1 H).  
3-(4-Benzyloxyphenyl)-propenoic acid chloride. Compound 5 0.31 g (1.22 mmol) 
was dissolved in dry DCM and a couple of drops DMF was added as a catalyser. Oxalyl 
chloride 0.47 mL (5.38 mmol) was added carefully to the mixture. The mixture was 
stirred at rt for 2.5 h, the solvent was evaporated and the product was dried well in the 
vacuum. The product was used immediately without further purification.   
2-(3-(4-Benzyloxyphenyl)-propenoyl-amino)-isobutyric acid tryptamide (7b). 
Compound 4b 0.3 g (1.22 mmol) was dissolved in dry DCM and Et3N 0.19 mL (1.35 
mmol) was added. 3-(4-Benzyloxyphenyl)-propenoic acid chloride was dissolved in dry 
DCM and added to the mixture. The mixture was stirred under argon at rt overnight. 
The mixture was washed twice with 30% citric acid, once with sat. NaCl aq. and twice 
with sat. NaHCO3 aq. The solvent was dried and evaporated. The product was purified 
by the chromatography on silica gel twice using ethyl acetate and recrystallized from 
ethyl acetate (14%). 1H NMR (CD3OD): δ = 1.48 (s, 6 H), 2.95 (t, 3J = 7.2 Hz, 2 H), 
3.50 (t, 3J = 7.3 Hz, 2 H), 5.12 (s, 2 H), 6.44–6.48 (m, 1 H), 6.98–7.07 (m, 5 H), 7.27–
7.32 (m, 2 H), 7.36–7.44 (m, 5 H), 7.48–7.50 (m, 2 H), 7.57–7.59 (m, 1 H). 13C NMR 
(CD3OD): δ = 25.67, 25.89, 41.38, 57.79, 70.92, 112.08, 112.99, 116.11, 119.16, 
119.41, 119.45, 122.15, 123.42, 128.36, 128.47, 128.82, 128.95, 129.38, 130.31, 
137.85, 138.01, 141.41, 161.38, 168.07, 176.73. ESI-MS (m/z): 482 [M + H]+. Anal. 
(C30H31N3O3·0.1H2O) C, H, N. 
Synthesis of 7c 
2-Amino-isobutyric acid methyl ester. 2-Amino-2-methyl-propionic acid 3.0 g (29 
mmol) was dissolved in MeOH. Thionylchloride 5.3 mL (73 mmol) was dissolved in 
MeOH and added to the mixture through the dropping funnel at 0oC. The mixture was 
refluxed for 3 h, evaporated and dried in the vacuum. The product was used without 
further purification. 1H NMR (DMSO-d6): δ = 1.51 (s, 6 H), 3.76 (s, 3 H), 8.80 (s, 
NH2). 
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3-(4-Methoxyphenyl)-propenoic acid (8). 4-Methoxy-benzaldehyde 0.89 mL (7.3 
mmol), malonic acid 1.7 g (16 mmol), pyridine 3.3 mL (41 mmol) and a couple of drops 
piperidine were refluxed for 1 h. After cooling the reaction flask, the mixture was 
poured into excess water containing enough HCl (>1.3 mL (41 mmol)) to combine with 
the pyridine, filtered and washed with H2O. The product was recrystallized three times 
from EtOH (31%) (Furniss et al. 1989). 1H NMR (DMSO-d6): δ = 3.78 (s, 3 H), 6.37 (d, 
3J = 16.0 Hz, 1 H), 6.96 (d, 3J = 8.7 Hz, 2 H), 7.55 (d, 3J = 16.0 Hz, 1 H), 7.62 (d, 3J = 
8.7 Hz, 2 H), 12.2 (s, OH).  
2-(3-(4-Methoxyphenyl)-propenoyl-amino)-isobutyric acid methyl ester (9). Acid 
8 2.5 g (14 mmol) and Et3N 2.1 mL (15 mmol) were dissolved in DCM. 
Pivaloylchloride 1.7 mL (14 mmol) was dissolved in DCM and added to the mixture 
through the dropping funnel at 0oC. The mixture was stirred for 1 h. Another portion of 
Et3N 2.1 mL (15 mmol) was added. 2-Amino-isobutyric acid methyl ester 1.6 g (14 
mmol) was dissolved in DCM and added to the mixture at rt. The mixture was stirred 
for 4 h. The mixture was washed twice with 30% citric acid, once with sat. NaCl aq. and 
twice with sat. NaHCO3 aq. The solvent was dried and evaporated. The product was 
purified by chromatography on silica column using manual gradient of DCM:MeOH 
(99:1→98:2) (43%). 1H NMR (CDCl3): δ = 1.63 (s, 6 H), 3.78 (s, 3 H), 3.83 (s, 3 H), 
6.17 (s, NH), 6.27 (d, 3J = 15.6 Hz, 1 H), 6.88 (d, 3J = 8.8 Hz, 2 H), 7.44 (d, 3J = 8.7 Hz, 
2 H), 7.55 (d, 3J = 15.6 Hz, 1 H). 
2-(3-(4-Methoxyphenyl)-propenoyl-amino)-isobutyric acid. Ester 9 1.7 g (6.0 
mmol) was dissolved in the mixture of MeOH 72 mL and LiOH·H2O 1.5 g (36 mmol) 
in H2O 24 mL. The mixture was stirred at rt for 5 h. MeOH was evaporated and more 
H2O was added. The mixture was washed twice with diethyl ether and, then the water 
phase was made acidic with 3 M HCl. The product started to precipitate when it was 
extracted from H2O to diethyl ether. The diethyl ether phase was evaporated (87%). 1H 
NMR (CDCl3): δ = 1.64 (s, 6 H), 3.82 (s, 3 H), 6.37 (d, 3J = 15.5 Hz, 1 H), 6.87 (d, 3J = 
8.7 Hz, 2 H), 7.45 (d, 3J = 8.7 Hz, 2 H), 7.61 (d, 3J = 15.6 Hz, 1 H). 
2-(3-(4-Methoxyphenyl)-propenoyl-amino)-isobutyric acid tryptamide (7c) was 
prepared from 2-(3-(4-methoxyphenyl)-propenoyl-amino)-isobutyric acid 1.4 g (5.2 
mmol) and tryptamine 0.84 g (5.2 mmol) using ethyl chloroformate 0.50 mL (5.2 mmol) 
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and two portions of Et3N 1.6 mL (12 mmol) in dry DCM according to the syntheses of 
4a. The mixture was stirred at rt for 2 d (Sam et al. 1959). EtOH was added to clarify 
the mixture before it was washed twice with 30% citric acid, once with sat. NaCl aq. 
and twice with sat. NaHCO3 aq. The organic phase was evaporated and the product was 
purified by chromatography on silica column using manual gradient of DCM:MeOH 
(99:1→98:2→97:3) (27%). 1H NMR ((CD3)2CO): δ = 1.53 (s, 6 H), 2.93 (t, 3J = 7.2 Hz, 
2 H), 3.50 (q, 3J = 6.8 Hz, 2 H), 3.83 (s, 3 H), 6.56–6.59 (m, 1 H), 6.95–7.01 (m, 3 H), 
7.05–7.08 (m, 1 H), 7.17 (s, 1 H), 7.34–7.37 (m, 3 H), 7.44–7.47 (m, 1 H), 7.51–7.53 
(m, 2 H), 7.60–7.61 (m, 1 H), 9.96 (s, NH). 13C NMR ((CD3)2CO): δ = 25.74, 26.23, 
41.01, 55.70, 57.74, 112.07, 112.12, 113.48, 115.14, 119.35, 119.37, 120.91, 122.04, 
123.40, 123.56, 128.84, 130.06, 139.96, 161.18, 165.97, 174.99. ESI-MS (m/z): 406 [M 
+ H]+. Anal. (C24H27N3O3·0.1H2O) C, H, N. 
Synthesis of 7d  
3-(4-Acetoxyphenyl)-propenoic acid (6). 3-(4-Hydroxyphenyl)-propenoic acid 13 g 
(80 mmol) was dissolved in pyridine and acetic anhydride 19 mL (200 mmol) was 
added. The mixture was stirred at rt overnight. The mixture was poured into the ice-
water (100 mL) and made acidic with 3 M HCl. The precipitated product was filtered 
and washed with water and diethyl ether (86%). 1H NMR (CD3OD): δ = 2.28 (s, 3 H), 
6.44–6.48 (m, 1 H), 7.16–7.18 (m, 2 H), 7.65–7.68 (m, 3 H).  
2-(3-(4-Acetoxyphenyl)-propenoyl-amino)-isobutyric acid tryptamide was 
prepared from compound 6 0.77 g (3.7 mmol) and compound 4b 0.91 g (3.7 mmol) 
using ethyl chloroformate 0.35 mL (3.7 mmol) and two portions of Et3N 1.1 mL (8.2 
mmol) in dry THF according to the syntheses of 3a (Sam et al. 1959). The solvent was 
evaporated. The residues was dissolved in DCM and washed twice with 30% citric acid, 
once with sat. NaCl aq. and twice with sat. NaHCO3 aq. The organic phase was dried 
and evaporated. The product was purified twice by chromatography on silica column 
using manual gradients of ethyl acetate:MeOH (95:5→90:10→0:100) and DCM:MeOH 
(97:3→95:5) (93%). 1H NMR (CD3OD): δ = 1.49 (s, 6 H), 2.30 (s, 3 H), 2.95–2.98 (m, 
2 H), 3.50–3.53 (m, 2 H), 6.53–6.56 (m, 1 H), 6.98–7.01 (m, 1 H), 7.05–7.08 (m, 2 H), 
7.12–7.14 (m, 2 H), 7.28–7.30 (m, 1 H), 7.44–7.48 (m, 1 H), 7.56–7.59 (m, 3 H).  
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2-(3-(4-Hydroxyphenyl)-propenoyl-amino)-isobutyric acid tryptamide (7d). 2-(3-
(4-Acetoxyphenyl)-propenoyl-amino)-isobutyric acid tryptamide 0.80 g (1.9 mmol) was 
dissolved in the mixture of H2O (20 mL) and MeOH (20 mL) at 0oC. K2CO3 0.28 g (20 
mmol) was added. Compound was dissolved fully when more MeOH (20 mL) was 
added. The mixture was stirred 10 min on an ice bath and, then overnight at rt. Next 
day, MeOH was evaporated and the residue was dissolved in DCM and a small amount 
of concentrated NaCl and stirred for a while. The phases were separated and the water 
phase was yet extracted once with the mixture of CHCl3 and EtOH (1:1). The product 
was purified twice by chromatography on silica column using first only ethyl acetate 
and then manual gradient of ethyl acetate and petrol ether (50:50→80:20→100:0) 
(41%). 1H NMR ((CD3)2CO): δ = 1.55 (s, 6 H), 2.93–2.96 (m, 2 H), 3.50–3.54 (m, 2 H), 
6.49–6.52 (m, 1 H), 6.85–6.87 (m, 2 H), 6.97–7.00 (m, 1 H), 7.04–7.08 (m, 1 H), 7.14–
7.14 (m, 1 H), 7.32–7.34 (m, 1 H), 7.39–7.47 (m, 5 H), 7.58–7.60 (m, 1 H), 8.88 (s, 
OH), 9.93 (s, NH). 13C NMR ((CD3)2CO): δ = 25.79, 26.20, 41.04, 57.72, 112.12, 
113.41, 116.63, 119.33, 119.35, 120.00, 122.02, 123.56, 127.73, 129.58, 130.24, 
137.74, 140.41, 159.84, 166.26, 175.18. ESI-MS (m/z): 392 [M + H]+. Anal. 
(C23H25N3O3·0.3H2O) C, H, N. 
Synthesis of (S)-7e 
N-Cbz-L-Alanine tryptamide ((S)-3e). The reaction was done according to Garcia-
López et al. (1987). N-Cbz-L-Alanine N-hydroxysuccinimide ester 1.2 g (3.8 mmol) 
and tryptamine 0.93 g (5.6 mmol) were reacted in dry THF under argon at rt overnight. 
The solvent was evaporated and the residue was dissolved in DCM and washed twice 
with 30% citric acid, once with sat. NaCl aq. and twice sat. NaHCO3 aq. DCM was 
dried and evaporated. The product was purified by CombiFlash® chromatography on 
siliga column using DCM:MeOH (99:1) (78%). 1H NMR (DMSO-d6): δ = 1.19 (d, 3J = 
7.2 Hz, 3 H), 2.82 (t, 3J = 7.3 Hz. 2 H), 3.28–3.38 (m, 2 H), 3.99–4.05 (m, 1 H), 4.99–
5.07 (m, 2 H), 6.96–6.99 (m, 1 H), 7.05–7.08 (m, 1 H), 7.14 (s, 1 H), 7.31–7.38 (m, 6 
H), 7.54–7.55 (m, 1 H), 7.92–7.94 (m, 1 NH), 10.80 (s, NH). 
L-Alanine tryptamide ((S)-4e). Compound (S)-3e 1.1 g (3.0 mmol) was dissolved in 
dry MeOH and 10% Pd/C 0.11 g (1.0 mmol) was added. Hydrogen gas was led into the 
reaction flask from the hydrogen balloon at rt for 1 h. The mixture was filtered through 
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Celite and the solvent was evaporated (98%). 1H NMR (DMSO-d6): δ = 1.10 (d, 3J = 6.9 
Hz, 3 H), 2.82 (t, 3J = 7.4 Hz, 2 H), 3.20–3.24 (m, 1 H), 3.32–3.37 (m, 2 H), 6.96–6.99 
(m, 1 H), 7.04–7.08 (m, 1 H), 7.14–7.15 (m, 1 H), 7.32–7.34 (m, 1 H), 7.54–7.56 (m, 1 
H), 7.87–7.98 (m, 1 NH), 10.80 (s, NH). 
N-(3-(4-Acetoxyphenyl)-propenoyl)-L-alanine tryptamide was prepared from acid 
6 0.56 g (2.7 mmol) and compound (S)-4e 0.66 g (2.9 mmol) using ethyl chloroformate 
0.26 mL (2.7 mmol) and two portions of Et3N 0.82 mL (6.0 mmol) in dry THF 
according to the syntheses of 3a (Sam et al. 1959). The carboxylic acid activation was 
done at 0oC. THF was evaporated and the residue was dissolved in DCM and washed 
with 30% citric acid, sat. NaCl aq. and sat. NaHCO3 aq. The organic phase was dried 
and evaporated (47%). 1H NMR (DMSO-d6): δ = 1.25 (d, 3J = 7.1 Hz, 3 H), 2.28 (s, 3 
H), 2.84 (t, 3J = 7.4 Hz, 2 H), 3.34–3.38 (m, 2 H), 4.38–4.44 (m, 1 H), 6.74–6.77 (m, 1 
H), 6.96–6.99 (m, 1 H), 7.04–7.07 (m, 1 H), 7.15–7.19 (m, 3 H), 7.33–7.34 (m, 1 H), 
7.43–7.46 (m, 1 H), 7.54–7.56 (m, 1 H), 7.60–7.62 (m, 2 H), 8.08–8.10 (m, NH), 8.26–
8.28 (m, NH), 10.80 (s, NH). 
N-(3-(4-Hydroxyphenyl)-propenoyl)-L-alanine tryptamide ((S)-7e). N-(3-(4-
Acetoxyphenyl)-propenoyl)-L-alanine tryptamide 0.53 g (1.3 mmol) was dissolved in 
DCM. A small amount of MeOH was added to dissolve the substance completely. The 
reaction flask was under argon at 0oC. 2.5 mL (2.5 mmol) of 1 M CH3ONa in MeOH 
was added (Boiadjiev and Lightner 1996). Color of the mixture was immediately 
changed to yellow and the reaction was over in 5 min. DCM was evaporated and the 
residue was dissolved in MeOH and acidified with 3 M HCl. H2O was added dropwise 
to precipitate the product. The product was filtered and washed with diethyl ether and 
DCM (32%). 1H NMR (CD3OD): δ = 1.34 (d, 3J = 7.1 Hz, 3 H), 2.96 (t, 3J = 7.2 Hz, 2 
H), 3.30–3.32 (m, 2 H), 4.42 (q, 3J = 7.1 Hz, 1 H), 6.43–6.46 (m, 1 H), 6.79–6.81 (m, 2 
H), 6.97–7.00 (m, 1 H), 7.05–7.08 (m, 2 H), 7.29–7.31 (m, 1 H), 7.40–7.48 (m, 3 H), 
7.55–7.57 (m, 1 H). 13C NMR (CD3OD): δ = 18.30, 25.97, 41.18, 50.38, 112.10, 112.86, 
116.58, 117.82, 119.10, 119.50, 122.18, 123.41, 127.48, 128.47, 130.52, 137.88, 
142.28, 160.32, 168.64, 174.79. ESI-MS (m/z): 378 [M + H]+. Anal. 
(C22H23N3O3·0.3H2O) C, H, N. 
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Synthesis of (R)-7e 
N-Cbz-D-Alanine N-hydroxysuccinimide ester. (R)-2-Benzyloxycarbonyl-amino-
propionic acid 2.0 g (9.0 mmol) and N-hydroxysuccinimide 1.0 g (9.0 mmol) were 
dissolved in dry acetonitrile. DCC 1.9 g (9.0 mmol) was dissolved in dry acetonitrile 
and added to the mixture through the dropping funnel under argon at -20oC. The 
reaction was reacted overnight at -20oC. The precipitate was filtered off and the solvent 
was evaporated. The product was recrystallized from hexane and dissolved in THF. 
Urea did not dissolve in THF and it was easy to remove by filtration. The solvent was 
evaporated (57%). 1H NMR (DMSO-d6): δ = 1.45 (d, 3J = 7.3 Hz, 3 H), 2.82 (s, 4 H), 
4.53 (q, 3J = 7.2 Hz, 1 H), 5.07 (s, 2 H), 7.33–7.40 (m, 4 H), 8.08–8.09 (m, 1H).   
N-Cbz-D-Alanine tryptamide ((R)-3e) was prepared from compound N-Cbz-D-
alanine N-hydroxysuccinimide ester 1.6 g (5.1 mmol) and tryptamine 1.3 g (7.6 mmol) 
according to Garcia-López et al. (1987) and the syntheses of (S)-3e. The product was 
washed four times with 30% citric acid, once with sat. NaCl aq. and three times with 
sat. NaHCO3 aq. The product was purified by chromatography on siliga column using 
ethyl acetate (71%). 1H NMR (CD3OD): δ = 1.26–1.28 (m, 3 H), 2.92–2.94 (m, 2 H), 
3.43–3.54 (m, 2 H), 4.07–4.12 (m, 1 H), 5.03–5.10 (m, 2 H), 6.98–7.09 (m, 3 H), 7.28–
7.34 (m, 6 H), 7.55–7.56 (m, 1 H). 
D-Alanine tryptamide ((R)-4e) was prepared from (R)-3e 1.3 g (3.6 mmol) and 10% 
Pd/C 0.13 g (1.2 mmol) according to the syntheses of (S)-4e for 0.5 h. The product was 
used without further purification. 1H NMR (CD3OD): δ = 1.20 (d, 3J = 6.9 Hz, 3 H), 
2.94–2.98 (m, 2 H), 3.32–3.36 (m, 1 H), 3.45–3.54 (m, 2 H), 6.98–7.01 (m, 1 H), 7.06–
7.09 (m, 2 H), 7.31–7.33 (m, 1 H), 7.54–7.57 (m, 1 H). 
N-(3-(4-Acetoxyphenyl)-propenoyl)-D-alanine tryptamide was prepared from acid 
6 0.77 g (3.7 mmol) and (R)-4e 0.86 g (3.7 mmol) using ethyl chloroformate 0.36 mL 
(3.7 mmol) and two portions of Et3N 1.1 mL (8.2 mmol) in THF according to the 
syntheses of 3a (Sam et al. 1959). The carboxylic acid activation was done at 0oC. THF 
was evaporated and the residue was dissolved in DCM and washed four times with 30% 
citric acid, once with sat. NaCl aq. and three times with sat. NaHCO3 aq. The organic 
phase was dried and the most of the DCM was evaporated. The product started to 
precipitate out of the solvent during the evaporation. It was filtered and washed with 
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DCM. The filtrate was evaporated and more product was recrystallized from DCM 
(40%). 1H NMR (CD3OD): δ = 1.34 (d, 3J = 7.2 Hz, 3 H), 2.28 (s, 3 H), 2.96 (t, 3J = 7.3 
Hz, 2 H), 3.46–3.55 (m, 2 H), 4.43 (q, 3J = 7.1 Hz, 1 H), 6.59–6.63 (m, 1 H), 6.97–7.00 
(m, 1 H), 7.04–7.07 (m, 2 H), 7.13–7.15 (m, 2 H), 7.29–7.31 (m, 1 H), 7.51–7.60 (m, 4 
H). 
N-(3-(4-Hydroxyphenyl)-propenoyl)-D-alanine tryptamide ((R)-7e). N-(3-(4-
acetoxyphenyl)-propenoyl)-D-alanine tryptamide 0.51 g (1.2 mmol) was dissolved in 
MeOH. The reaction flask was under argon at 0oC. 2.4 mL (2.4 mmol) of 1 M CH3ONa 
in MeOH was added slowly (Boiadjiev and Lightner 1996). Color of the mixture was 
immediately changed to yellow and the reaction was over in 15 min. Most of the MeOH 
was evaporated and the residue was acidified with 3 M HCl. H2O was added drop wise 
to precipitate the product. The product was filtered and washed with H2O (75%). 1H 
NMR (CD3OD): δ = 1.34 (d, 3J = 7.2 Hz, 3 H), 2.96 (t, 3J = 7.1 Hz, 2 H), 3.45-3.56 (m, 
2 H), 4.42 (k, 3J = 7.1 Hz, 1 H), 6.43–6.46 (m, 1 H), 6.79–6.81 (m, 2 H), 6.97–7.01 (m, 
1 H), 7.05–7.08 (m, 2 H), 7.30–7.31 (m, 1 H), 7.41–7.43 (m, 2 H), 7.45–7.48 (m, 1 H), 
7.55–7.57 (m, 1 H). 13C NMR (CD3OD): δ = 18.37, 26.13, 41.35, 50.61, 112.21, 113.06, 
116.72, 118.00, 119.24, 119.61, 122.30, 123.54, 127.66, 128.70, 130.67, 138.11, 
142.39, 160.59, 168.84, 175.04. ESI-MS (m/z): 378 [M + H]+. Anal. 
(C22H23N3O3·0.4H2O) C, H, N. 
Synthesis of 7f 
N-Cbz-Glycine (2f) was prepared from glycine 2.0 g (27 mmol) and benzyl 
chloroformate 9.1 g (7.6 mmol) according to the syntheses of 2b. The product was used 
directly for the following coupling reaction.  
N-Cbz-Glycine tryptamide (3f). Compound 2f 1.5 g (7.2 mmol), tryptamine 1.2g 
(7.2 mmol) and DMAP 0.09g (0.72 mmol) were dissolved in dry CHCl3. After 2 min 
the mixture was precipitated. DCC 1.9 g (9.3 mmol) was dissolved in CHCl3 and added 
to the reaction flask under argon at 0oC (Jung and Gervay 1991). The mixture dissolved 
again while it was refluxed for a couple of hours. The mixture was filtered through 
Celite and the solvent was evaporated (18%). 1H NMR (CD3OD): δ = 2.94 (t, 3J = 7.2 
Hz, 2 H), 3.49 (t, 3J = 7.2 Hz, 2 H), 3.73 (s, 2 H), 5.09 (s, 2 H), 6.98–7.01 (m, 1 H), 
7.06–7.09 (m, 2 H), 7.29–7.35 (m, 6 H), 7.55–7.56 (m, 1 H). 
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Glycine tryptamide (4f) was prepared from compound 3f 0.46 g (1.3 mmol) using 
10% Pd/C 0.05 g (0.43 mmol) according to the syntheses of (S)-4e (99%). 1H NMR 
(CD3OD): δ = 2.96–2.99 (m, 2 H), 3.55–3.57 (m, 2 H), 3.83 (s, 2 H), 6.98–7.03 (m, 1 
H), 7.06–7.09 (m, 2 H), 7.32–7.33 (m, 1 H), 7.55–7.57 (m, 1 H). 
N-(3-(4-Acetoxyphenyl)-propenoyl)-glycine tryptamide. Compound 6 0.26 g (1.29 
mmol), compound 4f 0.27 g (1.29 mmol) and DMAP 0.02 g (0.16 mmol) were 
dissolved in dry DCM. DCC 0.35 g (1.69 mmol) was dissolved in DCM and added to 
the reaction flask under argon at 0oC (Jung and Gervay 1991). The reaction was 
proceeded only a little during 3 d. 1,4-Dioxane was added to improve the solubility. 
Also, more DCC 0.60 g (2.9 mmol) was added. Next day, the mixture was filtered 
through Celite and the solvent was evaporated. The product was purified by 
CombiFlash® chromatography on siliga column using manual gradient of DCM:MeOH 
(99:1→20:80) (23%). 1H NMR (CDCl3:CD3OD): δ = 2.25 (s, 3 H), 2.91 (t, 3J = 6.9 Hz, 
2 H), 3.51 (t, 3J = 6.9 Hz, 2 H), 3.84 (s, 2 H), 6.33–6.37 (m, 1 H), 6.98–7.10 (m, 5 H), 
7.26–7.29 (m, 2 H), 7.45–7.52 (m, 4 H). 
N-(3-(4-Hydroxyphenyl)-propenoyl)-glycine tryptamide (7f) was prepared from N-
(3-(4-acetoxyphenyl)-propenoyl)-glycine tryptamide 0.12 g (0.30 mmol) using 0.59 mL 
(0.59 mmol) of 1 M CH3ONa in MeOH according to the syntheses of (S)-7e (82%) 
(Boiadjiev and Lightner 1996). 1H NMR (CD3OD): δ = 2.97 (t, 3J = 7.2 Hz, 2 H), 3.53 
(t, 3J = 7.3 Hz, 2 H), 3.92 (s, 2 H), 6.41–6.44 (m, 1 H), 6.80–6.82 (m, 2 H), 6.99–7.02 
(m, 1 H), 7.06–7.09 (m, 2 H), 7.31–7.32 (m, 1 H), 7.41–7.43 (m, 2 H), 7.47–7.50 (m, 1 
H), 7.55–7.57 (m, 1 H). 13C NMR (CD3OD): δ = 25.96, 41.21, 43.70, 112.10, 112.81, 
116.56, 117.64, 119.02, 119.50, 122.17, 123.34, 127.38, 128.42, 130.51, 137.83, 
142.37, 160.30, 169.33, 171.28. ESI-MS (m/z): 364 [M + H]+. Anal. (C21H21N3O3) C, 
H, N. 
Synthesis of 7g 
2-(Cbz-amino)-isobutyric acid 5-fluorotryptamide (3g) was prepared from acid 2b 
0.33 g (1.4 mmol) and 5-fluorotryptamine hydrochloride 0.50 g (2.3 mmol), which was 
made basic with Et3N, using ethyl chloroformate 0.16 mL (1.7 mmol) and two portions 
of Et3N 0.50 mL (3.6 mmol) in dry THF according to the syntheses of 3a. The 
carboxylic acid activation was done at 0oC (Sam et al. 1959). The solvents were 
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evaporated and the residue was dissolved in DCM. The mixture was washed twice with 
30% citric acid, once with sat. NaCl aq. and three times with sat. NaHCO3 aq. The 
organic phase was dried, filtered and evaporated (60%). 1H NMR (CD3OD): δ = 1.41 (s, 
6 H), 2.86–2.89 (m, 2 H), 3.44 (s, 2 H), 5.01 (s, 2 H), 6.82–6.86 (m, 1 H), 7.11 (s, 1 H), 
7.20–7.33 (m, 7 H). 
2-Amino-isobutyric acid 5-fluorotryptamide (4g) was prepared from compound 3g 
0.56 g (1.4 mmol) using 10% Pd/C 0.05 g (0.46 mmol) according to the syntheses of 
(S)-4e (92%). 1H NMR (CD3OD): δ = 1.24–1.26 (m, 6 H), 2.86–2.93 (m, 2 H), 3.45–
3.48 (m, 2 H), 6.83–6.86 (m, 1 H), 7.12–7.14 (m, 1 H), 7.23–7.29 (m, 2 H). 
2-(3-(4-Acetoxyphenyl)-propenoyl-amino)-isobutyric acid 5-fluorotrypt-amide 
was prepared from acid 6 0.32 g (1.5 mmol) and compound 4g 0.34 g (1.3 mmol) using 
ethyl chloroformate 0.12 mL (1.3 mmol) and two portions of Et3N 0.20 mL (1.4 mmol) 
in THF according to the syntheses of 3a (Furniss et al. 1989, Sam et al. 1959). The 
carboxylic acid activation was done at 0oC. The reaction was stirred for 3 d. The 
product was dissolved in CHCl3/MeOH 2:1-mixture and washed as described above. 
The product was yet recrystallized from DCM (43%). 1H NMR (CD3OD): δ = 1.49 (s, 6 
H), 2.29 (s, 3 H), 2.89–2.93 (m, 2 H), 3.46–3.52 (m, 2 H), 6.56 (d, 3J = 15.8 Hz, 1 H), 
6.79–6.86 (m, 1 H), 7.12–7.14 (m, 3 H), 7.21–7.28 (m, 2 H), 7.46 (d, 3J = 15.8 Hz, 1 H), 
7.57–7.58 (m, 2 H). 
2-(3-(4-Hydroxyphenyl)-propenoyl-amino)-isobutyric acid 5-fluorotrypt-amide 
(7g) was prepared from 2-(3-(4-acetoxyphenyl)-propenoyl-amino)-isobutyric acid 5-
fluorotryptamide 0.25 g (0.56 mmol) using 1.12 mL (1.12 mmol) of 1 M CH3ONa in 
MeOH according to the syntheses of (S)-7e (95%)  (Boiadjiev and Lightner 1996). 1H 
NMR (CD3OD): δ = 1.48 (s, 6 H), 2.91 (t, 3J = 7.3 Hz, 2 H), 3.47 (t, 3J = 7.3 Hz, 2 H), 
6.40–6.44 (m, 1 H), 6.79–6.81 (m, 3 H), 7.12 (s, 1 H), 7.21–7.25 (m, 2 H), 7.39–7.42 
(m, 3 H). 13C NMR (CD3OD): δ = 25.73, 25.92, 41.35, 57.81, 103.77, 103.96, 110.15, 
110.37, 112.76, 112.83, 113.35, 116.61, 118.46, 125.48, 127.63, 130.52, 134.49, 
141.90, 157.76, 159.61, 160.35, 168.39, 176.94. ESI-MS (m/z): 410 [M + H]+. Anal. 
(C23H24FN3O3·0.1H2O) C, H, N. 
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7 CHARACTERIZATION OF THE BINDING PROPERTIES OF SIRT2 
INHIBITORS WITH A N-(3-PHENYLPROPENOYL)-GLYCINE 
TRYPTAMIDE BACKBONE * 
 
 
Abstract: SIRT2 inhibitors with a N-(3-phenylpropenoyl)-glycine tryptamide backbone 
were studied. This backbone has been developed in our group, and it is derived from a 
compound originally found by virtual screening. In addition, compounds with a smaller 
3-phenylpropenoic acid tryptamide backbone were also included in the study. The 
binding modes for the new compounds and the previously reported compounds were 
analyzed with molecular modelling methods. Based on the results, three binding modes 
A, B, and C were chosen for further characterization. The N-(3-phenylpropenoyl)-
glycine tryptamide backbone is a good backbone for SIRT2 inhibitors, and the series of 
compounds includes several potent SIRT2 inhibitors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Adapted with permission from: Kiviranta PH,# Salo HS,# Leppänen J, Rinne VM, 
Kyrylenko S, Kuusisto E, Suuronen T, Salminen A, Poso A, Lahtela-Kakkonen M, 
Wallén EAA.  Characterization of the binding properties of SIRT2 inhibitors with a N-
(3-phenylpropenoyl)-glycine tryptamide backbone. Bioorganic & Medicinal Chemistry 
16: 8054-8062, 2008. Copyright 2008 Elsevier Ltd. # Authors contributed equally to this 
work.  
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7.1 Introduction 
The first SIRT2 inhibitor with a N-(3-phenylpropenoyl)-glycine tryptamide backbone 
was compound 1, which was found by virtual screening (Tervo et al. 2006). The study 
in which the size of compound 1 was reduced resulting in a series of N-(3-(4-
hydroxyphenyl)-propenoyl)-amino acid tryptamides was described in the previous 
Chapter 6. 2-(3-(4-Hydroxyphenyl)-propenoyl-amino)-isobutyric acid tryptamide 5 and 
N-(3-(4-hydroxyphenyl)-propenoyl)-L-alanine tryptamide 6 were the most potent 
compounds of the series (figure 7.1) (Kiviranta et al. 2007). 
 
Figure 7.1. Compound 1 found by using virtual screening and its potent derivatives 5 
and 6 (Kiviranta et al. 2007, Tervo et al. 2006). 
   
In order to study the N-(3-phenylpropenoyl)-glycine tryptamide backbone, a new 
series of more modified compounds were synthesized. The modifications also included 
changes in the N-(3-phenylpropenoyl)-glycine tryptamide backbone, such as reduction 
of the double bond and replacing the indole ring by another aromatic ring. The new 
series of compounds was designed to include more variations than the earlier presented 
series of compounds. The study also included compounds with a shorter 3-
phenylpropenoic acid tryptamide backbone. 
Molecular modelling methods were used to characterize the binding and interaction 
properties of all compounds (also the previously presented N-(3-(4-hydroxyphenyl)-
propenoyl)-amino acid tryptamides 1–9). So far only a little is known about the binding 
properties of SIRT2 inhibitors. Currently there is only one experimental crystal 
structure of SIRT2 publicly available (Finnin et al. 2001). As the only published 
structure is in apo-form it does not provide any experimental data on the binding sites 
and binding modes of the small-molecule regulators. The search was concentrated on 
the active site and the cavity formations around the catalytic site. 
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7.2 Synthetic chemistry 
The new compounds 10–27 are based on a similar chemical backbone as the earlier 
presented compounds 1–9, and they were synthesized by similar methods as described in 
previous Chapter 6. A few simplified compounds without the amino acid in the middle of 
the backbone were also synthesized (compounds 28–30). General structures of the new 
compounds are described in figure 7.2. 
  
 
Figure 7.2. The general structures of new compounds 10–30.  
 
In amide formation reactions the carboxylic acid was activated either as an anhydride 
using ethyl chloroformate or pivaloyl chloride, as an acid chloride using oxalyl chloride 
or thionyl chloride, or as an N-hydroxysuccinimide ester using HOSu and DCC. The 
latter procedure was used for activation of the carboxylic acid terminal of L-alanine to 
avoid racemization (Garcia-Lopez et al. 1987). 
 
7.3 Results and discussion 
7.3.1 Inhibitory activities 
The structures of the compounds, their inhibitory activities at 200 µM and the IC50 
values for the most potent compounds are presented in tables 7.1 and 7.2, respectively.  
The inhibitory activities are compared to the results of the earlier presented compounds 
1–9. From the presented 21 new compounds, five compounds gave an inhibition of over 
50% at 200 µM (11, 12, 15, 27, and 29), and their IC50 values were determined. 
The earlier presented compounds showed that the central amino acids α-
aminoisobutyric acid and L-alanine gave equipotent compounds, whereas the central 
amino acid glycine resulted in less potent compounds. All of these central amino acids 
were also used in the new series.   
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In the first group of new compounds 10–20 the substitution of phenyl ring was varied 
and the adjacent double bond was reduced. Compounds 11, 12, and 15 gave over 50% 
inhibition at 200 µM. Compounds 11 and 12 without the substituent on the phenyl ring 
gave inhibitions of 49.5% and 59.6% at 200 µM and IC50 values of 100 µM and 109 
µM, respectively. Compound 15 with the para-fluoro substituent on the phenyl ring 
gave an inhibition of 61.3% at 200 µM and an IC50 of 105 µM. These compounds are 
not as potent as the corresponding earlier presented para-hydroxy substituted 
compounds 5 and 6, but more potent than the corresponding meta-hydroxy and meta- or 
ortho-methoxy substituted compounds 10, 13, and 14. Also a meta-nitro substituted 
compound 16 gave an equipotent inhibitory activity with compound 13.  
Replacing the central amino acid alanine by glycine gave 17 and 18, which gave the 
lower inhibitory activities, 22.7% and 24.2% at 200 µM, respectively. Reduction of the 
adjacent double bond of the phenyl group resulted in compounds 19 and 20. Increased 
flexibility decreased the inhibitory activity. These two compounds were clearly less 
potent than the corresponding compounds 11 and 5 with the double bond, respectively. 
The second group of compounds constitute of 21 and 22 where the indole ring has 
been replaced by a 3-pyridyl and a phenyl ring. These compounds gave lower inhibitory 
activities as compared to the corresponding indole ring containing compounds 5 and 12. 
The 3-pyridyl ring reduced the inhibitory activity strongly, whereas the phenyl ring only 
lowered the inhibitory activity slightly.  
The effect of a more rigid central amino acid proline was studied with compounds 23 
and 24. Compound 23 has an intermediate inhibitory activity as compared to 
compounds 12 and 17 with the central amino acids L-alanine and glycine, respectively. 
The third group of compounds constitute of 24–27, which have a benzyloxy group in 5-
position of the indole ring. The benzyloxy group did not have a significant effect on the 
inhibitory activity. Also a similar effect was observed with a methoxy group in the 5-
position of the indole ring in compound 18. However, compound 27 with a reduced 
double bond in combination with a benzyloxy group in the 5-position of the indole ring 
gave a good inhibitory activity, with an inhibition of 50.2% at 200 µM and an IC50 value 
of 86 µM. It was even slightly more potent than the corresponding compound with a 
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double bond 25 and the other reduced compounds without the benzyloxy substituents 19 
and 20. 
The fourth group of compounds 28–30 with the shorter 3-phenylpropenoic acid 
tryptamide backbone is presented in table 7.2. Interestingly, this group of relatively 
small compounds gave good inhibitory activities as compared to compounds discussed 
above. The best compound 29 gave an inhibition of 58.0% at 200 µM and an IC50 of 
173 µM.  
 
7.3.2 Binding mode prediction 
The interaction possibilities between the area around the active site and the inhibitors 
were investigated with a molecular modelling approach, which includes a combination 
of molecular dynamics and molecular docking. In the molecular modelling studies 
performed on the most potent compound belonging to the series, compound 6, brought 
out three distinct binding modes, which were used for analyzing the effects of structural 
modifications on the binding properties of the compounds. The binding modes are later 
referred as binding modes A, B, and C (figure 7.3). The structure-activity relationships 
analyses were made in the light of these three possible binding modes. 
 
 
Figure 7.3. Binding modes A, B, and C.  
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Table 7.1. SIRT2 inhibitors with N-(3-phenylpropenoyl)-glycine tryptamide backbone 
(95% confidence intervals for IC50 given in parentheses). 
Compd Structure Inhibition at 200 µM ± SD, a % IC50 (µM) b 
1c 
 
77.3 ± 4.8 51 (27–75) 
2 c 
 
79.1 ± 1.4 63 (41–96) 
3 c 
 
32.6 ± 18.2 - 
4 c 
 
55.4 ± 3.3 99 (66–150) 
5 c 
 
83.3 ± 3.7 50 (23–109) 
6 c 
 
88.6 ± 0.8 47 (28–79) 
7 c ON
H O
H
N
HO
H
NH
 
8.5 ± 6.0 - 
8 c O
N
H O
H
N
HO
NH
 
44.3 ± 10.6 - 
9 c 
 
67.5 ± 1.1 80 (53–120) 
10 
 
46.7 ± 0.1 - 
11 
 
49.5 ± 0.7 100 (71–141) 
12 
 
59.6 ± 11.3 109 (49–243) 
13 
 
45.9 ± 15.5 - 
14 
 
35.0 ± 8.5 - 
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15 
 
61.3 ± 0.5 105 (53–209) 
16 
 
42.1 ± 15.3 - 
17 
 
22.7 ± 11.9 - 
18 
 
24.2 ± 3.7 - 
19 
 
12.5 ± 1.3 - 
20 
 
19.5 ± 1.2 - 
21 
 
2.0 ± 2.8 - 
22 
 
29.6 ± 1.8 - 
23 
 
36.6 ± 8.4 - 
24 
 
29.8 ± 3.2 - 
25 
 
43.7 ± 2.7 - 
26 
 
32.9 ± 2.3 - 
27 
 
50.2 ± 1.1 86 (34–216) 
a SD, standard deviation.  
b IC50 were determined for compounds which had over 50% inhibition at 200 µM for SIRT2. 
c (Kiviranta et al. 2007) 
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Table 7.2. SIRT2 inhibitors with 3-phenylpropenoic acid tryptamide backbone (95% 
confidence intervals for IC50 given in parentheses) 
Compd Structure Inhibition at 200 µM ± SD a % IC50 (µM) b 
28 
 
44.3 ± 4.1 - 
29 
 
58.0 ± 11.1 173 (108–276) 
30 
 
44.1 ± 7.4 - 
a SD, standard deviation. b IC50 were determined for compounds which had over 50% inhibition at 200 
µM for SIRT2. 
 
7.3.3 SAR 
The differently substituted phenyl groups showed that a hydroxyl group in the para-
position of the phenyl ring had a positive effect on the inhibitory activity. Compounds 
5, 6, and 9 had an inhibition in the range 67.5–88.6% at 200 μM. In binding modes A 
and B hydrogen bonding possibilities for a hydroxyl group can be found at the end of 
the narrow channel connected to the active site of the protein. Compounds without a 
hydroxyl group in this position cannot form these interactions. In these binding modes 
any of the substituents, which compounds 10, 13, 14, and 16 have in the meta- and 
ortho-positions, do not offer any hydrogen bond interaction possibilities. Neither does 
the binding mode offer the hydrogen bond possibility for compound 4 that has a 
methoxy substituent in para-position. However, compound 4 gave an inhibition of 
55.4% at 200 μM and IC50 was 99 μM. Binding mode C also offers a hydrogen bond 
possibility for a hydroxyl group in the para-position. The same as in the binding modes 
A and B, the binding mode C does not offer additional hydrogen bonding interactions 
for structures with other substituents or substituents in other positions. 
Changes made to the central amino acids located between the amide structures had 
various effects on the inhibitory activity. Changing the alanine residue of 6 to glycine 
residue of 8 or proline residue of 23 lowered the inhibition to 40% at 200 μM. However, 
changing the alanine residue of 6 or 12 to α-aminoisobutyric acid in 5 or 11 had no 
effect on the inhibitory activity. Explanations for the effect of such small changes could 
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not be easily found based on the binding modes. The proline residue could restrict 
forming of low energy conformations, which would allow favorable interactions with 
the protein. In the case of the glycine residue the inhibitory activity could be affected by 
the increased conformational flexibility. As the flexibility increases the binding process 
has larger negative effect on the entropic term of the binding free energy as in the case 
of more rigid compounds.  
Compounds 11 and 12 gave higher inhibitions of 49.5% and 59.6% at 200 μM than 
similar compounds 21 and 22 with the indole ring replaced by other aryl groups. The 
inhibitory activities of 21 and 22 were 2.0% and 29.6% at 200 μM, respectively. This 
clearly indicates that the indole ring is forming important interactions in the binding 
site. The interactions of the indole ring in all of the binding modes A, B, and C are 
mainly hydrophobic and aromatic interactions. Similar interactions are also possible for 
compounds 21 and 22. The larger molecular structure of the indole ring could, however, 
make such interactions stronger. Compound 21 was obtained low scoring values in both 
scoring functions and in all individual docking series. A clear difference could not be 
seen in the binding modes of these compounds. 
Addition of a benzyloxy group to the 5-position of the indole ring of compounds 12 
and 17 resulting in compounds 25 and 26 had no effect on the inhibitory activity. 
Compounds 12 and 25 had inhibitions in the range of 59.6–43.7% at 200 μM, and 
compounds 17 and 26 had inhibitions in the range 22.7–32.9% at 200 μM. As increased 
molecular structure offers more interactions upon binding and thus higher inhibitory 
activity, the fact that the inhibitory activity does not increase indicate that there are no 
favorable interaction partners for the benzyloxy group in the binding site.  
In addition, the relatively small compounds 28–30 were almost equipotent. The 
inhibitory activities of 28, 29, and 30 were 44.3%, 58.0%, and 44.1% at 200 μM, 
respectively, and the IC50 value of 29 was 173 μM. The para-hydroxy substituent on 
phenyl ring did not seem to be as important for the inhibitory activity among these 
compounds as in the case of the bigger compounds. Removal of the para-hydroxy 
substituent of 28 did not lower the inhibitory activity. Neither did the removal of the 
double bond in the propenoyl side-chain lower the inhibitory activity. These differences 
could raise the question whether the binding of these smaller compounds differs from 
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the binding of the other compounds. Based on the molecular modelling results, the 
compounds 28–30 had docking poses resembling binding modes B and C. However, 
these modelling results do not explain the differences, and further studies would be 
needed.  
Compound 28 is also a known natural product isolated from kernels of maize, 
safflower seed and Ravensara anisata Danguy, among others (Andrianaivoravelona et 
al. 1999, Sato et al. 1985, Takii et al. 2003). 
 
7.4 Conclusions 
The most potent new compounds were 11, 12, 15, 27, and 29 with IC50 values in the 
range 86–173 μM. As compared to the best earlier presented compounds with the same 
backbones 5 and 6 with IC50 values in the range 47–50 μM, these new compounds did 
not lead to an improvement of the inhibitory activity. However, the new compounds 
clearly indicate that the N-(3-phenylpropenoyl)-glycine tryptamide backbone is a good 
backbone for the design of SIRT2 inhibitors. One-third of the synthesized compounds 
have over 50% inhibition at the concentration of 200 μM. In addition, the study revealed 
that a series of compounds with a smaller 3-phenylpropenoic acid tryptamide backbone 
also were good SIRT2 inhibitors. 
The study gave important information about how the compounds interact with SIRT2. 
Reasonable binding modes were found for these compounds in the area, which has been 
earlier postulated as a binding site for sirtuin inhibitors (Huhtiniemi et al. 2006, 
Neugebauer et al. 2008, Outeiro et al. 2007). However, prediction of a binding mode 
without experimental structural data is an extremely challenging task.  
 
7.5 Synthetic procedures and analytical data 
2-(Cbz-amino)-isobutyric acid (10a). 2-Amino-2-methyl-propionic acid (3.0 g, 29 
mmol) was dissolved in the mixture of 1,4-dioxane:water (1:2) where 5% K2CO3 (0.36 
M) was added. Benzyl chloroformate (8.3 mL, 58 mmol) was dissolved in the small 
amount of 1,4-dioxane and added to the mixture. The mixture was stirred at rt 
overnight. Afterwards, diethyl ether and sat. NaHCO3 aq. were added. Phases were 
separated and the organic phase was yet extracted ones with NaHCO3. The water phases 
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were combined and made acidic with 2 M HCl. The product was extracted with DCM, 
dried and evaporated. The product was used directly for the following coupling reaction. 
1H NMR ((CD3)2CO): δ = 1.52 (s, 6 H), 5.04 (s, 2 H), 6.54 (s, NH), 7.27–7.37 (m, 5 H), 
10.91 (s, OH).  
2-(Cbz-amino)-isobutyric acid tryptamide (10b). 10a (1.50 g, 6.32 mmol) and Et3N 
(1.0 mL, 6.95 mmol) were dissolved in dry DCM and ethyl chloroformate (0.60 mL, 
6.32 mmol) was added to active the carboxylic acid during an hour at -20oC under argon 
atmosphere. Another portion of Et3N (0.88 mL, 6.32 mmol) and tryptamine (1.11 g, 
6.95 mmol) were added, and the mixture was stirred under an argon atmosphere at rt 
overnight (Sam et al. 1959). The mixture was washed twice with 30% citric acid, once 
with sat. NaCl aq. and twice with sat. NaHCO3 aq. Some of the product was already 
crystallized during citric acid wash. The organic phase was dried and evaporated. The 
product was recrystallized from ethyl acetate and hexane (49%). 1H NMR (CDCl3): δ = 
1.46 (s, 6 H), 2.93–2.96 (m, 2 H), 3.56–3.60 (m, 2 H), 5.04 (s, 2 H), 6.97 (s, 1 H), 7.10–
7.13 (m, 1 H), 7.18–7.21 (m, 1 H), 7.32–7.37 (m, 5 H), 7.59–7.61 (m, 1 H), 7.88 (s, 1 
H).  
2-Amino-isobutyric acid tryptamide (10c). 10b (1.17 g, 3.08 mmol) was dissolved 
in dry MeOH and ammoniumformate (0.58 g, 9.25 mmol) and 10% Pd/C (0.10 g, 0.92 
mmol) were added. The mixture was stirred under an argon atmosphere at rt overnight, 
filtered through Celite and evaporated. The residue was dissolved in DCM, washed with 
sat. Na2CO3 aq., and the solvent was evaporated (98%). 1H NMR (CD3OD): δ = 1.25 (s, 
6 H), 2.96 (t, 3J = 7.2 Hz, 2 H), 3.49 (t, 3J = 7.2 Hz, 2 H), 6.98–7.01 (m, 1 H), 7.06–7.10 
(m, 2 H), 7.32–7.33 (m, 1 H), 7.57–7.58 (m, 1 H). 
3-(3-Acetoxyphenyl)-propenoic acid (10d). 3-(3-Hydroxyphenyl)-propenoic acid 
(0.20 g, 1.22 mmol) was dissolved in pyridine and acetic anhydride (0.30 mL, 3.05 
mmol) was added. The mixture was stirred at rt overnight. The mixture was poured into 
the ice-water (100 mL) and made acidic with 3 M HCl. The precipitated product was 
filtered and washed with water and diethyl ether (28%). 1H NMR (DMSO-d6): δ = 2.28 
(s, 3 H), 6.55 (d, 3J = 16.1 Hz, 1 H), 7.16–7.19 (m, 1 H), 7.43–7.47 (m, 1 H), 7.49–7.50 
(m, 1 H), 7.56–7.59 (m, 2 H), 12.44 (s, OH).  
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2-(3-(3-Acetoxyphenyl)-propenoyl-amino)-isobutyric acid tryptamide (10e) was 
prepared from 10d (0.06 g, 0.27 mmol) and 10c (0.06 g, 0.26 mmol) using ethyl 
chloroformate (0.03 mL, 0.32 mmol) and two portions of Et3N (0.09 mL, 0.66 mmol) in 
THF according to the syntheses of 10b, except the carboxylic acid activation was done 
under argon atmosphere at 0oC for 1.5 h (Sam et al. 1959). THF was evaporated. The 
residue was dissolved in DCM and washed with 30% citric acid, sat. NaCl aq. and sat. 
NaHCO3 aq. The organic phase was dried and evaporated. The product was purified by 
CombiFlash® chromatography on silica column (DCM:MeOH, 99:1) (69%).   
2-(3-(3-Hydroxyphenyl)-propenoyl-amino)-isobutyric acid tryptamide (10). 10e 
(0.08 g, 0.18 mmol) was dissolved in DCM. A small amount of MeOH was added to 
dissolve the substance completely. The reaction flask was under argon at 0oC. 1 M 
CH3ONa (0.36 mL, 0.36 mmol) in MeOH was added (Boiadjiev and Lightner 1996). 
Colour of the mixture was immediately changed to yellow. Another portion of 1 M 
CH3ONa in MeOH was added and the ice-water bath was removed. The mixture was 
stirred at rt overnight. DCM was evaporated and the residue was dissolved in MeOH 
and acidified with 3 M HCl. Water was added dropwise to precipitate the product. The 
product was filtered and washed with diethyl ether and DCM (71%). 1H NMR 
(CD3OD): δ = 1.48 (s, 6 H), 2.96 (t, 3J = 7.2 Hz, 2 H), 3.50 (t, 3J = 7.3 Hz, 2 H), 6.54 (d, 
3J = 15.8 Hz, 1 H), 6.80–6.81 (m, 1 H), 6.97–7.07 (m, 5 H), 7.18–7.22 (m, 1 H), 7.28–
7.30 (m, 1 H), 7.40 (d, 3J = 15.8 Hz, 1 H), 7.58–7.59 (m, 1 H). 13C NMR (CD3OD): δ = 
25.71, 26.05, 41.58, 57.94, 112.18, 113.20, 115.19, 117.90, 119.29, 119.55, 120.39, 
121.87, 122.25, 123.52, 128.68, 130.84, 137.59, 138.06, 141.95, 158.88, 167.91, 
176.85. ESI-MS (m/z): 392 [M + H]+. Anal. (C23H25N3O3·0.3H2O): C, H, N. 
2-Amino-isobutyric acid methyl ester (11a). 2-Amino-2-methyl-propionic acid (3.0 
g, 29 mmol) was dissolved in MeOH. Thionylchloride (5.3 mL, 73 mmol) was 
dissolved in MeOH and added to the mixture through the dropping funnel at 0oC. The 
mixture was refluxed for 3 h, evaporated and dried in the vacuum. The product was 
used without further purification. 1H NMR (DMSO-d6): δ = 1.51 (s, 6 H), 3.76 (s, 3 H), 
8.80 (s, NH2). 
2-(3-Phenyl-propenoic acid-amino)-isobutyric acid methyl ester (11b). The 
compound 11a (1.2 g, 11 mmol) is dissolved in DCM and Et3N (1.6 mL, 12 mmol) is 
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added. 3-Phenyl-propenoic acid chloride (1.8 g, 11 mmol) is partly dissolved in DCM 
and added slowly to the mixture. The mixture is stirred at rt for 3 d. The mixture was 
washed with 30% citric acid, sat. NaCl aq. and sat. NaHCO3 aq., dried and evaporated. 
The product was purified by flash chromatography using a manual gradient of ethyl 
acetate:petrol ether (50:50→60:40) (44%). 1H NMR (CDCl3): δ = 1.64 (s, 6 H), 3.78 (s, 
3 H), 6.24 (s, NH), 6.38-6.42 (m, 1 H), 7.35-7.36 (m, 3 H), 7.48-7.50 (m, 2 H), 7.58-
7.61 (m, 1 H). 
2-(3-Phenyl-propenoic acid-amino)-isobutyric acid (11c). The compound 11b (1.14 
g, 4.61 mmol) was dissolved in the mixture of H2O (55 mL) and MeOH (18 mL). 
LiOH·H2O (1.16 g, 27.7 mmol) was added. The mixture was stirred at rt overnight. 
MeOH was evaporated and more H2O was added. The mixture was washed with DCM. 
The H2O phase was made acidic with 2 M HCl. The product started to precipitate out of 
the solution. The H2O phase was separated and the organic phase was evaporated. The 
product was dried in vacuum (87%). 1H NMR (DMSO-d6): δ = 1.41 (s, 6 H), 6.66-6.69 
(m, 1 H), 7.36-7.43 (m, 3 H), 7.54-7.55 (m, 2 H), 8.25 (s, 1 H), 12.15 (s, OH). 
2-(3-Phenyl-propenoic acid-amino)-isobutyric acid tryptamide (11) was prepared 
from 11c (0.93 g, 4.0 mmol) and tryptamine (0.64 g, 4.0 mmol) using ethyl 
chloroformate (0.38 mL, 4.0 mmol) and two portions of Et3N (1.22 mL, 8.8 mmol) in 
DCM according to the syntheses of 10b (Sam et al. 1959). The product was purified by 
flash chromatography using a manual gradient of DCM:MeOH (98:2→97:3) (7%). 1H 
NMR (CD3OD): δ = 1.48 (s, 6 H), 2.95 (t, 3J = 7.3 Hz, 2 H), 3.50 (t, 3J = 7.4 Hz, 2 H), 
6.61 (d, 3J = 15.8 Hz, 1 H), 6.96–6.99 (m, 1 H) 7.03–7.06 (m, 2 H), 7.27–7.29 (m, 1 H), 
7.34-7.40 (m, 3 H), 7.47 (d, 3J = 15.8 Hz, 1 H), 7.54–7.59 (m, 3 H). 13C NMR 
(CD3OD): δ = 25.72, 26.08, 41.63, 57.97, 112.18, 113.25, 119.32, 119.56, 122.09, 
122.26, 123.54, 128.76, 128.86, 129.91, 130.81, 136.34, 138.13, 141.77, 167.87, 
176.90. ESI-MS (m/z): 376 [M + H]+. Anal. (C23H25N3O2·1.1H2O): C, H, N. 
3-Propenoic acid chloride (12a). 3-Phenylpropenoic acid (1.5 g, 10 mmol) was 
dissolved in dry DCM (40 mL) and oxalyl chloride (1.05 mL, 12 mmol) was added. A 
couple of drops DMF were added as a catalyser. The mixture was stirred at rt overnight, 
the solvent was evaporated, and the product was dried well in the vacuum. The product 
was used without further purification.   
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N-(3-Phenylpropenoyl)-L-alanine (12b). Compound 12a (1.7 g, 10 mmol) was 
dissolved in diethyl ether (20 mL) and L-alanine (0.89 g, 10 mmol) was dissolved in 1 
M NaOH (40 mL). The solutions were combined and stirred at rt overnight. Next day, 
more H2O and diethyl ether were added. The mixture was stirred, and the phases were 
separated. Water phase was made acidic and the product was extracted with DCM. The 
solvent was dried and evaporated. The product was used without further purification. 
  N-(3-Phenylpropenoyl)-L-alanine N-hydroxysuccinimide ester (12c). Compound 
12b (0.80 g, 3.65 mmol) and N-hydroxysuccinimide (0.42 g, 3.65 mmol) were dissolved 
in dry ACN. N,N'-Dicyclohexylcarbodiimide (0.75 g, 3.65 mol) was dissolved in dry 
ACN and added dropwise to the reaction mixture at -20oC. The reaction was stirred at -
20oC for 2.5 h and stored in a freezer overnight. The mixture was filtered and the filtrate 
was evaporated. The product was washed with hexane and dried in a vacuum. The 
product was used without further purification. 
N-(3-Phenyl-propenoic acid)-L-alanine tryptamide (12). Compound 12c (1.27 g, 
4.01 mmol) was dissolved in THF and tryptamine (1.29 g, 8.03 mmol) was added. The 
mixture was stirred at rt overnight. THF was evaporated and the residue was dissolved 
in DCM and washed twice with 30% citric acid, once with sat. NaCl aq. and twice with 
sat. NaHCO3 aq. The organic phase was dried and evaporated. The product was purified 
twice by flash chromatography using manual gradients of ethyl acetate:petrol ether 
(50:50→100:0) and DCM:MeOH (99:1→98:2) (20%). 1H NMR (CD3OD): δ = 1.35 (d, 
3J = 7.2 Hz, 3 H), 2.96 (t, 3J = 7.2 Hz, 2 H), 3.46–3.55 (m, 2 H), 4.43 (k, 3J = 7.1 Hz, 1 
H), 6.65 (d, 3J = 15.8 Hz, 1 H), 6.97–7.00 (m, 1 H), 7.04–7.07 (m, 2 H), 7.29–7.31 (m, 1 
H), 7.35–7.41 (m, 3 H), 7.52–7.57 (m, 4 H). 13C NMR (CD3OD): δ = 18.37, 26.14, 
41.38, 50.67, 112.22, 113.08, 119.26, 119.62, 121.52, 122.30, 123.56, 128.73, 128.90, 
129.93, 130.88, 136.26, 138.14, 142.19, 168.23, 174.93. ESI-MS (m/z): 362 [M + H]+. 
Anal. (C22H23N3O2·0.2H2O): C, H, N. 
3-(3-Methoxyphenyl)-propenoic acid (13a). 3-Methoxybenzaldehyde (0.89 mL, 7.3 
mmol), malonic acid (1.7 g, 16 mmol), pyridine (3.3 mL, 41 mmol) and a couple of 
drops piperidine were refluxed for 1 h. After cooling the flask, the mixture was poured 
into excess water containing enough HCl (>1.3 mL, 41 mmol) to combine with the 
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pyridine, filtered and washed with H2O. The product was recrystallized from EtOH 
(Furniss et al. 1989). 
2-(3-(3-Methoxyphenyl)-propenoyl-amino)-isobutyric acid methyl ester (13b). 
Acid 13a (2.0 g, 11 mmol) and Et3N (1.8 mL, 13 mmol) were dissolved in DCM. 
Pivaloyl chloride (1.4 mL, 11 mmol) was dissolved in DCM and added to the mixture 
through the dropping funnel at 0oC. The mixture was stirred for 1 h. Another portion of 
Et3N (1.8 mL, 13 mmol) was added. 2-Aminoisobutyric acid methyl ester 11a (1.3 g, 11 
mmol) was dissolved in DCM and added to the mixture at rt (Sam et al. 1959). The 
mixture was stirred for 3.5 h. The mixture was washed twice with 30% citric acid, once 
with sat. NaCl aq. and twice with sat. NaHCO3 aq. The solvent was dried and 
evaporated. The product was purified by flash chromatography using a manual gradient 
of DCM:MeOH (99:1→98:2) (52%). 1H NMR (CDCl3): δ = 1.64 (s, 6 H), 3.78 (s, 3 H), 
3.82 (s, 3 H), 6.24 (s, 1 H), 6.39 (d, 3J = 15.6 Hz, 1 H), 6.89–6.91 (m, 1 H), 7.01–7.02 
(m, 1 H), 7.08–7.09 (m, 1 H), 7.56 (d, 3J = 15.6 Hz, 1 H). 
2-(3-(3-Methoxyphenyl)-propenoyl-amino)-isobutyric acid (13c) was prepared 
from 13b (1.6 g, 5.9 mmol) in the mixture of MeOH (72 mL) and LiOH·H2O (1.5 g, 35 
mmol) in H2O (24 mL) according to the syntheses of 11c. The mixture was washed 
twice with diethyl ether, and the H2O phase was made acidic with 3M HCl. The product 
was extracted with diethyl ether. The product started to precipitate. Diethyl ether was 
evaporated and the residue was yet washed with cold diethyl ether (100%). 1H NMR 
(CDCl3): δ = 1.62 (s, 6 H), 3.83 (s, 3 H), 6.54 (d, 3J = 15.7 Hz, 1 H), 6.88–6.90 (m, 1 
H), 7.01–7.02 (m, 1 H), 7.08–7.09 (m, 1 H), 7.44 (s, 1 H), 7.50 (d, 3J = 15.7 Hz, 1 H). 
2-(3-(3-Methoxyphenyl)-propenoyl-amino)-isobutyric acid tryptamide (13) was 
prepared from 2-(3-(3-methoxyphenyl)-propenoyl-amino)-isobutyric acid (1.09 g, 4.14 
mmol) and tryptamine (0.66 g, 4.14 mmol) using ethyl chloroformate (0.39 mL, 4.14 
mmol) and two portions of Et3N (1.26 mL, 9.10 mmol) in dry DCM according to the 
syntheses of 10b (Sam et al. 1959). The product was washed twice with 30% citric acid, 
once with sat. NaCl aq. and twice with sat. NaHCO3 aq. EtOH was added to dissolve the 
precipitated product. The phases were separated and the H2O phase was extracted with 
the mixture of DCM/EtOH. The organic phase was evaporated and the product was 
purified by flash chromatography using a manual gradient of DCM:MeOH (99:1→97:3) 
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(20%). 1H NMR (CD3OD): δ = 1.48 (s, 6 H), 2.95 (t, 3J = 7.3 Hz, 2 H), 3.49 (t, 3J = 7.4 
Hz, 2 H), 3.82–3.82 (m, 3 H), 6.58–6.61 (m, 1 H), 6.93–6.99 (m, 2 H), 7.03–7.06 (m, 2 
H), 7.09 (s, 1 H), 7.12–7.14 (m, 1 H), 7.27–7.31 (m, 2 H), 7.42–7.45 (m, 1 H), 7.57–
7.59 (m, 1 H). 13C NMR (DMSO-d6): δ = 25.09, 25.20, 39.85, 55.03, 56.09, 111.26, 
111.85, 112.38, 115.13, 118.08, 118.24, 119.86, 120.78, 122.58, 123.25, 127.21, 
129.88, 136.20, 136.45, 138.22, 159.54, 164.26, 173.73. ESI-MS (m/z): 406 [M + H]+. 
Anal. (C24H27N3O3·0.3H2O): C, H, N. 
3-(3-Methoxyphenyl)-propenoic acid (14a) was prepared from 2-
methoxybenzaldehyde (1.0 g, 7.3 mmol), malonic acid (1.7 g, 16 mmol), pyridine (3.3 
mL, 41 mmol) and a couple of drops piperidine according to the syntheses of 13a 
(Furniss et al. 1989). 
2-(3-(2-Methoxyphenyl)-propenoyl-amino)-isobutyric acid methyl ester (14b) was 
prepared from acid 14a (2.3 g, 13 mmol) and 2-aminoisobutyric acid methyl ester 11a 
(1.5 g, 13 mmol) using  pivaloylchloride (1.6 mL, 13 mmol) and two portions of Et3N 
(3.9 mL, 28 mmol) in DCM according to the syntheses of 13b (Sam et al. 1959). The 
mixture was stirred at rt for 3 d. The mixture was washed three times with 30% citric 
acid, once with sat. NaCl aq. and twice with sat. NaHCO3 aq. The solvent was dried and 
evaporated. The product was purified twice by flash chromatography (DCM:MeOH, 
80:20 and 99:1) (50%). 1H NMR (CDCl3): δ = 1.56 (s, 6 H), 3.70 (s, 3 H), 3.79 (s, 3 H), 
6.23 (s, 1 H), 6.47 (d, 3J = 15.8 Hz, 1 H), 6.81–6.91 (m, 2 H), 7.21–7.25 (m, 1 H), 7.37–
7.39 (m, 1 H), 7.78 (d, 3J = 15.8 Hz, 1 H). 
2-(3-(2-Methoxyphenyl)-propenoyl-amino)-isobutyric acid (14c) was prepared 
from 14b (1.9 g, 7.0 mmol) using the mixture of MeOH (84 mL) and LiOH·H2O (1.8 g, 
42 mmol) in H2O (28 mL) according to the syntheses of 11c. The mixture was washed 
twice with diethyl ether, and the H2O phase was made acidic with 3 M HCl. The 
product started to precipitate during the diethyl ether extraction. The H2O phase was 
separated and extracted once with DCM. The organic phase was evaporated, and dried 
well in a vacuum (92%). 1H NMR (CDCl3): δ = 1.60 (s, 6 H), 3.88 (s, 3 H), 6.64 (d, 3J = 
15.9 Hz, 1 H), 6.92–6.96 (m, 2 H), 7.30–7.33 (m, 1 H), 7.46–7.48 (m, 1 H), 7.81 (d, 3J = 
15.8 Hz, 1 H).  
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2-(3-(2-Methoxyphenyl)-propenoyl-amino)-isobutyric acid tryptamide (14) was 
prepared from 2-(3-(2-methoxyphenyl)-propenoyl-amino)-isobutyric acid 1.72 g (6.53 
mmol) and tryptamine (1.05 g, 6.53 mmol) using ethyl chloroformate (0.62 mL, 6.53 
mmol) and two portions of Et3N (2.0 mL, 14 mmol) in dry DCM according to the 
syntheses of 10b. The mixture was stirred at rt for 2 d (Sam et al. 1959). The mixture of 
EtOH/DCM (100 mL) was added to the reaction, and it was washed twice with 30% 
citric acid, once with sat. NaCl aq. and twice with sat. NaHCO3 aq. The organic phase 
was evaporated, and the product was purified by flash chromatography using a manual 
gradient of DCM:MeOH (99:1→95:5) (35%). 1H NMR (CD3OD): δ = 1.47 (s, 6 H), 
2.95 (t, 3J = 7.3 Hz, 2 H), 3.49 (t, 3J = 7.4 Hz, 2 H), 3.89–3.89 (m, 3 H), 6.66–6.70 (m, 1 
H), 6.94–6.99 (m, 2 H), 7.01–7.07 (m, 3 H), 7.27–7.29 (m, 1 H), 7.33–7.36 (m, 1 H), 
7.52–7.53 (m, 1 H), 7.57–7.59 (m, 1 H), 7.79–7.82 (m, 1 H). 13C NMR (CD3OD): δ = 
25.77, 26.09, 41.60, 56.04, 57.95, 112.18, 112.40, 113.26, 119.34, 119.57, 121.75, 
122.27, 122.43, 123.58, 124.99, 128.74, 129.47, 132.15, 137.24, 138.12, 159.65, 
168.48, 176.97. ESI-MS (m/z): 406 [M + H]+. Anal. (C24H27N3O3·0.2H2O): C, H, N. 
2-(3-(4-Fluorophenyl)-propenoyl-amino)-isobutyric acid tryptamide (15) was 
prepared from 3-(4-fluoro)-propenoic acid (0.20 g, 1.22 mmol) and 10c (0.30 g, 1.22 
mmol) using ethyl chloroformate (0.12 mL, 1.22 mmol) and two portions of Et3N (0.37 
mL, 2.69 mmol) in THF according to the syntheses of 10b, except the carboxylic acid 
activation was done at 0oC for 1 h. The mixture was stirred under an argon atmosphere 
at rt for 3 d (Sam et al. 1959). THF was evaporated. The residue was dissolved in DCM 
and washed with 30% citric acid, sat. NaCl aq. and sat. NaHCO3 aq. The organic phase 
was dried and evaporated. The product was purified by recrystallization from DCM and 
by CombiFlash® chromatography on silica column (DCM:MeOH, 98:2) (17%).  1H 
NMR (CD3OD): δ = 1.48 (s, 6 H), 2.95 (t, 3J = 7.2 Hz, 2 H), 3.50 (t, 3J = 7.3 Hz, 2 H), 
6.53 (d, 3J = 15.8 Hz, 1 H), 6.97–7.00 (m, 1 H), 7.04–7.07 (m, 2 H), 7.10–7.13 (m, 2 H), 
7.27–7.29 (m, 1 H), 7.44 (d, 3J = 15.8 Hz, 1 H), 7.56–7.59 (m, 3 H). 13C NMR 
(CD3OD): δ = 25.72, 26.07, 41.61, 57.98, 112.19, 113.22, 116.78 (d, 2JCF = 22.10 Hz), 
119.32, 119.57, 121.95, 121.96, 122.27, 123.55, 128.74, 130.89 (d, 3JCF = 8.44 Hz), 
132.76 (d, 4JCF = 3.35 Hz), 138.11, 140.46, 164.98 (d, 1JCF = 248.79 Hz), 167.71, 
176.85. ESI-MS (m/z): 394 [M + H]+. Anal. (C23H24FN3O2·0.1H2O): C, H, N. 
109 
 
3-(3-Nitrophenyl)-propenoic acid (16a) was prepared from 3-nitrobenzaldehyde (1.0 
g, 6.6 mmol), malonic acid (1.5 g, 15 mmol), pyridine (3.0 mL, 37 mmol) and a couple 
of drops piperidine according to the syntheses of 13 (Furniss et al. 1989). 
2-(3-(3-Nitrophenyl)-propenoyl-amino)-isobutyric acid methyl ester (16b) was 
prepared from acid 16a (1.3 g, 6.9 mmol) and 2-aminoisobutyric acid methyl ester 11a 
(0.84 g, 6.9 mmol) using  pivaloylchloride (0.86 mL, 6.9 mmol) and two portions of 
Et3N (2.1 mL, 15 mmol) in DCM according to the syntheses of 13b (Sam et al. 1959). 
The mixture was stirred at rt for 2 d, washed twice with 30% citric acid, once with sat. 
NaCl aq. and twice with sat. NaHCO3 aq. The solvent was dried and evaporated. The 
product was purified twice by flash chromatography using a manual gradient of ethyl 
acetate:petrol ether (50:50→100:0) (64%). 1H NMR (CDCl3): δ = 1.66 (s, 6 H), 3.79 (s, 
3 H), 6.35 (s, 1 H), 6.54 (d, 3J = 15.9 Hz, 1 H), 7.54–7.57 (m, 1 H), 7.64 (d, 3J = 15.9 
Hz, 1 H), 7.76–7.77 (m, 1 H), 8.19–8.20 (m, 1 H), 8.37 (s, 1 H). 
2-(3-(3-Nitrophenyl)-propenoyl-amino)-isobutyric acid (16c) was prepared from 
16b (1.29 g, 4.41 mmol) using the mixture of MeOH (53 mL) and LiOH·H2O (1.11 g, 
27 mmol) in H2O (18 mL) according to the syntheses of 11c. The mixture was washed 
with DCM, and the H2O phase was made acidic with 2 M HCl. The product precipitated 
in the extraction funnel. The H2O phase was separated, and the product was filtered and 
dried well in a vacuum. The H2O phase and the filtrate contained yet some product that 
was extracted with the mixture of DCM:THF (4:1) (overall 97%). 1H NMR (CDCl3): δ 
= 1.43 (s, 6 H), 6.89 (d, 3J = 15.9 Hz, 1 H), 7.50 (d, 3J = 15.9 Hz, 1 H), 7.69–7.73 (m, 1 
H), 7.99–8.01 (m, 1 H), 8.20–8.21 (m, 1 H), 8.34–8.39 (m, 1 H), 12.22 (s, OH). 
2-(3-(3-Nitrophenyl)-propenoyl-amino)-isobutyric acid tryptamide (16) was 
prepared from 2-(3-(3-nitrophenyl)-propenoyl-amino)-isobutyric acid (0.89 g, 3.20 
mmol) and tryptamine (0.51 g, 3.20 mmol) using ethyl chloroformate (0.31 mL, 3.20 
mmol) and two portions of Et3N (0.98 mL, 7.04 mmol) in the mixture of dry DCM and 
THF according to the syntheses of 10b (Sam et al. 1959). The product was purified by 
flash chromatography using a manual gradient of DCM:MeOH (98:2→97:3) (7%). 1H 
NMR (CD3OD): δ = 1.49 (s, 6 H), 2.95 (t, 3J = 7.2 Hz, 2 H), 3.50 (t, 3J = 7.3 Hz, 2 H), 
6.74 (d, 3J = 15.8 Hz, 1 H), 6.96–6.99 (m, 1 H), 7.03–7.07 (m, 2 H), 7.26–7.27 (m, 1 H), 
7.51 (d, 3J = 15.8 Hz, 1 H), 7.57–7.59 (m, 1 H), 7.63–7.66 (m, 1 H), 7.91–7.93 (m, 1 H), 
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8.21–8.23 (m, 1 H), 8.41–8.42 (m, 1 H). 13C NMR (DMSO-d6): δ = 25.02, 25.10, 39.83, 
56.13, 111.22, 111.77, 118.04, 118.19, 120.73, 121.24, 122.58, 123.49, 125.86, 127.17, 
130.40, 133.83, 135.82, 136.15, 136.90, 148.22, 163.62, 173.54. ESI-MS (m/z): 421 [M 
+ H]+. Anal. (C23H24N4O4·0.1H2O): C, H, N. 
N-(3-Phenylpropenoyl)-glycine (17a) was prepared from 3-phenyl propenoic acid 
chloride (1.67 g, 10.0 mmol) in diethyl ether and glysine (0.75 g, 10.0 mmol) in 1 M 
NaOH (40 mL) according to the syntheses of 12b. The H2O phase was made acidic. The 
precipitated product was extracted with the DCM/EtOH mixture. The organic phase was 
dried and evaporated (87%). The product was used without further purification. 
N-(3-Phenylpropenoyl)-glycine tryptamide (17) was prepared from 17a (0.89 g, 
4.34 mmol) and tryptamine (0.70 g, 4.34 mmol) using pivaloyl chloride (0.53 mL, 4.34 
mmol) and two portions of Et3N (1.33 mL, 9.54 mmol) in DCM according to the 
syntheses of 13b. The mixture was stirred at rt for 3 d (Sam et al. 1959). The mixture 
was washed twice with 30% citric acid, ones with sat. NaCl aq. and twice with sat. 
NaHCO3 aq. A small amount of EtOH was added to dissolve the formed precipitate. 
The organic phase was dried and evaporated. The product was purified by flash 
chromatography using a manual gradient of ethyl acetate:petrol ether:MeOH 
(66.5:33.5:0→100:0:0→90:0:10→0:0:100) (39%). 1H NMR (CD3OD): δ = 2.96 (t, 3J = 
7.2 Hz, 2 H), 3.52 (t, 3J = 7.3 Hz, 2 H), 3.94 (s, 2 H), 6.62–6.65 (m, 1 H), 6.98–7.01 (m, 
1 H), 7.05–7.08 (m, 2 H), 7.30–7.31 (m, 1 H), 7.35–7.41 (m, 3 H), 7.54–7.58 (m, 4 H). 
13C NMR (CD3OD): δ = 26.14, 41.42, 43.78, 112.20, 113.05, 119.18, 119.61, 121.38, 
122.28, 123.47, 128.69, 128.87, 129.90, 130.88, 136.16, 138.09, 142.25, 168.93, 
171.39. ESI-MS (m/z): 348 [M + H]+. Anal. (C21H21N3O2·0.2H2O): C, H, N. 
N-(3-Phenylpropenoyl)-glycine-5-methoxytryptamide (18) was prepared from 17a 
(0.27 g, 1.32 mmol) and 5-methoxytryptamine (0.25 g, 1.32 mmol) using pivaloyl 
chloride (0.16 mL, 1.32 mmol) and two portions of Et3N (0.40 mL, 2.89 mmol) 
according to the syntheses of 13b. The mixture was stirred at rt for 3 h (Sam et al. 
1959). The mixture was washed twice with 30% citric acid, ones with sat. NaCl aq. and 
twice with sat. NaHCO3 aq. The organic phase was dried and evaporated. The product 
was purified by flash chromatography using a manual gradient of ethyl acetate:petrol 
ether:MeOH (75:25:0→100:0:0→99:0:1 (36%). 1H NMR (CD3OD): δ = 2.93 (t, 3J = 
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7.3 Hz, 2 H), 3.51 (t, 3J = 7.3 Hz, 2 H), 3.82 (s, 3 H), 3.94 (s, 2 H), 6.63–6.66 (m, 1 H), 
6.72–6.74 (m, 1 H), 7.05–7.06 (m, 2 H), 7.18–7.20 (m, 1 H), 7.35–7.41 (m, 3 H), 7.54–
7.57 (m, 3 H). 13C NMR (CD3OD): δ = 26.21, 41.32, 43.84, 56.37, 101.27, 112.61, 
112.84, 112.91, 121.39, 124.29, 128.91, 129.01, 129.93, 130.92, 133.38, 136.20, 
142.29, 154.96, 168.97, 171.45. ESI-MS (m/z): 378 [M + H]+. Anal. 
(C22H23N3O3·0.1H2O): C, H, N. 
2-(3-Phenyl-propanoyl-amino)-isobutyric acid methyl ester (19a). 3-
Phenylpropionic acid (2.0 g, 13 mmol) was dissolved in thionyl chloride (3.0 mL, 40 
mmol) and the mixture was refluxed for 1.5 h. Thionyl chloride was evaporated and the 
product was dried in a vacuum. 3-Phenylpropionic acid chloride (2.2 g, 13 mmol) was 
used in the reaction with 2-aminoisobutyric acid methyl ester 11a (2.1 g, 18 mmol). The 
reaction was prepared using Et3N (2.0 mL, 15 mmol) according to the syntheses of 11b. 
The mixture was stirred at rt overnight. The product was washed three times with 30% 
citric acid, once with sat. NaCl aq. and twice with sat. NaHCO3 aq. The organic phase 
was dried and evaporated. The product was purified by flash chromatography using a 
manual gradient of ethyl acetate:petrol ether (50:50→40:60) (56%). 1H NMR (CDCl3): 
δ = 1.50 (s, 6 H), 2.47 (t, 3J = 7.7 Hz, 2 H), 2.95 (t, 3J = 7.7 Hz, 2 H), 3.72 (s, 3 H), 5.89 
(s, 1 H), 7.18–7.21 (m, 3 H), 7.26–7.29 (m, 2 H). 
2-(3-Phenyl-propanoyl-amino)-isobutyric acid (19b) was prepared from 19a (1.9 g, 
7.5 mmol) using the mixture of MeOH (90 mL) and LiOH·H2O (1.9 g, 45 mmol) in 
H2O (30 mL) according to the syntheses of 11c. The mixture was washed with DCM, 
and the H2O phase was made acidic with 2 M HCl. The precipitated product was 
extracted with DCM (the product not fully soluble) and the solvent was evaporated 
(97%). 1H NMR (CDCl3): δ = 1.49 (s, 6 H), 2.53 (t, 3J = 7.5 Hz, 2 H), 2.97 (t, 3J = 7.5 
Hz, 2 H), 5.75 (s, 1 H), 7.19–7.22 (m, 3 H), 7.26–7.31 (m, 2 H). 
2-(3-Phenyl-propanoyl-amino)-isobutyric acid tryptamide (19) was prepared from 
2-(3-phenyl)-propenoyl-amino)-isobutyric acid (0.80 g, 3.40 mmol) and tryptamine 
(0.62 g, 3.74 mmol) using ethyl chloroformate 0.36 mL (3.40 mmol) and two portions 
of Et3N (1.04 mL, 7.48 mmol) in the mixture of dry THF according to the syntheses of 
10b (Sam et al. 1959). DCM was added to the mixture. The product was washed 30% 
citric acid, sat. NaCl aq. and sat. NaHCO3 aq. The organic phase was dried and 
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evaporated. The product was purified by flash chromatography using a manual gradient 
of DCM:MeOH (98:2→97:3) (17%). 1H NMR (CD3OD): δ = 1.34 (s, 6 H), 2.41–2.45 
(m, 2 H), 2.82–2.85 (m, 2 H), 2.88–2.91 (m, 2 H), 3.41–3.45 (m, 2 H), 6.99–7.02 (m, 1 
H), 7.06–7.09 (m, 2 H), 7.12–7.15 (m, 1 H), 7.17–7.19 (m, 2 H), 7.21–7.25 (m, 2 H), 
7.31–7.32 (m, 1 H), 7.57–7.58 (m, 1 H). 13C NMR (CD3OD): δ = 25.61, 26.06, 32.52, 
38.71, 41.50, 57.73, 112.24, 113.21, 119.35, 119.59, 122.32, 123.55, 127.20, 128.76, 
129.42, 129.45, 138.15, 142.14, 174.59, 176.91. ESI-MS (m/z): 378 [M + H]+. Anal. 
(C23H27N3O2): C, H, N. 
2-Amino-isobutyric acid tryptamide (20a). Compound 10b (2.47 g, 6.51 mmol) was 
dissolved in dry MeOH and 10% Pd/C (0.23 g, 2.15 mmol) was added. Hydrogen gas 
was led into the reaction flask from the hydrogen balloon at rt for 1 h. The mixture was 
filtered through Celite and the solvent was evaporated. The residue was dissolved in 
DCM and washed with NaCO3. The product was extracted back with DCM. The 
organic phase was dried and evaporated (75%). 1H NMR (CD3OD): δ = 1.25 (s, 6 H), 
2.94-2.97 (m, 2 H), 3.48-3.50 (m, 2 H), 6.98-7.02 (m, 1 H), 7.07-7.10 (m, 2 H), 7.32-
7.33 (m, 1 H), 7.57-7.58 (m, 1 H). 
3-(4-Acetoxyphenyl)-propionic acid (20b). 3-(4-Hydroxyphenyl)-propionic acid 
(0.50 g, 3.0 mmol), acetic anhydride (1.42 ml, 15.0 mmol) and DMAP (73.30 mg, 0.6 
mmol) were dissolved in pyridine (~ 3 ml) and stirred at rt overnight. Diethyl ether was 
added, and the mixture was washed with 2 M HCl and NaCl. The solvents were 
evaporated (Yang et al. 2000). The product was used directly for the following coupling 
reaction.   
2-(3-(4-Acetoxyphenyl)-propanoyl-amino)-isobutyric acid tryptamide (20c) was 
prepared from the acid 20b (0.84 g, 4.03 mmol) and 20a (1.19 g, 4.84 mmol) using 
ethyl chloroformate (0.38 ml, 4.03 mmol) and two portions of Et3N (1.24 ml, 8.88 
mmol) in THF according to the syntheses of 10b. A small amount of DCM was used to 
dissolve 20b better. The carboxylic acid activation was done under argon atmosphere at 
0oC for 1h (Sam et al. 1959). THF was evaporated. The residue was dissolved in DCM 
and washed with 30% citric acid, sat. NaCl aq. and sat. NaHCO3 aq. The organic phase 
was dried and evaporated. The product was purified by flash chromatography (ethyl 
acetate:petrol ether, 70:30) (27%). 1H NMR (CD3OD): δ = 1.35 (s, 6 H), 2.24 (s, 3 H), 
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2.41-2.44 (m, 2 H), 2.81-2.92 (m, 4 H), 3.42-3.46 (m, 2 H), 6.86-7.32 (m, 8 H), 7.57-
7.59 (m, 1 H). 
2-(3-(4-Hydroxyphenyl)-propanoyl-amino)-isobutyric acid tryptamide (20) was 
prepared from 20c (0.56 g, 1.29 mmol) in DCM using 1 M CH3ONa in MeOH (2.57 
mmol) according to the syntheses of 10 (Boiadjiev and Lightner 1996). The mixture 
was stirred on the ice-water bath for 1 h, until the color of the mixture was changed. 
DCM was evaporated and the residue was dissolved in MeOH and acidified with 3 M 
HCl. The product did not precipitate when H2O was added. The product was purified by 
flash chromatography using a manual gradient of ethyl acetate:petrol ether 
(70:30→100:0) (80%). 1H NMR (CD3OD): δ = 1.34 (s, 6 H), 2.39 (t, 3J = 7.6 Hz, 2 H), 
2.75 (t, 3J = 7.6 Hz, 2 H), 2.90 (t, 3J = 7.3 Hz, 2 H), 3.42-3.46 (m, 2H), 6.69-6.71 (m, 2 
H), 6.98-7.02 (m, 3 H), 7.06-7.09 (m, 2 H), 7.17-7.19 (m, NH), 7.30-7.32 (m, 1 H), 
7.57-7.59 (m, 1 H). 13C NMR (CD3OD): δ = 25.62, 26.06, 31.74, 39.04, 41.49,* 41.61,* 
57.71,* 57.73,* 112.20, 113.18, 116.17, 119.35, 119.58, 122.29, 123.56, 128.75, 130.40, 
132.83, 138.10, 156.73, 174.81, 176.91,* 176.99* (*) Due to the conformational effect 
these peaks are duplets.). ESI-MS (m/z): 394 [M + H]+. Anal. (C23H27N3O3·0.2H2O): C, 
H, N. 
2-(Cbz-amino)-isobutyric acid 2-pyridinamide (21a) was prepared from 10a (2.30 
g, 9.69 mmol) and 3-(2-aminoethyl) pyridine (0.32 g, 2.64 mmol) (the amount of the 
reagent left) in THF using ethyl chloroformate (0.92 mL, 9.69 mmol) and two portions 
of Et3N (2.98 mL, 21.4 mmol) overnight according to the syntheses of 10b, except the 
carboxylic acid activation was at 0oC under argon atmosphere (Sam et al. 1959). THF 
was evaporated and the residue was dissolved in DCM. The mixture was washed with 
H2O. Some of the product was already crystallized during H2O wash. The H2O phase 
was yet extracted ones with DCM. The organic phases were combined and evaporated. 
The product was purified by chromatography using ethyl acetate:MeOH (90:10) (20%). 
1H NMR (MeOD): δ = 1.38 (s, 6 H), 2.80-2.84 (m, 2 H), 3.42 (s, 2 H), 5.04 (s, 2 H), 
7.28-7.34 (m, 6 H), 7.72-7.73 (m, 1 H), 8.36-8.40 (m, 2 H).   
2-Amino-isobutyric acid 2-pyridinamide (21b) was prepared from compound 21a 
(0.66 g, 1.93 mmol) in MeOH using 10% Pd/C (0.07 g, 0.64 mmol) and hydrogen gas at 
rt for 2 h according to the syntheses of 20a (97%). 1H NMR (CD3OD): δ = 1.24 (s, 6 H), 
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2.86 (t, 3J = 7.1 Hz, 2 H), 3.45 (t, 3J = 7.1 Hz, 2 H), 7.35-7.38 (m, 1 H), 7.73-7.74 (m, 1 
H), 8.38-8.41 (m, 2 H). 
3-(4-Acetoxyphenyl)-propenoic acid (21c) was prepared from 3-(4-hydroxyphenyl)-
propenoic acid (13 g, 80 mmol) and acetic anhydride (19 mL, 200 mmol) in pyridine 
according to the syntheses of 10d (86%). 1H NMR (CD3OD): δ = 2.28 (s, 3 H), 6.44–
6.48 (m, 1 H), 7.16–7.18 (m, 2 H), 7.65–7.68 (m, 3 H). 
2-(3-(4-Acetoxyphenyl)-propenoyl-amino)-isobutyric acid 2-pyridinamide (21d) 
was prepared from the acid 21c (0.39 g, 1.88 mmol) and 21b (0.39 g, 1.88 mmol) using 
ethyl chloroformate (0.19 ml, 1.88 mmol) and two portions of Et3N (0.58 ml, 4.14 
mmol) in THF according to the syntheses of 10b, except the carboxylic acid activation 
was done under argon atmosphere at 0oC for 1 h (Sam et al. 1959). THF was 
evaporated. The residue was dissolved in DCM and washed twice with 30% citric acid, 
ones with sat. NaCl aq. and twice with sat. NaHCO3 aq. The product was extracted to 
the H2O phase. The product was tried to salt out from the water phase. Extractions with 
CHCl3:EtOH (3:1) and MeOH gave the mixture of the product and salts. The product 
was purified by flash chromatography using ethyl acetate:MeOH (90:10) (60%). 1H 
NMR (CD3OD): δ = 1.45 (s, 6 H), 1.99 (s, 3 H), 2.84-2.86 (m, 2 H), 3.42-3.46 (m, 2 H), 
6.42-6.45 (m, 1 H), 6.79-6.80 (m, 2 H), 7.31-7.33 (m, 1 H), 7.40-7.46 (m, 3 H), 7.75-
7.76 (m, 1 H), 8.33-8.34 (m, 1 H), 8.41 (s, 1 H). 
2-(3-(4-Hydroxyphenyl)-propenoyl-amino)-isobutyric acid 2-pyridinamide (21) 
was prepared from 21c (0.45 g, 1.14 mmol) in DCM (and a small amount of MeOH 
dissolve 21c completely) using 1 M CH3ONa in MeOH (2.28 mmol) according to the 
syntheses of 10 (Boiadjiev and Lightner 1996). The mixture was stirred on the ice-water 
bath for 40 min. DCM was evaporated and the residue was dissolved in MeOH and 
acidified with 3 M HCl. The product did not precipitate when H2O was added. The 
product was purified by flash chromatography using DCM:MeOH (90:10) (83%). 1H 
NMR (CD3OD): δ = 1.46 (s, 6 H), 2.85 (t, 3J = 7.0 Hz, 2 H), 3.44 (t, 3J = 7.0 Hz, 2 H), 
6.43-6.46 (m, 1 H), 6.79-6.81 (m, 2 H), 7.30-7.34 (m, 1 H), 7.40-7.50 (m, 3 H), 7.73-
7.75 (m, 1 H), 8.32-8.34 (m, 1 H), 8.40-8.41 (m, 1 H). 13C NMR (CD3OD): δ = 25.75, 
33.47, 41.57, 57.76, 116.70, 118.50, 125.04, 127.62, 130.55, 137.15, 138.86, 141.99, 
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147.77, 150.43, 160.48, 168.37, 177.16. ESI-MS (m/z): 354 [M + H]+. Anal. 
(C20H23N3O3·0.5H2O): C, H, N. 
N-(3-Phenylpropenoyl)-L-alanine phenethylamide (22). Compound 12c (0.53 g, 
1.68 mmol) was dissolved in dry THF. Et3N (0.23 mL, 1.68 mmol) and 2-
phenylethylamine (0.21 mL, 1.68 mmol) were added. The reaction was stirred at rt 
overnight. THF was evaporated and the residue was dissolved in DCM and washed 
twice with 30% citric acid, once with sat. NaCl aq. and twice with sat. NaHCO3 aq. The 
organic phase was dried and evaporated. The product was purified three times by 
chromatography using manual gradients of petrol ether:ethyl acetate (60:40→0:100) 
and DCM:MeOH (95.5:0.5→98:2 and 99:1) (16%). 1H NMR (CD3OD): δ = 1.33–1.34 
(m, 3 H), 2.80 (t, 3J = 7.2 Hz, 2 H), 3.36–3.49 (m, 2 H), 4.39–4.43 (m, 1 H), 6.64–6.68 
(m, 1 H), 7.14–7.17 (m, 1 H), 7.20–7.27 (m, 4 H), 7.35–7.41 (m, 3 H), 7.53–7.57 (m, 3 
H). 13C NMR (CD3OD): δ = 18.32, 36.50, 42.00, 50.69, 121.55, 127.35, 128.90, 129.51, 
129.92, 129.99, 130.94, 136.29, 140.46, 142.25. ESI-MS (m/z): 323 [M + H]+. Anal. 
(C20H22N2O2·0.02H2O): C, H, N. 
N-(3-Phenylpropenoyl)-L-proline (23a) was prepared from 12a (1.67 g, 10.0 mmol) 
in diethyl ether (20 mL) and L-proline (1.15 g, 10.0 mmol) in 1 M NaOH (40 mL) 
according to the syntheses of 12b. The H2O phase was made acidic. The product was 
extracted several times with diethyl ether. The product started to precipitate in the 
extraction funnel. DCM and EtOH were added to dissolve the product. The organic 
phase was dried and evaporated (93%). 1H NMR (CDCl3): δ = 1.98–2.17 (m, 3 H), 
2.51–2.55 (m, 1 H), 3.66–3.71 (m, 1 H), 3.77–3.81 (m, 1 H), 4.73–4.75 (m, 1 H), 6.72 
(d, 3J = 15.5 Hz, 1 H), 7.39–7.40 (m, 3 H), 7.54–7.56 (m, 2 H), 7.82 (d, 3J = 15.4 Hz, 1 
H), 9.99 (s, OH).  
N-(3-Phenylpropenoyl)-L-proline tryptamide (23) was prepared from 23a (1.0 g, 
4.08 mmol) and tryptamine (0.65 g, 4.08 mmol) using pivaloyl chloride (0.50 mL, 4.08 
mmol) and two portions of Et3N (1.26 mL, 8.96 mmol) according to the syntheses of 
13b, except the carboxylic acid activation was done at 0oC for 2 h. After the addition of 
tryptamine, the mixture was stirred at rt for a couple of hours and stored in a refrigerator 
overnight (Sam et al. 1959). The mixture was washed twice with 30% citric acid, ones 
with sat. NaCl aq. and twice with sat. NaHCO3 aq. The organic phase was dried and 
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evaporated. The product was purified by flash chromatography using ethyl acetate 
(91%). 1H NMR (CD3OD): δ (major, 70%) = 1.80–2.28 (m, 4 H), 2.96 (t, 3J = 7.2 Hz, 2 
H), 3.49–3.77 (m, 4 H), 4.44–4.46 (m, 1 H), 6.85–6.88 (m, 1 H), 6.95–7.07 (m, 3 H), 
7.29–7.59 (m, 8 H). 1H NMR (CD3OD): δ (minor, 30%) = 1.80–2.28 (m, 4 H), 2.91 (t, 
3J = 7.2 Hz, 2 H), 3.49–3.77 (m, 4 H), 4.51–4.53 (m, 1 H), 6.59–6.62 (m, 1 H), 6.95–
7.07 (m, 3 H), 7.29–7.59 (m, 8 H). 13C NMR (CD3OD): δ (major, 70%) = 25.55, 25.99, 
30.65, 41.31, 48.60, 61.93, 112.21, 113.05, 119.22, 119.45, 119.57, 122.25, 123.57, 
128.72, 129.06, 129.87, 130.99, 136.24, 138.01, 143.68, 167.36, 174.31. 13C NMR 
(CD3OD): δ (minor, 30%) = 23.63, 26.23, 33.02, 41.09, 48.25, 62.15, 112.25, 112.81, 
119.17, 119.45, 119.58, 122.34, 123.23, 128.59, 128.90, 129.90, 131.03, 136.06, 
138.03, 143.73, 167.61, 174.55. ESI-MS (m/z): 388 [M + H]+. Anal. 
(C24H25N3O2·0.3EtOAc): C, H, N.  
N-(3-Phenylpropanoyl)-L-proline (24a). 3-Phenyl propanoic acid (0.75 g, 5.00 
mmol) was dissolved in 1.1 mL (15.0 mmol) of thionyl chloride. The mixture was 
refluxed gently for 1.5 h, and the solvents were evaporated. N-(3-Phenylpropanoyl)-L-
proline was prepared from 3-phenyl propanoic acid chloride in diethyl ether and L-
proline 0.58 g (5.00 mmol) in 1 M NaOH (40 mL) according to the syntheses of 12b. 
The H2O phase was made acidic with 2 M HCl and the product was extracted with 
DCM. The organic phase was dried and evaporated. 1H NMR (CDCl3): δ = 1.86–2.02 
(m, 3 H), 2.44–2.52 (m, 1 H), 2.66–2.70 (m, 2 H), 2.95–3.03 (m, 2 H), 3.27–3.32 (m, 1 
H), 3.38–3.42 (m, 1 H), 4.59–4.61 (m, 1 H), 7.20–7.23 (m, 3 H), 7.26–7.31 (m, 2 H). 
N-(3-Phenylpropanoyl)-L-proline-5-benzyloxytryptamide (24) was prepared from 
24a (0.41 g, 1.65 mmol) and 5-benzyloxytryptamine (0.50 g, 1.65 mmol) using pivaloyl 
chloride (0.20 mL, 1.65 mmol) and two portions of Et3N (0.51 mL, 3.64 mmol) in DCM 
according to the syntheses of 13b. The mixture was stirred at rt overnight (Sam et al. 
1959). The mixture was washed twice with 30% citric acid, ones with sat. NaCl aq. and 
twice with sat. NaHCO3 aq. The organic phase was dried and evaporated. The product 
was purified by flash chromatography using ethyl acetate (64%). 1H NMR (CD3OD): δ 
(major, 70%) = 1.72–2.09 (m, 4 H), 2.55–2.65 (m, 2 H), 2.74–2.92 (m, 4 H), 3.40–3.55 
(m, 4 H), 4.32–4.34 (m, 1 H), 5.09 (s, 2 H), 6.83–6.86 (m, 1 H), 7.06 (s, 1 H), 7.09–7.47 
(m, 12 H). 1H NMR (CD3OD): δ (minor, 30%) = 1.72–2.09 (m, 4 H), 2.23–2.40 (m, 2 
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H), 2.74–2.92 (m, 4 H), 3.40–3.55 (m, 4 H), 4.07–4.09 (m, 1 H), 5.08 (s, 2 H), 6.83–
6.86 (m, 1 H), 6.97 (s, 1 H), 7.09–7.47 (m, 12 H). 13C NMR (CD3OD): δ (major, 70%) 
= 25.45, 26.02, 30.64, 31.89, 37.27, 41.18, 48.57, 61.55, 72.16, 103.32, 112.88, 112.89, 
113.23, 124.52, 127.15, 128.69, 129.08, 129.36, 129.39, 129.43, 133.55, 139.32, 
142.30, 153.97, 173.95, 174.41. 13C NMR (CD3OD): δ (minor, 30%) = 23.52, 26.03, 
32.14, 32.97, 37.14, 40.92, 47.90, 62.16, 72.12, 103.28, 112.60, 112.95, 113.33, 124.35, 
127.16, 128.65, 129.04, 129.33, 129.36, 129.45, 133.57, 139.30, 142.17, 153.99, 
174.05, 174.24. ESI-MS (m/z): 495 [M + H]+ and 518 [M + Na]+. Anal. (C31H33N3O3): 
C, H, N.  
N-(3-Phenylpropenoyl)-L-alanine-5-benzyloxytryptamide (25). Compound 12c 
(0.50 g, 1.58 mmol) was dissolved in dry THF. Et3N (0.22 mL, 1.58 mmol) and 5-
benzyloxytryptamine (0.48 g, 1.58 mmol) were added. The mixture was stirred at rt 
overnight. THF was evaporated and the residue was dissolved in DCM and a small 
amount of EtOH. The product was washed twice with 30% citric acid, once with sat. 
NaCl aq. and twice with sat. NaHCO3 aq. The organic phase was dried and evaporated. 
The product was purified three times by flash chromatography using manual gradients 
of ethyl acetate:petrol ether (75:25 and 40:60→100:0) and DCM:MeOH (99:1) (22%). 
1H NMR (CD3OD): δ = 1.34–1.36 (m, 3 H), 2.91 (t, 3J = 7.3 Hz, 2 H), 3.44–3.53 (m, 2 
H), 4.40–4.45 (m, 1 H), 5.09 (m, 2 H), 6.62–6.66 (m, 1 H), 6.80–6.82 (m, 1 H), 7.05 (s, 
1 H), 7.16 (s, 1 H), 7.19–7.21 (m, 1 H), 7.26–7.29 (m, 1 H), 7.34–7.40 (m, 5 H), 7.45–
7.47 (m, 2 H), 7.51–7.55 (m, 3 H). 13C NMR (CD3OD): δ = 18.35, 26.11, 41.19, 50.60, 
72.15, 103.21, 112.82, 112.86, 113.32, 121.40, 124.40, 128.63, 128.69, 128.84, 128.96, 
129.33, 129.85, 130.81, 133.53, 136.15, 139.27, 142.17, 153.92, 168.14, 174.84. ESI-
MS (m/z): 468 [M + H]+. Anal. (C29H29N3O3·0.3H2O): C, H, N. 
N-(3-Phenylpropenoyl)-glycine-5-benzyloxytryptamide (26) was prepared from 
17a (0.27 g, 1.32 mmol) and 5-benzyloxytryptamine (0.40 g, 1.32 mmol) using pivaloyl 
chloride (0.16 mL, 1.32 mmol) and two portions of Et3N (0.40 mL, 2.89 mmol) 
according to the syntheses of 13b. The mixture was stirred at rt for 3 h (Sam et al. 
1959). The mixture was washed twice with 30% citric acid, ones with sat. NaCl aq. and 
twice with sat. NaHCO3 aq. The organic phase was dried and evaporated. The product 
was purified by flash chromatography using a manual gradient of petrol ether:ethyl 
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acetate (60:40→0:100) (17%). 1H NMR (CD3OD): δ = 2.92 (t, 3J = 7.3 Hz, 2 H), 3.50 
(t, 3J = 7.3 Hz, 2 H), 3.94 (s, 2 H), 5.09 (s, 2 H), 6.62–6.65 (m, 1 H), 6.80–6.83 (m, 1 
H), 7.05 (s, 1 H), 7.16–7.16 (m, 1 H), 7.20–7.22 (m, 1 H), 7.26–7.29 (m, 1 H), 7.34–
7.41 (m, 5 H), 7.45–7.47 (m, 2 H), 7.53–7.56 (m, 3 H). 13C NMR (CD3OD): δ = 26.09, 
41.23, 43.92, 72.43, 103.55, 112.89, 112.89, 113.44, 121.37, 124.42, 128.61, 128.65, 
128.83, 129.01, 129.32, 129.82, 130.78, 133.63, 136.16, 139.28, 142.30, 154.01, 
168.86, 171.29. ESI-MS (m/z): 454 [M + H]+. Anal. (C28H27N3O3): C, H, N.  
N-(3-Phenylpropanoyl)-L-alanine (27a). 3-Phenyl propanoic acid (0.75 g, 5.00 
mmol) was dissolved in thionyl chloride (1.1 mL). The mixture was refluxed gently for 
1.5 h, and the solvents were evaporated. N-(3-Phenylpropanoyl)-L-alanine was prepared 
from 3-phenyl propanoic acid chloride in diethyl ether (30 mL) and L-alanine (0.45 g, 
5.00 mmol) in 1 M NaOH (40 mL) according to the syntheses of 12b. The H2O phase 
was made acidic with 2 M HCl, and the product was extracted with DCM. The organic 
phase was dried and evaporated. The product was used without further purification. 
N-(3-Phenylpropanoyl)-L-alanine N-hydroxysuccinimide ester (27b) was prepared 
from 27a (0.80 g, 3.62 mmol) and N-hydroxysuccinimide (0.42 g, 3.62 mmol) using 
N,N'-Dicyclohexylcarbodiimide (0.75 g, 3.62 mol) in dry ACN according to the 
syntheses of 12c. The reaction was stirred at -20oC for 2 h. The yield was 60%. The 
product was used without further purification. 
N-(3-Phenylpropanoyl)-L-alanine-5-benzyloxytryptamide (27). Compound 27b 
(0.45 g, 1.40 mmol) was dissolved in THF and 5-benzyloxytryptamine (0.42 g, 1.40 
mmol) was added. 5-Benzyloxytryptamine did not dissolve completely. The mixture 
was stirred at rt overnight. More THF was added. Two portions of Et3N (0.20 mL, 1.40 
mmol) was yet added to complete the reaction. The mixture was stirred overnight. THF 
was evaporated and the residue was dissolved in DCM and washed twice with 30% 
citric acid, once with sat. NaCl aq. and twice with sat. NaHCO3 aq. The organic phase 
was dried and evaporated. The product was purified by flash chromatography using a 
manual gradient of DCM:MeOH (99:1→98:2) (36%). 1H NMR (CD3OD): δ = 1.20–
1.22 (m, 3 H), 2.47–2.50 (m, 2 H), 2.85–2.88 (m, 4 H), 3.41–3.44 (m, 2 H), 4.24–4.28 
(m, 1 H), 5.09 (s, 2 H), 6.82–6.84 (m, 1 H), 7.03 (s, 1 H), 7.12–7.18 (m, 4 H), 7.21–7.24 
(m, 3 H), 7.27–7.30 (m, 1 H), 7.34–7.37 (m, 2 H), 7.46–7.47 (m, 2 H). 13C NMR 
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(CD3OD): δ = 18.08, 26.01, 32.53, 38.43, 41.00, 50.22, 72.11, 103.21, 112.69, 112.86, 
113.24, 124.34, 127.08, 128.58, 128.62, 128.86, 129.24, 129.28, 129.31, 133.45, 
139.13, 141.88, 153.85, 174.68, 174.74. ESI-MS (m/z): 470 [M + H]+. Anal. 
(C29H31N3O3·0.3H2O): C, H, N. 
N-3-(4-Acetoxyphenylpropenoyl)-tryptamide (28a). 21c (0.51 g, 2.49 mmol) was 
dissolved in DCM and thionyl chloride (5 mL) was added. The mixture was refluxed 
gently for 1 h, and the solvents were evaporated. Tryptamine (0.40 g, 2.49 mmol) and 
Et3N (0.35 mL, 2.49 mmol) were dissolved in DCM and 3-(4-acetoxyphenyl)-propenoic 
acid chloride was added through the dropping funnel to the mixture. The mixture was 
stirred at rt overnight. The mixture was washed three times with 30% citric acid, once 
with sat. NaCl aq. and twice with sat. NaHCO3 aq. The solvent was dried and 
evaporated. The product was washed with DCM (50%). 1H NMR (CD3OD): δ = 2.27 (s, 
3 H), 3.02 (t, 3J = 7.3 Hz, 2 H), 3.61 (t, 3J = 7.3 Hz, 2 H), 6.54 (d, 3J = 15.8 Hz, 1 H), 
6.98–7.02 (m, 1 H), 7.07–7.13 (m, 4 H), 7.32–7.34 (m, 1 H), 7.51 (d, 3J = 15.8 Hz, 1 H), 
7.55–7.59 (m, 3 H). 
N-3-(4-Hydroxyphenylpropenoyl)-tryptamide (28). 28a (0.43 g, 1.23 mmol) was 
dissolved in MeOH. The flask was under argon at 0oC. 1 M CH3ONa (2.47 mL, 2.47 
mmol) in MeOH was added. The reaction was over in 15 min (Boiadjiev and Lightner 
1996). MeOH was acidified with 3 M HCl. The product started to precipitate when 
DCM was added. The product was filtered (84%). 1H NMR (CD3OD): δ = 3.00 (t, 3J = 
7.3 Hz, 2 H), 3.59 (t, 3J = 7.3 Hz, 2 H), 6.39 (d, 3J = 15.7 Hz, 1 H), 6.78–6.79 (m, 2 H), 
6.98–7.01 (m, 1 H), 7.06–7.09 (m, 2 H), 7.32–7.33 (m, 1 H), 7.38–7.40 (m, 2 H), 7.45 
(d, 3J = 15.7 Hz, 1 H), 7.57–7.59 (m, 1 H). 13C NMR (CD3OD): δ = 26.42, 41.63, 
112.21, 113.32, 116.71, 118.60, 119.31, 119.59, 122.32, 123.41, 127.78, 128.80, 
130.54, 138.19, 141.70, 160.49, 169.30. ESI-MS (m/z): 307 [M + H]+. Anal. 
(C19H18N2O2): C, H, N.  
N-3-Phenylpropenoyl-tryptamide (29) was prepared from tryptamine (0.20 g, 1.25 
mmol) in DCM, 1 M NaOH (8 mL, 8 mmol) and 3-phenyl propenoic acid chloride in 
DCM according to the syntheses of 12b. The mixture was stirred strongly for 1.5 h. The 
mixture was washed three times with 30% citric acid, ones with sat. NaCl aq. and twice 
with sat. NaHCO3 aq. The organic phase was dried and evaporated (64%). 1H NMR 
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(CD3OD): δ = 3.02 (t, 3J = 7.3 Hz, 2 H), 3.61 (t, 3J = 7.3 Hz, 2 H), 6.56–6.59 (m, 1 H), 
6.98–7.01 (m, 1 H), 7.07–7.10 (m, 2 H), 7.32–7.39 (m, 4 H), 7.51–7.54 (m, 3 H), 7.58–
7.59 (m, 1 H). 13C NMR (DMSO-d6): δ = 25.19, 39.59, 111.30, 111.76, 118.16, 118.20, 
120.85, 122.40, 122.57, 127.19, 127.39, 128.81, 129.24, 134.94, 136.23, 138.38, 
164.87. ESI-MS (m/z): 291 [M + H]+. Anal. (C19H18N2O·0.02H2O): C, H, N. 
N-3-Phenylpropanoyl-tryptamide (30). 3-Phenyl propanoic acid (0.40 g, 2.7 mmol) 
was dissolved in thionyl chloride (0.58 mL, 8.0 mmol). The mixture was refluxed gently 
for 1.5 h. Thionyl chloride was evaporated. N-3-Phenylpropanoyl-tryptamide was 
prepared from tryptamine (0.36 g, 2.2 mmol) in DCM, 1 M NaOH (13 mL, 13 mmol) 
and 3-phenyl propanoic acid chloride in DCM according to the syntheses of 12b. The 
mixture was stirred strongly for 1 h. The mixture was washed three times with 30% 
citric acid, ones with sat. NaCl aq. and twice with sat. NaHCO3 aq. The organic phase 
was dried and evaporated (76%). 1H NMR (CD3OD): δ = 2.42–2.45 (m, 2 H), 2.85–2.88 
(m, 4 H), 3.42–3.44 (m, 2 H), 6.95 (s, 1 H), 6.98–7.01 (m, 1 H), 7.06–7.09 (m, 1 H), 
7.14–7.18 (m, 3 H), 7.22–7.25 (m, 2 H), 7.31–7.33 (m, 1 H), 7.52–7.54 (m, 1 H). 13C 
NMR (DMSO-d6): δ = 25.14, 31.06, 37.05, 39.40, 111.25, 111.79, 118.10, 118.13, 
120.78, 122.47, 125.73, 127.16, 128.11, 128.14, 136.17, 141.33, 171.10. ESI-MS (m/z): 
293 [M + H]+. Anal. (C19H20N2O): C, H, N.  
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8 Nε-THIOACETYL-LYSINE-CONTAINING TRI-, TETRA-, AND 
PENTAPEPTIDES AS SIRT1 AND SIRT2 INHIBITORS * 
 
 
Abstract: A series of Nε-thioacetyl-lysine containing tri-, tetra-, and pentapeptides were 
studied as SIRT1 and SIRT2 inhibitors. The peptides were based on the α-tubulin and 
p53 protein sequences. The most potent peptides had nanomolar inhibitory activities 
against SIRT1 and micromolar inhibitory activities against SIRT2. Lys-Lys(ε-thioAc)-
Leu-Met and Lys-Lys(ε-thioAc)-Leu are highly potent and selective SIRT1 inhibitors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Adapted with permission from: Kiviranta PH, Suuronen T, Wallén EAA, Leppänen J, 
Tervonen J, Kyrylenko S, Salminen A, Poso A, Jarho EM. Nε-Thioacetyl-Lysine-
containing Tri-, Tetra-, and Pentapeptides as SIRT1 and SIRT2 Inhibitors. Manuscript, 
Submitted. 
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8.1 Introduction 
A new series of short Nε-thioacetyl-lysine containing tri-, tetra-, and pentapeptides was 
designed based on two substrate sequences; human α-tubulin (38–42) and human p53 
tumor suppressor protein (380–384) (figure 8.1), in order to determine important amino 
acid side chains and minimum peptide length for SIRT1 and SIRT2 inhibitory activity. 
Fatkins and Zheng have reported earlier pentapeptide 6 with an IC50 value of about 10 
μM (the exact value was not reported) (2008). Garske and Denu have shown that for the 
peptide substrates the amino acids beyond positions –2 and +2 (the second residues 
towards the N-terminus and C-terminus, respectively, calculating from the Nε-acetyl-
lysine) are not necessary for efficient binding and activity of sirtuins (Garske and Denu 
2006). In this study we show that several pentapeptides are potent SIRT1 and SIRT2 
inhibitors. Further truncation by removal of the –2 and +2 amino acids is tolerated by 
SIRT1 but not by SIRT2, which provides access to potent and selective substrate-based 
SIRT1 inhibitors. 
 
 
Figure 8.1. Human α-tubulin (S-D-K(thioAc)-T-I) 1 and human p53 tumor suppressor 
protein (H-K-K(thioAc)-L-M) 6 sequences.  
 
8.2 Synthetic chemistry 
Peptides were synthesized manually or on a peptide synthesizer using an Fmoc strategy 
with TBTU or HBTU and DIPEA as the coupling reagents and Wang resin or NovaSyn 
TGA as the solid phase. Nα-Fmoc-Nε-thioacetyl-lysine was synthesized as described in 
the literature (Fatkins et al. 2006). All other amino acids used were common natural 
amino acids. Reference compound 24 (EX-527) was synthesized as described in the 
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literature and tested as a racemate (Napper et al. 2005). The inhibitory activities were 
tested in a Fluor de Lys fluorescence-based assay.  
 
8.3 Results and discussion 
The synthesized peptides and their inhibitory activities are presented in table 8.1. 
Peptides 1–5 based on human α-tubulin (38–42) sequence and peptides 6–9 based on 
human p53 protein (380–384) sequence were synthesized to study the effect of the 
peptide length. Pentapeptide 6 has been reported earlier by Fatkins and Zheng with an 
IC50 value of about 10 μM (the exact value was not reported) (2008). In general, the 
p53–based peptides gave better inhibitory activities for SIRT1 and SIRT2 than the α-
tubulin–based peptides. This observation prompted us to synthesize peptides 10–15, in 
which one or two amino acids of the α-tubulin sequence were replaced by the 
corresponding amino acids from the p53 sequence. Peptides 16–23 with the alanine 
replacements on the α-tubulin and p53 sequences were synthesized to study the 
importance of the individual amino acid side chains. 
At the –2 position, the serine residue of the α-tubulin–based sequence 1 was replaced 
by either a histidine or an alanine residue, resulting in peptides 10 and 16, respectively. 
Serine and histidine side chains are able to form hydrogen bonds while an alanine side 
chain is not. All three peptides were equipotent against SIRT1 and SIRT2 indicating 
that the hydrogen bonding of the –2 side chain is not prerequisite for a good inhibitory 
activity. 
Removal of the –2 amino acid resulted in the α-tubulin–based tetrapeptide 3, which, 
interestingly, was equipotent against SIRT1 but almost three times less potent against 
SIRT2 than pentapeptide 1. The same effect was observed with the p53–based 
sequences; tetrapeptide 8 was equipotent against SIRT1 but almost eight times less 
potent against SIRT2 than pentapeptide 6. It seems that SIRT1 and SIRT2 differ in their 
binding interactions with the –2 amino acid of the peptides. For SIRT2, the presence of 
an amino acid at this position was more important than the identity of its side chain, 
indicating that the main chain interactions of the –2 residue may be more relevant than 
the side chain interactions. 
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At the –1 position, the aspartic acid residue of the α-tubulin–based peptide 1 was 
replaced either by a lysine or an alanine residue, resulting in peptides 11 and 17, 
respectively. Both peptides were clearly more potent than the parent peptide 1 for 
SIRT1 and SIRT2. In fact, peptides 11 and 17 were slightly more potent for SIRT1 and 
equipotent for SIRT2 as compared to the most potent p53–based peptide 6. It is clear 
that a negatively charged aspartic acid residue at the position –1 was the reason for the 
lower inhibitory activities of the α-tubulin–based sequences 1–4 compared to the p53–
based sequences 6–9. However, it is noteworthy that the sequence 1 is based on a 
SIRT2 substrate, and the studied replacements of the  aspartic acid residue increased the 
SIRT2 inhibitory activity only five–fold but SIRT1 inhibitory activity about 25–fold.     
At the +1 position, the threonine residue of the α-tubulin–based peptide 1 was 
replaced by either an alanine or a leucine residue, resulting in peptides 18 and 12, 
respectively. For SIRT1, the replacement by alanine gave an equipotent peptide but the 
replacement by leucine resulted in a clearly less potent peptide. For SIRT2, both 
replacements resulted in less potent peptides. In the p53–based sequences, peptide 6 
with a leucine residue and peptide 22 with an alanine residue at the position +1 are 
equipotent. 
At the +2 position, the isoleucine residue of the α-tubulin–based peptide 1 was 
replaced by a methionine or an alanine residue, resulting in peptides 13 and 19, 
respectively. The replacement by a methionine residue slightly increased and the 
replacement by an alanine residue slightly decreased the inhibitory activity. The same 
trend was observed with the p53–based sequences. The +2 methionine residue increased 
the inhibitory activity compared to isoleucine (15 vs. 12) or alanine (6 vs. 23).    
Removal of the amino acid at the position +2 in the α-tubulin–based peptide 1 
resulted in peptide 2, which had slightly decreased inhibitory activities for SIRT1 and 
SIRT2. The effect of the removal of the amino acid at position +2 was also confirmed 
with the p53–based sequences 6 and 7. The inhibitory activity is not significantly 
dependent on the presence of an amino acid at the position +2. 
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Table 8.1. Peptide sequences and their inhibitory activities for SIRT1 and SIRT2. 
Peptide Sequence a IC50 (µM) for SIRT1b IC50 (µM) for SIRT2b 
Peptides based on the human α-tubulin protein sequence (38-42) 
1 Ser-Asp-Lys(ε-thioAc)-Thr-Ile 5.0  (4.3-5.9) 29.1  (18.7-45.3) 
2 Ser-Asp-Lys(ε-thioAc)-Thr 11.1 (9.5-12.9) 44.0  (27.5-70.3) 
3 Asp-Lys(ε-thioAc)-Thr-Ile 4.5  (3.8-5.4) 83.4  (44.9-154.8) 
4 Asp-Lys(ε-thioAc)-Thr 12.0  (9.7-14.9) 175  (109-283) 
5 Ser-Asp-Lys(ε-thioAc) 11.8 ± 1.9%  
at 200 μMc 
13.9 ± 4.4%  
at 200 μMc 
Peptides based on the human p53 protein sequence (380–384) 
6 His-Lys-Lys(ε-thioAc)-Leu-Met 0.33 (0.27-0.40) 6.4  (5.3-7.7) 
7 His-Lys-Lys(ε-thioAc)-Leu 0.48 (0.32-0.71) 19.9  (17.4-22.6) 
8 Lys-Lys(ε-thioAc)-Leu-Met 0.33 (0.26-0.42) 49.8  (37.9-65.6) 
9 Lys-Lys(ε-thioAc)-Leu 0.57  (0.38-0.84) 151  (104-218) 
p53 Replacements on the human α-tubulin sequence (38–42) 
10 His-Asp-Lys(ε-thioAc)-Thr-Ile 4.3  (2.9-6.3) 31.1  (23.8-40.8) 
11 Ser-Lys-Lys(ε-thioAc)-Thr-Ile 0.18  (0.15-0.21) 6.9  (6.2-7.7) 
12 Ser-Asp-Lys(ε-thioAc)-Leu-Ile 23.2 (20.8-25.8) 238  (186-305) 
13 Ser-Asp-Lys(ε-thioAc)-Thr-Met 1.4  (1.0-1.9) 10.6  (0.9-12.8) 
14 His-Lys-Lys(ε-thioAc)-Thr-Ile 0.23 (0.19-0.27) 7.6  (6.7-8.6) 
15 Ser-Asp-Lys(ε-thioAc)-Leu-Met 10.8  (8.2-14.2) 92.9  (80.0-107.8) 
Alanine replacements on the α-tubulin protein sequence (38–42) 
16 Ala-Asp-Lys(ε-thioAc)-Thr-Ile 3.2   (2.4-4.3) 37.4  (17.3-80.9) 
17 Ser-Ala-Lys(ε-thioAc)-Thr-Ile 0.22  (0.18-0.26) 5.5  (3.1-10.1) 
18 Ser-Asp-Lys(ε-thioAc)-Ala-Ile 6.7  (4.5-9.8) 72.8  (62.3-85.1) 
19 Ser-Asp-Lys(ε-thioAc)-Thr-Ala 8.8  (5.0-15.6) 84.6  (31.8-224.9) 
Alanine replacements on the p53 protein sequence (380–384) 
20 Ala-Lys-Lys(ε-thioAc)-Leu-Met 0.38  (0.30-0.49) 8.5  (7.1-10.3) 
21 His-Ala-Lys(ε-thioAc)-Leu-Met 0.55  (0.38-0.79) 16.5  (8.2-33.0) 
22 His-Lys-Lys(ε-thioAc)-Ala-Met 0.18  (0.14-0.23) 3.8  (1.9-7.5) 
23 His-Lys-Lys(ε-thioAc)-Leu-Ala 0.90  (0.69-1.17) 33.3  (23.5-47.2) 
Reference compound EX-527  
24 d 
 
0.28  (0.23-0.34) 14.0  (8.0-25.0) 
a The sequences were tested with free amino- and carboxy-terminals. b 95% Confidence intervals for IC50 
values are given in parentheses. Each experiment was repeated at least three times. c Inhibition-% at 200 
μM ± standard deviation. The IC50 value could not be determined due to the weak inhibitory activity. d 
Compound 24 was tested as a racemate. 
 
Nα-Fmoc-Nε-thioacetyl-lysine and Nα-acetyl-Nε-thioacetyl-lysine have been reported 
to show no inhibitory activity towards SIRT1 (Fatkins et al. 2006) but the inhibitory 
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activities of tri- or tetrapeptides against SIRT1 and SIRT2 have not been reported 
before. Removal of the amino acids from the –2 and +2 positions did not affect the 
inhibitory activity for SIRT1 but significantly decreased the inhibitory activity for 
SIRT2. The α-tubulin–based tripeptide 4 and the p53–based tripeptide 9 had IC50 values 
of 12.0 µM and 0.57 µM for SIRT1 and 175 µM and 151 µM for SIRT2, respectively. 
Removal of the amino acids from the positions +1 and +2 resulted in substantial loss of 
activity against both enzymes. The α-tubulin–based tripeptide 5 had a significantly 
decreased inhibitory activity: 11.8% inhibition at 200 µM against SIRT1 and 13.9% 
inhibition at 200 µM against SIRT2.  
Two of the p53–based tri- and tetrapeptides showed increased selectivity for SIRT1 
over SIRT2; tetrapeptide 8 and, in particular, tripeptide 9 were more selective for SIRT1 
than the well-known SIRT1 selective inhibitor 24, which was used as the reference 
compound. None of the sequences showed selectivity for SIRT2. 
 
8.4 Conclusions 
In conclusion, p53– and α-tubulin–based Nε-thioacetyl-lysine containing tri-, tetra-, and 
pentapeptides are potent SIRT1 and SIRT2 inhibitors. The p53–based sequences gave 
overall better inhibitory activities than the α-tubulin–based sequences, mainly due to the 
unfavorable aspartic acid residue in the position –1 of the α-tubulin sequence. The 
studied series shows that the correct selection of side chains is important for good 
inhibitory activity. In fact, the difference in the IC50 values between the most potent and 
the least potent pentapeptide inhibitors is 130-fold for SIRT1 and 46-fold for SIRT2. 
Four of the most potent SIRT1 inhibitors 11, 14, 17, and 22 had IC50 values of 180-230 
nM, equipotent to the reference compound 24. The most potent SIRT2 inhibitor 22 had 
an IC50 value of 3.8 µM. These peptides are among the most potent SIRT1 and SIRT2 
inhibitors published so far. In addition, the peptides 8 and 9 were selective for SIRT1 
over SIRT2, indicating that there are differences in the main chain interactions. As it has 
been claimed that it is difficult to design peptidomimetics for peptides larger than four 
amino acids (Adessi and Soto 2002), peptides 8 and 9 provide a promising starting point 
for the development of small peptidomimetic SIRT1 inhibitors. 
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8.5 Synthetic procedures and analytical data 
General. Fmoc-amino acids in the peptide synthesis were commercial (Fluka or GL 
Biochem) except for Nα-Fmoc-Nε-thioacetyl-lysine, and had the following side chain 
protection: O-t-Bu for Asp, Trt for His, Boc for Lys, and t-Bu for Thr and Ser.  
Nα-Fmoc-Nε-thioacetyl-lysine. Nα-Fmoc-Nε-thioacetyl-lysine was synthesized as 
described previously by Fatkins et al.(2006). Fmoc-Lys-OH · HCl (2.2 g, 5.43 mmol) 
was suspended in ethanol (11 mL) and made alkaline with 10% (w/v) aqueous solution 
of Na2CO3 (10 mL) at 0oC. Ethyl dithioacetate (0.69 mL, 5.98 mmol) was added at rt 
and the mixture was stirred overnight. The mixture was diluted with water (5 mL) and 
ethanol was removed under reduced pressure. The residual aqueous solution was 
acidified with 6 M HCl to pH ~ 1–2 and extracted three times with DCM. The 
combined organic phases were washed three times with sat. NaCl aq., dried over 
anhydrous Na2SO4, filtered and evaporated to yield white solid (1.98 g, 85%) which 
was used directly for peptide syntheses. 1H NMR (DMSO-d6): δ = 1.33-1.42 (m, 2 H), 
1.51-1.77 (m, 4 H), 2.38 (s, 3 H), 3.43-3.49 (m, 2 H), 3.92-3.96 (m, 1 H), 4.21-4.30 (m, 
3 H), 7.32-7.35 (m, 2 H), 7.40-7.43 (m, 2 H), 7.62-7.64 (m, NH), 7.72-7.73 (m, 2 H), 
7.88-7.89 (m, 2 H), 9.95 (s, NH), 12.56 (s, OH).    
Nα-Fmoc-Nε-thioacetyl-lysine attachment to Wang resin. Nα-Fmoc-Nε-thioacetyl-
lysine attachment to Wang resin was done as described by Novabiochem 
(Novabiochem). Wang resin 350 mg (0.35 mmol, concentration about 1 mmol/g) was 
placed to the flask and sufficient amount of DMF was added to cover the resin. Resin 
was allowed to swell for 30 min. Nα-Fmoc-Nε-thioacetyl-lysine (1.18 g, 2.77 mmol) was 
dissolved in dry DCM (7 mL). A couple of drops to DMF was added to complete 
dissolution. The flask was placed on ice. Diisopropylcarbodiimide (0.22 g, 1.8 mmol) 
was added. The flask was closed with a calcium chloride drying tube and the mixture 
was stirred for 20 min at 0oC. DCM was evaporated, the residue was dissolved in small 
amount of DMF (5 mL) and added to the Wang resin solution. 4-
Dimethylaminopyridine (0.004 g, 0.04 mmol) was yet added to the amino acid / resin 
solution and the flask was closed. The mixture was stood at rt for 1.5 h with occasional 
swirling. The mixture was placed to the syringe and washed five times with DMF and 
five times with DCM. Loaded resin was used directly for the synthesis of peptide 5.      
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Manual peptide synthesis. Peptides 1–15, 18, 20, and 23 were synthesized manually 
using Fmoc strategy with TBTU/DIPEA as the coupling reagent and Wang resin as 
solid phase (Fluka). The first resin-bound Nα-Fmoc-amino acid (300-350 mg) was 
swelled for 1 h in 3 mL of DMF. The N-terminal amino acid was deprotected with 5 mL 
of 20% (v/v) piperidine in DMF for 10-15 min and washed 5 times with DMF. The Nα-
Fmoc-amio acids (Fluka) were dissolved in 3-5 mL of DMF and preactivated by mixing 
with TBTU (4 eq)/ DIPEA (10eq). The amino acid was added on the resin and shaken at 
rt for 45-50 min and washed five times with DMF. Cycles of deprotection of Fmoc and 
coupling with the subsequent amino acids were repeated until the desired peptide-bond 
resin was completed. The resin was washed ones with acetic acid, five times with DCM 
and twice with methanol and evaporated under vacuum overnight. The product was 
cleaved from the resin with 5 mL of Reagent K (cleavage cocktail which contains 
82.5% TFA, 5% H2O, 5% phenol, 5% thioanisol, and 2.5% ethanedithiol; 5mL per 300-
350 mg per resin) and reacted at rt for 45-90 min. The crude product was precipitated 
with cold ether, collected by centrifugation (5 min at 4000 rpm) and washed ones with 
cold ether to remove any residual scavengers. The crude product was dried in vacuum 
overnight.  
Peptide synthesizer. The peptides 16, 17, 19, 21, and 22 were synthesized on an 
Apex 396 DC multiple peptide synthesizer (Advanced ChemTech, Louisville, KY) 
using Fmoc strategy with HBTU/DIPEA as the coupling reagent and Wang resin and 
NovaSyn TGA as the solid phase (Fluka, Novabiochem and GL Biochem (Shanghai)). 
The cleavage was done using the mixture of 95% TFA, 3% ethanedithiol, 1% tris-
isopropylsilane, and 1% H2O. 
HPLC purification. Peptides were purified by preparative HPLC (Shimadzu LC-
10Avp (Fennolab, Fenno Medical Oy)) described in Chapter 4.2. 
NMR Data. 1H NMR shifts are assigned in tables 8.2-8.24. Overlapping solvent 
residual signals were observed for acetonitrile CH3 and acetate CH3. 13C NMR shifts are 
also assigned below. Solvent residual signals were observed in the 13C- and APT-
spectra as follows: acetonitrile CH3 at 2.2-2.4 ppm in D2O and at 1.4 ppm in DMSO-d6; 
acetate CH3 at 22.0-22.5 ppm in D2O and at 21.3-21.4 in DMSO-d6; trifuoroacetate CF3 
at 117.8 ppm and C=O at 164.3 ppm in D2O. 
 130 
T
ab
le
  8
.2
. C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
1 
(C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
2O
))
.  
R
es
id
ue
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
Se
r 
4.
17
 (t
, 3
J=
 4
.9
 H
z,
 C
H
) 
4.
01
 (d
, 3
J=
 4
.9
 H
z,
 
C
H
2) 
- 
- 
- 
- 
A
sp
 
4.
78
-4
.8
4 
(m
, C
H
) 
2.
77
 (d
d,
 3 J
= 
16
.5
 H
z,
 
2 J
= 
8.
0 
H
z,
 C
H
)  
2.
89
 (d
d,
 3 J
= 
16
.4
 H
z,
 
2 J
= 
5.
6 
H
z,
 C
H
)  
- 
- 
- 
- 
Ly
s 
(t
hi
oA
c)
 
4.
40
 (d
d,
 3
J=
 8
.6
 H
z,
 3 J
= 
5.
7 
H
z,
 C
H
) 
1.
74
-1
.8
3 
(m
, C
H
) 
1.
85
-1
.9
4 
(m
, C
H
) 
1.
35
-1
.5
3 
(m
, C
H
2) 
1.
65
-1
.7
4 
(m
, C
H
2) 
 
3.
61
 (t
, 3
J=
 7
.0
 H
z,
 C
H
2) 
2.
53
 (s
, C
H
3) 
Th
r 
4.
36
 (d
, 3
J=
 5
.2
 H
z,
 C
H
) 
4.
18
-4
.2
3 
(m
, C
H
) 
1.
23
 (d
,3
J=
 6
.4
 H
z,
 C
H
) 
- 
- 
- 
Ile
 
4.
25
 (d
, 3
J=
 5
.9
 H
z,
 C
H
) 
1.
89
-1
.9
8 
(m
, C
H
) 
0.
96
 (d
,3
J=
 6
.9
 H
z,
 C
H
3) 
1.
19
-1
.2
9 
(m
, C
H
) 
1.
44
-1
.5
4 
(m
, C
H
) 
0.
93
  
(t,
 3
J=
 7
.5
 H
z,
 C
H
3) 
 
- 
- 
 T
ab
le
  8
.3
. C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
2 
(C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
M
SO
-d
6))
.  
R
es
id
ue
 
N
H
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
Se
r 
- 
3.
71
-3
.8
0 
(m
, C
H
) 
3.
62
-3
.6
8 
(m
, C
H
)
3.
70
-3
.7
6 
(m
, C
H
) 
- 
- 
- 
- 
A
sp
 
8.
68
 (s
, N
H
) 
2.
54
  (
dd
, 3
J=
 1
4.
8 
H
z,
 
2 J
= 
7.
9 
H
z,
 C
H
)  
2.
69
 (d
d,
 3 J
= 
16
.3
 H
z,
 
2 J
= 
5.
4 
H
z,
 C
H
) 
4.
62
 (s
, C
H
) 
- 
- 
- 
- 
Ly
s 
(t
hi
oA
c)
 
8.
06
 (d
, 3
J=
 
8.
1 
H
z,
 N
H
) 
4.
27
-4
.3
2 
(m
, C
H
) 
1.
52
-1
.6
1 
(m
, C
H
) 
1.
69
-1
.7
9 
(m
, C
H
) 
1.
26
-1
.3
8 
(m
, C
H
2) 
1.
47
-1
.6
1 
(m
, C
H
2) 
 
3.
39
-3
.4
7 
(m
, C
H
2) 
9.
98
 (s
, N
H
) 
2.
38
 (s
, C
H
3) 
Th
r 
7.
77
 (d
, 3
J=
 
7.
7 
H
z,
 N
H
) 
4.
04
-4
.0
9 
(m
, C
H
) 
4.
04
-4
.0
9 
(m
, C
H
) 
1.
03
  
(d
, 3
J=
 5
.9
 H
z,
 C
H
3) 
- 
- 
- 
        
 131 
T
ab
le
  8
.4
. C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
3 
(C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
M
SO
-d
6))
.  
R
es
id
ue
 
N
H
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
A
sp
 
- 
3.
85
-3
.9
1 
(m
, C
H
) 
2.
44
 (d
d,
 3 J
= 
16
.6
 H
z,
 2 J
= 
8.
8 
H
z,
 C
H
)  
2.
61
 (d
d,
 3 J
= 
16
.6
 H
z,
 2 J
= 
4.
4 
H
z,
 C
H
) 
- 
- 
- 
- 
Ly
s 
(t
hi
oA
c)
 
8.
54
 (d
, 
3 J
= 
7.
1 
H
z,
 
N
H
) 
4.
31
-4
.3
7 
(m
, C
H
) 
1.
52
-1
.6
2 
(m
, C
H
) 
1.
70
-1
.8
2 
(m
, C
H
) 
1.
28
-1
.4
5 
(m
, C
H
2) 
1.
49
-1
.6
2 
(m
, C
H
2) 
3.
39
-3
.4
8 
(m
, C
H
2)
 
10
.0
5 
(s
,N
H
) 
2.
38
 (s
, C
H
3) 
Th
r 
8.
09
  
(d
, 3
J=
 8
.3
 
H
z,
 N
H
) 
4.
17
-4
.2
1 
(m
, C
H
) 
3.
94
-4
.0
1 
(m
, C
H
) 
1.
05
 (d
, 3
J=
 6
.3
 H
z,
 C
H
3) 
- 
- 
- 
Ile
 
7.
68
 (d
, 
3 J
= 
8.
3 
H
z,
 
N
H
) 
4.
11
-4
.1
5 
(m
, C
H
) 
1.
73
-1
.8
2 
(m
, C
H
) 
0.
80
-0
.8
8 
(m
, C
H
3) 
1.
11
-1
.2
1 
(m
, C
H
) 
1.
36
-1
.4
8 
(m
, C
H
) 
0.
80
-0
.8
8 
(m
, C
H
3) 
- 
- 
 T
ab
le
  8
.5
. C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
4 
(C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
M
SO
-d
6))
.  
R
es
id
ue
 
N
H
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
A
sp
 
- 
3.
98
 (d
d,
 3 J
= 
8.
6 
H
z,
 2 J
= 
4.
2 
H
z,
 C
H
) 
2.
54
 (d
d,
 3 J
= 
15
.2
 H
z,
 2 J
= 
8.
8 
H
z,
 C
H
)  
2.
69
 (d
d,
 3 J
= 
17
.0
 H
z,
 2 J
= 
4.
2 
H
z,
 C
H
) 
- 
- 
- 
- 
Ly
s 
(t
hi
oA
c)
 
8.
53
 (d
, 3
J=
 
7.
9 
H
z,
 N
H
) 
4.
38
-4
.4
3 
(m
, C
H
) 
1.
48
-1
.6
1 
(m
, C
H
) 
1.
70
-1
.8
1 
(m
, C
H
) 
1.
27
-1
.4
3 
(m
, C
H
2) 
1.
48
-1
.6
1 
(m
, C
H
2)
 
3.
39
-3
.4
9 
(m
, C
H
2)
 
9.
97
 (s
, N
H
) 
2.
38
 (s
, C
H
3) 
Th
r 
7.
96
 (d
, 3
J=
 
8.
1 
H
z,
 N
H
) 
4.
10
-4
.1
5 
(m
, C
H
) 
4.
10
-4
.1
5 
(m
, C
H
) 
1.
06
 (d
,3
J=
 6
.2
 H
z,
 
C
H
3) 
- 
- 
- 
 T
ab
le
  8
.6
. C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
5 
(C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
2O
))
.  
R
es
id
ue
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
Se
r 
4.
19
-4
.2
1 
(m
, C
H
) 
3.
99
-4
.0
6 
(m
, C
H
2) 
- 
- 
- 
- 
A
sp
 
4.
73
-4
.7
9 
(m
, C
H
) 
2.
81
 (d
d,
 3 J
= 
16
.8
 H
z,
 2 J
= 
8.
6 
H
z,
 C
H
)  
2.
94
 (d
d,
 3 J
= 
16
.8
 H
z,
 2 J
= 
4.
9 
H
z,
 C
H
) 
- 
- 
- 
- 
Ly
s 
(t
hi
oA
c)
 
4.
27
-4
.3
0 
(m
, C
H
) 
1.
76
-1
.8
2 
(m
, C
H
) 
1.
85
-1
.9
4 
(m
, C
H
) 
1.
37
-1
.4
7 
(m
, C
H
2) 
1.
64
-1
.7
6 
(m
, C
H
2) 
3.
62
 (t
, 3
J 
= 
7.
0 
H
z,
 C
H
2) 
2.
52
 (s
, C
H
3) 
    
 132 
T
ab
le
  8
.7
. C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
6 
(C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
2O
))
.  
R
es
id
ue
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
H
is 
4.
30
-4
.4
3 
(m
, C
H
) 
3.
39
-3
.4
8 
(m
, C
H
2) 
- 
- 
- 
7.
45
 (s
, 4
’C
H
) 
8.
72
 (s
, 2
´C
H
) 
(im
id
az
ol
e)
 
Ly
s 
4.
30
-4
.4
3 
(m
, C
H
) 
1.
75
-1
.9
1 
(m
, C
H
2) 
1.
36
-1
.5
3 
(m
, C
H
2) 
1.
63
-1
.7
9 
(m
, C
H
2) 
3.
02
 (t
, 3
J 
= 
7.
6 
H
z,
 C
H
2) 
- 
Ly
s 
(t
hi
oA
c)
 
4.
30
-4
.4
3 
(m
, C
H
) 
1.
75
-1
.9
1 
(m
, C
H
2) 
1.
36
-1
.5
3 
(m
, C
H
2) 
1.
63
-1
.7
9 
(m
, C
H
2) 
3.
63
 (t
, 3
J 
= 
7.
0 
H
z,
 C
H
2) 
2.
52
 (s
, C
H
3) 
L
eu
 
4.
30
-4
.4
3 
(m
, C
H
) 
1.
61
-1
.7
6 
(m
, C
H
2) 
1.
61
-1
.7
6 
(m
, C
H
) 
0.
91
 (d
, 3
J 
= 
5.
9 
H
z,
 C
H
3) 
0.
96
 (d
, 3
J 
= 
5.
7 
H
z,
 C
H
3) 
- 
- 
M
et
 
4.
30
-4
.4
3 
(m
, C
H
) 
1.
94
-2
.0
5 
(m
, C
H
) 
2.
14
-2
.2
0 
(m
, C
H
) 
2.
45
-2
.6
1 
(m
, C
H
2) 
2.
12
 (s
, C
H
3) 
- 
- 
 T
ab
le
 8
.8
. C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
7 
(C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
2O
))
.  
R
es
id
ue
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
H
is 
4.
29
-4
.4
7 
(m
, C
H
) 
3.
38
-3
.4
9 
(m
, C
H
2) 
- 
- 
- 
7.
46
 (s
, 4
’C
H
) 
8.
75
 (s
, 2
´C
H
) 
(im
id
az
ol
e)
 
Ly
s 
4.
29
-4
.4
7 
(m
, C
H
) 
1.
78
-1
.9
1 
(m
, C
H
2) 
1.
41
-1
.5
3 
(m
, C
H
2) 
1.
66
-1
.7
8 
(m
, C
H
2) 
3.
01
 (t
, 3
J=
 7
.3
 H
z,
 C
H
2) 
- 
Ly
s 
(t
hi
oA
c)
 
4.
29
-4
.4
7 
(m
, C
H
) 
1.
78
-1
.9
1 
(m
, C
H
2) 
1.
41
-1
.5
3 
(m
, C
H
2) 
1.
66
-1
.7
8 
(m
, C
H
2) 
3.
63
 (t
, 3
J=
 6
.8
 H
z,
 C
H
2) 
2.
52
 (s
, C
H
3) 
L
eu
 
4.
29
-4
.4
7 
(m
, C
H
) 
1.
65
-1
.7
5 
(m
, C
H
2) 
1.
65
-1
.7
5 
(m
, C
H
) 
0.
92
 (d
,3
J=
 5
.7
 H
z,
 C
H
3) 
0.
98
 (d
, 3
J=
 5
.9
 H
z,
 C
H
3) 
- 
- 
 Ta
bl
e 
 8
.9
. C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
8 
(C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
2O
))
.  
R
es
id
ue
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
Ly
s 
4.
04
 (t
, 3
J=
 6
.5
 H
z,
 
C
H
) 
1.
61
-1
.8
7 
(m
, C
H
) 
1.
89
-1
.9
7 
(m
, C
H
) 
1.
37
-1
.5
4 
(m
, C
H
2) 
1.
61
-1
.8
7 
(m
, C
H
2) 
3.
03
 (t
, 3
J=
 7
.6
 H
z,
 C
H
2) 
- 
Ly
s 
(t
hi
oA
c)
 
4.
36
 (t
, 3
J=
 7
.2
 H
z,
 
C
H
) 
1.
61
-1
.8
7 
(m
, C
H
) 
1.
89
-1
.9
7 
(m
, C
H
) 
1.
37
-1
.5
4 
(m
, C
H
2) 
1.
61
-1
.8
7 
(m
, C
H
2) 
3.
62
 (t
, 3
J=
 7
.0
 H
z,
 C
H
2) 
2.
53
 (s
, C
H
3)
 
L
eu
 
4.
37
-4
.4
3 
(m
, C
H
) 
1.
63
-1
.7
4 
(m
, C
H
2) 
1.
63
-1
.7
4 
(m
, C
H
) 
0.
92
 (d
, 3
J 
= 
5.
9 
H
z,
 C
H
3) 
0.
98
 (d
, 3
J 
= 
5.
8 
H
z,
 C
H
3) 
- 
- 
M
et
 
4.
45
 (d
d,
 3
J=
 8
.9
 H
z,
 
3 J
= 
4.
5 
H
z,
 C
H
) 
1.
97
-2
.0
6 
(m
, C
H
) 
2.
15
-2
.2
2 
(m
, C
H
) 
2.
54
-2
.6
4 
(m
, C
H
2) 
2.
13
 (s
, C
H
3) 
- 
- 
 
 133 
T
ab
le
  8
.1
0.
 C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
9 
(C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
2O
))
.  
R
es
id
ue
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
Ly
s 
4.
04
  (
t, 
3 J
= 
6.
5 
H
z,
 C
H
) 
1.
89
-1
.9
7 
(m
, C
H
2) 
1.
40
-1
.5
4 
(m
, C
H
2) 
1.
89
-1
.9
7 
(m
, C
H
2) 
3.
02
 (t
, 3
J=
 7
.6
 H
z,
 C
H
2) 
- 
Ly
s 
(t
hi
oA
c)
 
4.
35
-4
.4
5 
(m
, C
H
) 
1.
89
-1
.9
7 
(m
, C
H
2) 
1.
40
-1
.5
4 
(m
, C
H
2) 
1.
76
-1
.8
9 
(m
, C
H
2) 
3.
63
 (t
, 3
J=
 7
.0
 H
z,
 C
H
2) 
2.
52
 (s
, C
H
3) 
L
eu
 
4.
35
-4
.4
5 
(m
, C
H
) 
1.
65
-1
.7
6 
(m
, C
H
2)
  
1.
65
-1
.7
6 
(m
, C
H
) 
0.
92
 (d
, 3
J=
 5
.8
 H
z,
 C
H
3) 
0.
98
 (d
, 3
J=
 5
.9
 H
z,
 C
H
3) 
- 
- 
 Ta
bl
e 
 8
.1
1.
 C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
10
 (C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
2O
))
.  
R
es
id
ue
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
H
is 
4.
35
 (t
, 3
J=
 6
.6
 H
z,
 C
H
) 
3.
44
 (d
, 3
J=
 6
.7
 H
z,
 C
H
) 
- 
- 
- 
7.
45
 (s
, 4
’C
H
) 
8.
74
 (s
, 2
´C
H
) 
(im
id
az
ol
e)
 
A
sp
 
4.
71
-4
.7
6 
(m
, C
H
) 
2.
73
 (d
d,
 3 J
= 
16
.7
 H
z,
 2 J
= 
8.
7 
H
z,
 C
H
)  
2.
88
 (d
d,
 3 J
= 
16
.7
 H
z,
 2 J
= 
5.
3 
H
z,
 C
H
) 
- 
- 
- 
- 
Ly
s 
(t
hi
oA
c)
 
4.
41
-4
.4
3 
(m
, C
H
) 
1.
78
-1
.9
7 
(m
, C
H
2) 
1.
38
-1
.5
2 
(m
, C
H
2) 
1.
66
-1
.7
6 
 
(m
, C
H
2)
 
3.
61
 (t
, 3
J=
 7
.0
 H
z,
 C
H
2) 
2.
51
 (s
, C
H
3) 
Th
r 
4.
38
 (d
, 3
J=
 5
.4
 H
z,
 
C
H
) 
4.
18
-4
.2
3 
(m
, C
H
) 
1.
24
 (d
, 3
J=
 1
6.
7 
H
z,
 
C
H
3) 
- 
- 
- 
Ile
 
4.
24
 (d
, 3
J=
 6
.1
 H
z,
 
C
H
) 
1.
89
-1
.9
5 
(m
, C
H
) 
0.
94
 (d
, 3
J=
 6
.9
 H
z,
 C
H
3) 
1.
17
-1
.2
3 
(m
, C
H
) 
1.
42
-1
.4
7 
(m
, C
H
) 
0.
90
 (t
, 3
J=
 7
.4
 
H
z,
 C
H
3) 
- 
- 
 T
ab
le
  8
.1
2.
 C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
11
 (C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
2O
))
.  
R
es
id
ue
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
Se
r 
4.
21
 (t
, 3
J=
 5
.9
 H
z,
 C
H
) 
3.
97
-4
.0
5 
(m
, C
H
2) 
- 
- 
- 
- 
Ly
s 
4.
36
-4
.4
5 
(m
, C
H
) 
1.
75
-1
.9
1 
(m
, C
H
2) 
1.
37
-1
.5
3 
(m
, C
H
2) 
1.
67
-1
.7
5 
(m
, C
H
2) 
3.
02
 (t
, 3
J=
 7
.0
 H
z,
 C
H
2) 
- 
Ly
s 
(t
hi
oA
c)
 
4.
36
-4
.4
5 
(m
, C
H
) 
1.
75
-1
.9
1 
(m
, C
H
2) 
1.
37
-1
.5
3 
(m
, C
H
2) 
1.
67
-1
.7
5 
(m
, C
H
2) 
3.
61
 (t
, 3
J=
 7
.0
 H
z,
 C
H
2) 
2.
52
 (s
, C
H
3)
 
Th
r 
4.
36
-4
.4
5 
(m
, C
H
) 
4.
12
-4
.3
1 
(m
, C
H
) 
1.
23
 (d
, 3
J=
 6
.4
 H
z,
 C
H
3) 
- 
- 
- 
Ile
 
4.
25
 (d
, 3
J=
 6
.2
 H
z,
 C
H
) 
1.
86
-2
.0
1 
 (m
, C
H
) 
0.
95
 (d
, 3
J=
 6
.8
 H
z,
 C
H
3) 
1.
22
-1
.2
8 
(m
, C
H
) 
1.
39
-1
.5
4 
(m
, C
H
) 
0.
92
  
(t,
 3 J
= 
7.
4 
H
z,
 C
H
3) 
 
- 
- 
 134 
T
ab
le
  8
.1
3.
 C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
12
 (C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
2O
))
.  
R
es
id
ue
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
Se
r 
4.
20
 (t
, 3
J=
 5
.0
 H
z,
 
C
H
) 
3.
98
-4
.0
6 
(m
, C
H
2) 
- 
- 
- 
- 
A
sp
 
4.
79
-4
.8
0 
(m
, C
H
) 
2.
76
 (d
d,
 3 J
= 
16
.8
 
H
z,
 2 J
= 
8.
4 
H
z,
 
C
H
)  
2.
88
 (d
d,
 3 J
= 
16
.8
 
H
z,
 2 J
= 
5.
3 
H
z,
 
C
H
) 
- 
- 
- 
- 
Ly
s 
(t
hi
oA
c)
 
4.
40
 (d
d,
 3
J=
 8
.0
 H
z,
 
3 J
= 
6.
3 
H
z,
 C
H
) 
1.
74
-1
.8
7 
(m
, C
H
2) 
1.
36
-1
.5
0 
(m
, C
H
2) 
 1
.6
0-
1.
74
 (m
, C
H
2) 
3.
61
 (t
, 3
J=
 7
.0
 H
z,
 C
H
2) 
2.
52
 (s
, C
H
3) 
L
eu
 
4.
41
-4
.4
4 
(m
, C
H
) 
1.
61
-1
.7
3 
(m
, C
H
2) 
1.
61
-1
.7
3 
(m
, C
H
) 
0.
88
-0
.9
5 
(m
, C
H
3) 
0.
97
 (d
, 3
J=
 5
.8
 H
z,
 C
H
3) 
- 
- 
Ile
 
4.
21
-4
-2
5 
(m
, C
H
) 
1.
87
-1
.9
7 
(m
, C
H
) 
0.
89
-0
.9
7 
(m
, C
H
3) 
1.
18
-1
.2
6 
(m
, C
H
) 
1.
43
-1
.5
1 
(m
, C
H
) 
0.
89
-0
.9
7 
(m
, C
H
3) 
 
- 
- 
 T
ab
le
  8
.1
4.
 C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
13
 (C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
2O
))
.  
R
es
id
ue
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
Se
r 
4.
13
 (7
, 3
J=
 4
.9
 H
z,
 C
H
) 
4.
00
 (d
, 3
J=
 4
.9
 H
z,
 C
H
) 
- 
- 
- 
- 
A
sp
 
4.
72
-4
.8
2 
(m
, C
H
) 
2.
78
 (d
d,
 3 J
= 
16
.7
 H
z,
 2 J
= 
7.
7 
H
z,
 C
H
)  
2.
88
 (d
d,
 3 J
= 
16
.6
 H
z,
 2 J
= 
5.
5 
H
z,
 C
H
) 
- 
- 
- 
- 
Ly
s 
(t
hi
oA
c)
 
4.
39
-4
.4
4 
(m
, C
H
) 
1.
74
-1
.8
2 
(m
, C
H
) 
1.
86
-1
.9
5 
(m
, C
H
) 
1.
38
-1
.5
5 
(m
, C
H
2) 
 1
.6
6-
1.
74
  
(m
, C
H
2)
 
3.
61
  
(t,
 3 J
= 
7.
0 
H
z,
 C
H
2) 
2.
54
 (s
, C
H
3) 
Th
r 
4.
31
 (d
, 3
J=
 4
.9
 H
z,
 C
H
) 
4.
19
-4
.2
4 
(m
, C
H
) 
1.
24
 (d
, 3
J=
 6
.4
 H
z,
 C
H
3) 
- 
- 
- 
M
et
 
4.
37
-4
.4
2 
(m
, C
H
) 
1.
98
-2
.0
7 
(m
, C
H
) 
2.
12
-2
.2
0 
(m
, C
H
) 
2.
55
-2
.6
4 
(m
, C
H
2) 
2.
14
 (s
, C
H
3) 
- 
- 
     
 135 
T
ab
le
  8
.1
5.
 C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
14
 (C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
2O
))
.  
R
es
id
ue
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
H
is 
4.
34
-4
.3
8 
(m
, C
H
) 
2.
97
-3
.0
6 
(m
, C
H
2) 
- 
- 
- 
7.
45
 (s
, 4
’C
H
) 
8.
76
 (s
, 2
´C
H
) 
(im
id
az
ol
e)
 
Ly
s 
4.
38
-4
.4
6)
 (m
, C
H
) 
1.
77
-1
.9
2 
(m
, C
H
2) 
1.
38
-1
.5
4 
(m
, C
H
2) 
1.
65
-1
.7
7 
(m
, C
H
2) 
3.
01
 (t
, 3
J=
 7
.6
 H
z,
 C
H
2) 
- 
Ly
s 
(t
hi
oA
c)
 
4.
38
-4
.4
6)
 (m
, C
H
) 
1.
77
-1
.9
2 
(m
, C
H
2) 
1.
38
-1
.5
4 
(m
, C
H
2) 
1.
65
-1
.7
7 
(m
, C
H
2) 
3.
55
-3
.6
7 
(m
, C
H
2) 
2.
52
 (s
, C
H
3) 
Th
r 
4.
38
-4
.4
6)
 (m
, C
H
) 
4.
16
-4
.2
3 
(m
, C
H
) 
1.
24
  (
d,
 3 J
= 
6.
4 
H
z,
 
C
H
3) 
- 
- 
- 
Ile
 
4.
30
-4
.3
5 
(m
, C
H
) 
1.
93
-2
.0
1 
(m
, C
H
) 
0.
97
 (d
, 3
J=
 6
.8
 H
z,
 
C
H
3) 
1.
22
-1
.3
1 
(m
, C
H
) 
1.
42
-1
.5
1 
(m
, C
H
) 
0.
92
 (t
, 3
J=
 7
.4
 H
z,
 
C
H
3) 
- 
- 
 T
ab
le
  8
.1
6.
 C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
15
 (C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
2O
))
.  
R
es
id
ue
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
Se
r 
4.
20
 (t
, 3
J=
 5
.0
 H
z,
 
C
H
) 
4.
00
-4
.0
4 
(m
, C
H
2) 
- 
- 
- 
- 
A
sp
 
4.
76
-4
.8
0 
(m
, C
H
) 
2.
78
 (d
d,
 3 J
= 
16
.7
 H
z,
 2 J
= 
8.
2 
H
z,
 C
H
)  
2.
89
 (d
d,
 3 J
= 
16
.6
 H
z,
 2 J
= 
5.
3 
H
z,
 C
H
) 
- 
- 
- 
- 
Ly
s 
(t
hi
oA
c)
 
4.
29
-4
.3
4 
(m
, C
H
) 
1.
74
-1
.9
0 
(m
, C
H
2) 
1.
36
-1
.4
8 
(m
, C
H
2) 
1.
59
-1
.7
4 
(m
, C
H
2) 
3.
62
 (t
, 3
J=
 7
.0
 H
z,
 C
H
2) 
2.
53
 (s
, C
H
3) 
L
eu
 
4.
37
-4
.4
1 
(m
, C
H
) 
1.
62
-1
.6
9 
(m
, C
H
2) 
1.
62
-1
.6
9 
(m
, C
H
) 
0.
91
 (d
, 3
J=
 5
.7
 H
z,
 C
H
3) 
0.
97
 (d
, 3
J=
 5
.7
 H
z,
 C
H
3) 
- 
- 
M
et
 
4.
44
 (d
d,
 3 J
= 
9.
0 
H
z,
 2 J
= 
4.
5 
H
z,
 
C
H
) 
1.
97
-2
.0
6 
(m
, C
H
) 
2.
14
-2
.2
1 
(m
, C
H
) 
2.
48
-2
.6
4 
(m
, C
H
2) 
2.
12
 (s
, C
H
3) 
- 
- 
     
 136 
T
ab
le
  8
.1
7.
 C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
16
 (C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
2O
))
.  
R
es
id
ue
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
A
la
 
4.
11
 (q
, 3
J=
 7
.1
 H
z,
 C
H
) 
1.
56
 (d
, 3
J=
 7
.1
 H
z,
 C
H
3) 
- 
- 
- 
- 
A
sp
 
4.
70
-4
.7
7 
(m
, C
H
) 
2.
74
 (d
d,
 3 J
= 
16
.6
 H
z,
 2 J
= 
8.
5 
H
z,
 C
H
)  
2.
89
 (d
d,
 3 J
= 
16
.6
 H
z,
 2 J
= 
5.
7 
H
z,
 C
H
) 
- 
- 
- 
- 
Ly
s 
(t
hi
oA
c)
 
4.
40
-4
.4
4 
(m
, C
H
) 
1.
76
-1
.8
5 
(m
, C
H
) 
1.
86
-1
.9
7 
(m
, C
H
) 
1.
39
-1
.4
8 
 
(m
, C
H
2)
 
1.
67
-1
.7
5 
 
(m
, C
H
2)
 
3.
61
 (t
, 3
J=
 
7.
1 
H
z,
 C
H
2) 
2.
52
 (s
, C
H
3) 
Th
r 
4.
37
 (d
, 3
J=
 5
.5
 H
z,
 C
H
) 
4.
17
-4
.2
3 
(m
, C
H
) 
1.
24
 (d
, 3
J=
 6
.4
 H
z,
 C
H
3) 
- 
- 
- 
Ile
 
4.
25
 (d
, 3
J=
 6
.1
 H
z,
 C
H
) 
1.
87
-1
.9
8 
(m
, C
H
) 
0.
95
 (d
, 3
J=
 6
.9
 H
z,
 C
H
3) 
1.
18
-1
.2
8 
(m
, C
H
) 
1.
43
-1
.5
1 
(m
, C
H
) 
0.
92
 (t
, 3
J=
 
7.
4 
H
z,
 C
H
3) 
- 
- 
 T
ab
le
  8
.1
8.
 C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
17
 (C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
2O
))
.  
R
es
id
ue
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
Se
r 
4.
16
-4
.2
0 
(m
, C
H
) 
3.
98
-4
.0
7 
(m
, C
H
2) 
- 
- 
- 
- 
A
la
 
4.
43
 (q
, 3
J=
 7
.7
 H
z,
 C
H
) 
1.
44
 (d
, 3
J=
 7
.2
 H
z,
 C
H
3) 
- 
- 
- 
- 
Ly
s 
(t
hi
oA
c)
 
4.
37
-4
.4
1 
(m
, C
H
) 
1.
76
-1
.8
4 
(m
, C
H
) 
1.
84
-1
.9
3 
(m
, C
H
) 
1.
38
-1
.5
2 
(m
, C
H
2) 
1.
71
 (q
, 3
J=
 7
.3
 
H
z,
 C
H
2) 
3.
62
 (t
, 3
J=
 7
.0
 H
z,
 C
H
2) 
2.
52
 (s
, C
H
3) 
Th
r 
4.
37
-4
.4
1 
(m
, C
H
) 
4.
21
-4
.2
5 
(m
, C
H
) 
1.
22
 (d
, 3
J=
 6
.4
 H
z,
 C
H
3) 
- 
- 
- 
Ile
 
4.
16
-4
.2
0 
(m
, C
H
) 
1.
84
-1
.9
4 
(m
, C
H
) 
0.
93
 (d
, 3
J=
 7
.0
 H
z,
 C
H
3) 
1.
14
-1
.2
6 
(m
, C
H
) 
1.
39
-1
.5
4 
(m
, C
H
) 
0.
91
 (t
, 3
J=
 7
.5
 
H
z,
 C
H
3) 
- 
- 
 T
ab
le
  8
.1
9.
 C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
18
 (C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
2O
))
.  
R
es
id
ue
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
Se
r 
4.
20
 (t
, 3
J=
 4
.9
 H
z,
 C
H
) 
3.
98
-4
.0
6 
(m
, C
H
2) 
- 
- 
- 
- 
A
sp
 
4.
72
-4
.7
9 
(m
, C
H
) 
2.
78
 (d
d,
 3 J
= 
16
.7
 H
z,
 2 J
= 
8.
2 
H
z,
 C
H
)  
2.
90
  (
dd
, 3
J=
 1
6.
7 
H
z,
 2 J
= 
5.
4 
H
z,
 C
H
) 
- 
- 
- 
- 
Ly
s 
(t
hi
oA
c)
 
4.
28
-4
.3
4 
(m
, C
H
) 
1.
74
-1
.8
1 
(m
, C
H
) 
1.
81
-1
.8
9 
(m
, C
H
) 
1.
42
-1
.5
2 
(m
, C
H
2) 
1.
70
 (q
, 3
J=
 
7.
2 
H
z,
 C
H
2) 
3.
61
 (t
, 3
J=
 7
.0
 
H
z,
 C
H
2) 
2.
52
 (s
, C
H
3) 
A
la
 
4.
40
 (q
, 3
J=
 7
.1
 H
z,
 C
H
) 
1.
41
 (d
, 3
J=
 7
.2
 H
z,
 C
H
3) 
- 
- 
- 
- 
Ile
 
4.
22
 (d
, 3
J=
 6
.0
 H
z,
 C
H
) 
1.
89
-1
.9
6 
(m
, C
H
) 
 
0.
95
 (d
, 3
J=
 6
.9
 H
z,
 C
H
3) 
1.
16
-1
.2
8 
(m
, C
H
) 
1.
41
-1
.5
3 
(m
, C
H
) 
0.
92
 (t
, 3
J=
 7
.4
 
H
z,
 C
H
3) 
- 
- 
 
 137 
T
ab
le
  8
.2
0.
 C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
19
 (C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
2O
))
.  
R
es
id
ue
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
Se
r 
4.
21
 (t
, 3
J=
 4
.9
 H
z,
 
C
H
) 
4.
01
-4
.0
5 
(m
, C
H
2) 
- 
- 
- 
- 
A
sp
 
4.
74
-4
.8
0 
(m
, C
H
) 
2.
85
 (d
d,
 3 J
= 
16
.9
 H
z,
 2 J
= 
7.
8 
H
z,
 C
H
)  
2.
95
 (d
d,
 3 J
= 
16
.9
 H
z,
 2 J
= 
5.
6 
H
z,
 C
H
) 
- 
- 
- 
- 
Ly
s 
(t
hi
oA
c)
 
4.
37
-4
.4
2 
(m
, C
H
) 
1.
76
-1
.8
5 
(m
, C
H
) 
1.
85
-1
.9
5 
(m
, C
H
) 
1.
36
-1
.5
1 
(m
, C
H
2) 
1.
70
 (q
, 3
J=
 
7.
3 
H
z,
 C
H
2) 
3.
62
 (t
, 3
J=
 7
.0
 
H
z,
 C
H
2) 
2.
52
 (s
, C
H
3) 
Th
r 
4.
31
-4
.3
7 
(m
, C
H
) 
4.
20
-4
.2
7 
(m
, C
H
) 
1.
25
 (d
, 3
J=
 6
.4
 H
z,
 C
H
3) 
- 
- 
- 
A
la
 
4.
31
-4
.3
9 
(m
, C
H
) 
1.
44
 (d
, 3
J=
 7
.3
 H
z,
 C
H
3) 
- 
- 
- 
- 
 T
ab
le
  8
.2
1.
 C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
20
 (C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
2O
))
.  
R
es
id
ue
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
A
la
 
4.
12
 (q
, 3
J=
 7
.1
 H
z,
 C
H
) 
1.
55
 (d
, 3
J=
 7
.1
 H
z,
 C
H
3) 
- 
- 
- 
- 
Ly
s 
4.
34
-4
.4
2 
(m
, C
H
) 
1.
76
-1
.8
9 
(m
, C
H
2) 
1.
36
-1
.5
0 
 
(m
, C
H
2)
 
1.
61
-1
.7
6 
(m
, C
H
2) 
3.
02
 (t
, 3
J=
 7
.6
 H
z,
 C
H
2) 
- 
Ly
s 
(t
hi
oA
c)
 
4.
34
-4
.4
2 
(m
, C
H
) 
1.
76
-1
.8
9 
(m
, C
H
2) 
1.
36
-1
.5
0 
 
(m
, C
H
2)
 
1.
61
-1
.7
6 
(m
, C
H
2) 
3.
63
 (t
, 3
J=
 7
.0
 H
z,
 C
H
2) 
2.
53
 (s
, C
H
3) 
L
eu
 
4.
36
-4
.4
3 
(m
, C
H
) 
1.
61
-1
.7
1 
(m
, C
H
2) 
1.
61
-1
.7
1 
(m
, C
H
) 
0.
91
 (d
, 3
J=
 5
.8
 H
z,
 C
H
3) 
0.
97
 (d
, 3
J=
 5
.8
 H
z,
 C
H
3) 
- 
- 
M
et
 
4.
30
-4
.3
5 
(m
, C
H
) 
1.
95
-2
.0
4 
(m
, C
H
) 
2.
10
-2
.2
1 
(m
, C
H
) 
2.
48
-2
.6
2 
(m
, 
C
H
2) 
2.
12
 (s
, C
H
3) 
- 
- 
 T
ab
le
  8
.2
2.
 C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
21
 (C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
2O
))
.  
R
es
id
ue
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
H
is 
4.
28
  
(t,
 3 J
= 
6.
3 
H
z,
 C
H
) 
3.
36
 (d
, 3
J=
 6
.4
 H
z,
 C
H
3) 
- 
- 
- 
7.
36
 (s
, 4
’C
H
) 
8.
44
 (s
, 2
´C
H
) 
(im
id
az
ol
e)
 
A
la
 
4.
41
-4
.4
5 
(m
, C
H
) 
1.
43
 (d
, 3
J=
 7
.2
 H
z,
 C
H
3) 
- 
- 
- 
- 
Ly
s 
(t
hi
oA
c)
 
4.
32
-4
.3
6 
(m
, C
H
) 
1.
78
-1
.9
0 
(m
, C
H
2) 
1.
38
-1
.5
1 
(m
, C
H
2) 
1.
68
-1
.7
5 
(m
, C
H
2) 
3.
62
 (t
, 3
J=
 7
.0
 H
z,
 C
H
2) 
2.
52
 (s
, C
H
3) 
L
eu
 
4.
39
-4
.4
2 
(m
, C
H
) 
1.
63
-1
.7
0 
(m
, C
H
2) 
1.
63
-1
.7
0 
(m
, C
H
) 
0.
90
 (d
, 3
J=
 5
.8
 H
z,
 C
H
3) 
0.
95
 (d
, 3
J=
 5
.8
 H
z,
 C
H
3) 
- 
- 
M
et
 
4.
29
-4
.3
3 
(m
, C
H
) 
1.
92
-2
.0
1 
(m
, C
H
) 
2.
08
-2
.1
7 
(m
, C
H
) 
2.
46
-2
.5
8 
(m
, C
H
2) 
2.
11
 (s
, C
H
3) 
- 
- 
 138 
T
ab
le
  8
.2
3.
 C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
22
 (C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
2O
))
.  
R
es
id
ue
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
H
is 
4.
33
-4
.3
7 
(m
, C
H
) 
3.
39
-3
.4
8 
(m
, C
H
2) 
- 
- 
- 
7.
46
 (s
, 4
’C
H
) 
8.
76
 (s
, 2
´C
H
) 
(im
id
az
ol
e)
 
Ly
s 
4.
31
-4
.3
5 
(m
, C
H
) 
1.
76
-1
.9
0 
(m
, C
H
2) 
1.
43
-1
.5
3 
(m
, C
H
2) 
1.
72
 (q
, 3
J=
 7
.3
 H
z,
 C
H
2) 
3.
02
 (t
, 3
J=
 7
.6
 H
z,
 C
H
2) 
- 
Ly
s 
(t
hi
oA
c)
 
4.
37
-4
.4
2 
(m
, C
H
) 
1.
76
-1
.9
0 
(m
, C
H
2) 
1.
43
-1
.5
3 
(m
, C
H
2) 
1.
72
 (q
, 3
J=
 7
.3
 H
z,
 C
H
2) 
3.
58
-3
.6
7 
(m
, C
H
2) 
2.
52
 (s
, C
H
3) 
A
la
 
4.
34
-4
.4
0 
(m
, C
H
) 
1.
43
 (d
, 3
J=
 7
.2
 H
z,
 
C
H
3) 
- 
- 
- 
- 
M
et
 
4.
54
 (d
d,
 3 J
= 
9.
5 
H
z,
 2 J
= 
4.
6 
H
z,
 
C
H
)  
1.
98
-2
.0
8 
(m
, C
H
) 
2.
17
-2
.2
5 
(m
, C
H
) 
2.
54
-2
.6
0 
(m
, C
H
) 
2.
62
-2
.6
9 
(m
, C
H
) 
2.
13
 (s
, C
H
3) 
- 
- 
 T
ab
le
  8
.2
4.
 C
he
m
ic
al
 sh
ift
s o
f p
ro
to
n 
re
so
na
nc
e 
fo
r p
ep
tid
e 
23
 (C
he
m
ic
al
 sh
ift
s i
n 
pp
m
 (D
2O
))
.  
R
es
id
ue
 
C
α H
 
C
β H
 
C
γ H
 
C
δ H
 
C
ε H
 
O
th
er
s 
H
is 
4.
34
-4
.3
9 
(m
, C
H
) 
3.
43
-3
.4
7 
(m
, C
H
2) 
- 
- 
- 
7.
46
 (s
, 4
’C
H
) 
8.
75
 (s
, 2
´C
H
) 
(im
id
az
ol
e)
 
Ly
s 
4.
30
-4
.4
2 
(m
, C
H
) 
1.
77
-1
.9
0 
(m
, C
H
2) 
1.
44
-1
.5
2 
(m
, C
H
2) 
1.
62
-1
.7
6 
(m
, C
H
2) 
3.
02
 (t
, 3
J=
 7
.6
 H
z,
 C
H
2) 
- 
Ly
s 
(t
hi
oA
c)
 
4.
30
-4
.4
2 
(m
, C
H
) 
1.
77
-1
.9
0 
(m
, C
H
2) 
1.
44
-1
.5
2 
(m
, C
H
2) 
1.
62
-1
.7
6 
(m
, C
H
2) 
3.
60
-3
.6
5 
(m
, C
H
2) 
2.
52
 (s
, C
H
3) 
L
eu
 
4.
38
-4
.4
2 
(m
, C
H
) 
1.
62
-1
.6
9 
(m
, C
H
2) 
1.
62
-1
.6
9 
(m
, C
H
) 
0.
91
 (d
, 3
J=
 6
.1
 H
z,
 C
H
3) 
0.
96
 (d
, 3
J=
 6
.0
 H
z,
 C
H
3) 
- 
- 
A
la
 
4.
29
-4
.3
5 
(m
, C
H
) 
1.
42
 (d
, 3
J=
 7
.3
 H
z,
 
C
H
3) 
- 
- 
- 
- 
 
139 
 
Ser-Asp-Lys(ε-thioAc)-Thr-Ile (1). 13C NMR (D2O/DMSO-d6, DMSO as an 
internal standard at 39.39 ppm) δ = 12.32, 16.64, 20.35, 23.77, 25.96, 27.75, 32.01, 
33.75, 37.96, 38.18, 47.28, 52.13, 54.93, 55.68, 59.66, 60.40, 61.46, 68.23, 168.84, 
172.27, 173.46, 174.77, 176.16, 176.94, 201.32. ESI-MS (m/z): 621.2 [M + H]+. 
Ser-Asp-Lys(ε-thioAc)-Thr (2). 13C NMR (DMSO-d6/CDCl3, CDCl3 as an internal 
standard at 79.16 ppm) δ = 20.29, 23.01, 27.06, 31.61, 33.01, 37.14, 45.60, 50.25, 
52.86, 54.92, 58.21, 61.40, 66.50, 168.18, 170.51, 171.68, 172.18, 172.42, 198.99. ESI-
MS (m/z): 508.2 [M + H]+. 
Asp-Lys(ε-thioAc)-Thr-Ile (3). 13C NMR (DMSO-d6/CDCl3, CDCl3 as an internal 
standard at 79.16 ppm) δ = 11.60, 15.69, 20.08, 23.07, 24.85, 27.14, 31.75, 33.00, 
36.82, 37.41, 45.56, 50.54, 53.18, 56.97, 58.94, 66.60, 169.91, 170.03, 171.56, 172.37, 
172.97, 199.01. ESI-MS (m/z): 534.2 [M + H]+.    
Asp-Lys(ε-thioAc)-Thr (4). 13C NMR (DMSO-d6/CDCl3, CDCl3 as an internal 
standard at 79.16 ppm) δ = 20.56, 23.10, 27.20, 31.73, 33.08, 36.77, 45.69, 49.96, 
53.08, 58.25, 66.55, 168.89, 171.86, 171.91, 172.31, 199.20. ESI-MS (m/z):  421.2 [M 
+ H]+.    
Ser-Asp-Lys(ε-thioAc) (5). 13C NMR (D2O/DMSO-d6, DMSO as an internal 
standard at 39.39 ppm) δ = 22.06 (Acetate CH3), 23.88, 27.88, 32.15, 33.79, 37.90, 
47.61, 52.21, 55.45, 55.96, 61.62, 169.15, 173.22, 176.44, 178.35, 201.62. ESI-MS 
(m/z):  407.2 [M + H]+.    
His-Lys-Lys(ε-thioAc)-Leu-Met (6). 13C NMR (D2O/DMSO-d6, DMSO as an 
internal standard at 39.39 ppm) δ = 15.67, 22.32, 23.44, 23.67, 23.94, 25.79, 27.77, 
27.88, 27.96, 30.98, 32.09 (2xCH2), 32.40, 33.83, 40.60, 40.98, 47.46, 53.21, 53.83, 
54.93, 55.17, 55.37, 117.84 (TFA CF3, q, 1JC,F = 292 Hz), 120.13, 127.27, 135.98, 
169.47, 174.59, 174.81, 174.87, 178.53, 201.67. ESI-MS (m/z): 714.4 [M + H]+.    
His-Lys-Lys(ε-thioAc)-Leu (7). 13C NMR (D2O/DMSO-d6, DMSO as an internal 
standard at 39.39 ppm) δ = 22.09, 23.36, 23.68, 23.75, 25.89, 27.59, 27.83, 27.93, 
32.00, 32.06, 33.81, 40.55, 40.77, 47.40, 52.87, 53.10, 55.14, 55.20, 117.83 (TFA CF3, 
q, 1JC,F = 293 Hz), 120.16, 127.03, 135.84, 169.29, 174.50, 174.88, 177.62, 201.66. ESI-
MS (m/z): 583.4 [M + H]+.    
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Lys-Lys(ε-thioAc)-Leu-Met (8). 13C NMR (D2O/DMSO-d6, DMSO as an internal 
standard at 39.39 ppm) δ = 15.66, 22.42, 22.56, 23.60, 23.85, 25.74, 27.83, 27.96, 
30.92, 31.88, 32.01, 32.14, 33.83, 40.45, 41.03, 47.44, 53.82, 54.15 (2xCH), 55.24, 
117.83 (TFA CF3, q, 1JC,F = 293 Hz), 170.77, 174.52, 175.05, 177.72, 201.65. ESI-MS 
(m/z): 577.4 [M + H]+. 
Lys-Lys(ε-thioAc)-Leu (9). 13C NMR (D2O/DMSO-d6, DMSO as an internal 
standard at 39.39 ppm) δ = 22.10, 22.48 (2xCH2), 23.68, 25.88, 27.82, 27.93, 31.88, 
32.00, 33.82, 40.44, 40.72, 47.39, 52.91, 54.14, 55.18, 170.75, 174.76, 177.56, 201.69. 
ESI-MS (m/z): 446.4 [M + H]+. 
His-Asp-Lys(ε-thioAc)-Thr-Ile (10). 13C NMR (D2O/DMSO-d6, DMSO as an 
internal standard at 39.39 ppm) δ = 12.23, 16.63, 20.35, 23.90, 26.10, 27.56, 27.91, 
32.00, 33.80, 38.11, 38.69, 47.47, 52.54, 53.25, 55.41, 60.19, 60.64, 68.51, 120.04, 
127.18, 135.99, 169.27, 172.58, 173.98, 175.19, 176.86, 177.86, 201.66. ESI-MS (m/z): 
671.3 [M + H]+. 
Ser-Lys-Lys(ε-thioAc)-Thr-Ile (11). 13C NMR (D2O/DMSO-d6, DMSO as an 
internal standard at 39.39 ppm) δ = 12.24, 16.64, 20.30, 23.41, 23.86, 26.12, 27.81, 
27.86, 32.03, 32.15, 33.81, 38.06, 40.56, 47.43, 55.15, 55.16, 55.89, 60.05, 60.37, 
61.68, 68.54, 117.83 (TFA CF3, q, 1JC,F = 293 Hz), 169.15, 172.54, 174.69, 175.25, 
177.66, 201.65. ESI-MS (m/z): 634.4 [M + H]+. 
Ser-Asp-Lys(ε-thioAc)-Leu-Ile (12). 13C NMR (D2O/DMSO-d6, DMSO as an 
internal standard at 39.39 ppm) δ = 12.20, 16.62, 22.35, 23.65, 23.83, 25.77, 26.07, 
27.87, 32.08, 33.82, 38.19, 38.33, 40.90, 47.50, 52.27, 53.76, 55.17, 55.90, 59.99, 
61.59, 169.10, 173.67, 174.77, 175.13, 176.75, 177.81, 201.66. ESI-MS (m/z): 633.4 
[M + H]+. 
Ser-Asp-Lys(ε-thioAc)-Thr-Met (13). 13C NMR (D2O/DMSO-d6, DMSO as an 
internal standard at 39.39 ppm) δ = 15.57, 20.40, 23.67, 27.63, 30.62, 31.88, 31.99, 
33.66, 37.92, 46.93, 51.75, 53.76, 54.60, 55.35, 60.19, 61.26, 67.84, 168.43, 171.78, 
172.94, 174.14, 175.21, 176.27, 200.87. ESI-MS (m/z): 639.2 [M + H]+. 
His-Lys-Lys(ε-thioAc)-Thr-Ile (14). 13C NMR (D2O/DMSO-d6, DMSO as an 
internal standard at 39.39 ppm) δ = 12.15, 16.53, 20.36, 23.40, 23.87, 26.14, 27.59, 
27.83, 27.95, 32.08, 32.13, 33.81, 37.84, 40.56, 47.41, 53.14, 55.16, 55.32, 59.14, 
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60.37, 68.57, 117.84 (TFA CF3, q, 1JC,F = 293 Hz), 120.13, 127.02, 135.89, 169.31, 
172.78, 174.69, 175.16, 176.61, 201.69. ESI-MS (m/z): 684.4 [M + H]+. 
Ser-Asp-Lys(ε-thioAc)-Leu-Met (15). 13C NMR (D2O/DMSO-d6, DMSO as an 
internal standard at 39.39 ppm) δ = 15.67, 22.31, 23.64, 23.83, 25.77, 27.90, 30.95, 
32.04, 32.06, 33.83, 38.16, 40.89, 47.54, 52.20, 53.80, 54.25, 55.24, 55.90, 61.61, 
169.13, 173.66, 174.80, 175.22, 176.60, 177.87, 201.66. ESI-MS (m/z): 651.3 [M + 
H]+. 
Ala-Asp-Lys(ε-thioAc)-Thr-Ile (16). 13C NMR (D2O/DMSO-d6, DMSO as an 
internal standard at 39.39 ppm) δ = 12.25, 16.63, 17.99, 20.32, 23.79, 26.07, 27.83, 
32.10, 33.79, 38.06, 38.26, 47.47, 50.31, 52.18, 55.04, 59.97, 60.59, 68.43, 171.92, 
172.54, 173.74, 175.09, 176.53, 177.54, 201.59. ESI-MS (m/z): 605.3 [M + H]+. 
Ser-Ala-Lys(ε-thioAc)-Thr-Ile (17). 13C NMR (D2O/DMSO-d6, DMSO as an 
internal standard at 39.39 ppm) δ = 12.34, 16.76, 18.11, 20.26, 23.89, 26.07, 27.86, 
32.15, 33.80, 38.36, 47.45, 51.19, 55.10, 55.93, 60.34, 61.03, 61.66, 68.54, 168.98, 
172.24, 175.32, 175.87, 178.80, 201.63. ESI-MS (m/z): 577.3 [M + H]+. 
Ser-Asp-Lys(ε-thioAc)-Ala-Ile (18). 13C NMR (D2O/DMSO-d6, DMSO as an 
internal standard at 39.39 ppm) δ = 12.24, 16.64, 17.86, 23.81, 26.07, 27.86, 32.13, 
33.81, 38.12, 38.16, 47.51, 50.96, 52.24, 55.07, 55.91, 60.03, 61.61, 169.16, 173.72, 
174.65, 175.63, 176.68, 177.99, 201.68. ESI-MS (m/z): 591.3 [M + H]+. 
Ser-Asp-Lys(ε-thioAc)-Thr-Ala (19). 13C NMR (D2O/DMSO-d6, DMSO as an 
internal standard at 39.39 ppm) δ = 18.04, 20.28, 23.83, 27.83, 31.98, 33.80, 37.50, 
47.48, 50.77, 51.96, 55.37, 55.90, 60.45, 61.64, 68.52, 169.18, 172.47, 173.66, 175.32, 
175.96, 178.41, 201.67. ESI-MS (m/z): 579.2 [M + H]+. 
Ala-Lys-Lys(ε-thioAc)-Leu-Met (20). 13C NMR (D2O/DMSO-d6, DMSO as an 
internal standard at 39.39 ppm) δ = 15.70, 18.09, 22.34, 23.47, 23.68, 23.86, 25.76, 
27.84, 27.90, 30.97, 32.02, 32.18, 32.41, 33.83, 40.61, 40.99, 47.48, 50.29, 53.82, 
54.88, 55.01, 55.02, 172.04, 174.57, 174.78, 174.88,178.43, 201.63. ESI-MS (m/z): 
648.4 [M + H]+. 
His-Ala-Lys(ε-thioAc)-Leu-Met (21). 13C NMR (D2O/DMSO-d6, DMSO as an 
internal standard at 39.39 ppm) δ = 15.69, 18.11, 22.27, 23.71, 23.95, 25.80, 27.93, 
28.68, 31.00, 32.07, 32.78, 33.82, 40.93, 47.49, 51.08, 53.64, 53.86, 55.31, 55.51, 
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119.71, 128.95, 136.52, 170.11, 174.70, 174.94, 175.90, 179.11, 201.65. ESI-MS (m/z): 
657.4 [M + H]+. 
His-Lys-Lys(ε-thioAc)-Ala-Met (22). 13C NMR (D2O/DMSO-d6, DMSO as an 
internal standard at 39.39 ppm) δ = 15.59, 17.99, 21.92 (Acetate CH3), 23.41, 23.84, 
27.61, 27.83, 27.98, 30.88, 31.57, 32.08, 32.18, 33.82, 40.56, 47.43, 50.94, 53.14, 
53.38, 55.16 (2xCH), 117.83 (TFA CF3, q, 1JC,F = 293 Hz), 120.13, 127.04, 135.90, 
169.31, 174.59, 174.65, 175.75, 177.02, 201.66. ESI-MS (m/z): 672.3 [M + H]+. 
His-Lys-Lys(ε-thioAc)-Leu-Ala (23). 13C NMR (D2O/DMSO-d6, DMSO as an 
internal standard at 39.39 ppm) δ = 18.07, 22.31, 23.41, 23.64, 23.85, 25.72, 27.61, 
27.83, 27.92, 31.99, 32.06, 33.80, 40.55, 41.23, 47.41, 50.60, 53.11, 53.54, 55.13, 
55.28, 117.83 (TFA CF3, q, 1JC,F = 292 Hz), 120.16, 127.04, 135.86, 164.20 (TFA C=O, 
q, 2JC,F = 35 Hz), 169.32, 174.57, 174.84, 175.05, 178.34, 201.65. ESI-MS (m/z): 654.4 
[M + H]+. 
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9 GENERAL DISCUSSION AND CONCLUSIONS 
 
9.1 General discussion 
SIRT2 was reported the first time in 1999 as one of the five human sirtuins 
characterized by that time (Frye 1999). Research around SIRT2 has rapidly increased 
since then, and SIRT2 together with SIRT1 are the most studied of the human sirtuins. 
However, the biological function of SIRT2 appears still to be largely unknown. In the 
beginning of this study, the only known SIRT2 inhibitors were sirtinol and A3, and their 
reported inhibitory activities were 38 µM and 45 µM, respectively (Grozinger et al. 
2001). There was a clear need for new types of potent inhibitors for SIRT2 to offer tools 
for biological research. 
Experts in molecular modelling methods in our research group started the SIRT 
project by virtual screening of commercial compound databases for new types of SIRT2 
inhibitors. Characterization of the binding and interaction properties of SIRT2 inhibitors 
was an important step in this process. However, the task was challenging and, probably, 
bigger than it was though to be in the beginning. There was only one experimental 
crystal structure of SIRT2 publicly available and this apo-form did not provide any 
experimental data on the binding sites and modes of the inhibitors (Finnin et al. 2001).  
The first search in the database from Maybridge (Maybridge Chemical Company Ltd) 
provided two related hit compounds (Tervo et al. 2004), which were used to design a 
new backbone for SIRT2 inhibitors. Three series of N,N'-bisbenzylidenebenzene-1,4-
diamine and N,N'-bisbenzylidenenaphthalene-1,4-diamine derivatives were synthesized 
and tested in the radioactive [3H]-substrate based deacetylation assay for SIRT2 
(Chapter 5).  
The series of potent compounds proved that the new backbone could be used for 
designing new SIRT2 inhibitors. The most potent compound, N,N'-bis(2-
hydroxybenzylidene)benzene-1,4-diamine, was equipotent with the most potent hit 
compound and sirtinol. Also, the new compounds were able to adopt binding modes that 
share similarities with the best ranked binding conformation of sirtinol. However, there 
were several reasons why the series of this new backbone were not continued. The 
synthesized compounds had a low solubility in water and also in DMSO. In addition, 
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the optic properties of the compounds disturbed the use of the fluorescence based assay 
and the compounds had to be tested with a time-consuming radioactivity based assay. 
Furthermore, the preliminary results from toxicity studies in Neuro-2a neuroblastoma 
cells suggested that the hit structures were toxic to cells at the concentration of 30 µM 
(unpublished results). Otherwise, the series would have been continued with 
unsymmetrical compounds as there was no requirement of symmetry in the binding site. 
The second search in the database from LeadQuest (Tripos Associates) provided the 
interesting hit structure with the N-(3-(4-hydroxyphenyl)-propenoyl)-amino acid 
tryptamide backbone (Tervo et al. 2006). However, as the molecular weight of the hit 
compound was relatively large, over 500 g/mol, it was reasonable to decrease the 
molecular size and look for the essential parts of the hit structure for the inhibitory 
activity (Chapter 6). As a result, the molecular size of the hit compound could 
drastically be decreased without loosing the inhibitory activity. The new compounds 
were also more drug-like than the compounds developed from the first database search. 
Although our research is in an early stage considering the whole drug development 
process, the drug-likeness of the compounds should also be considered. 
The research of this new interesting backbone was continued and the structure-activity 
relationships were studied by different replacements in the original hit structure 
(Chapter 7). Unfortunately, the inhibitory activities could not be improved. However, 
the complete series of the compounds with the N-(3-phenylpropenoyl)-glycine 
tryptamide backbone and the series of the compounds with the smaller 3-
phenylpropenoic acid tryptamide backbone provided tools to molecular modellers to 
analyze binding modes of the compounds with molecular modelling methods. 
The SIRT2 activity with the hit compounds 1 and 2 found by molecular modeling and 
virtual screening (Tervo et al. 2004, 2006) and synthesized compounds 3–5 (figure 9.1) 
has also been tested using acetylated α-tubulin as the substrate (figure 9.2). Before the 
enzymatic reaction, acetylated α-tubulin shows an intensive band at 0 hour and after the 
enzymatic reaction the amount of acetylated α-tubulin is barely visible with SIRT2 at 
five hours. With compounds 1 and 2 the SIRT2 inhibitory activity was clearly noticed at 
a concentration of 200 µM. On the other hand, for compounds 3–5 the amount of 
acetylated α-tubulin seems to be identical to the spot after the uninhibited enzymatic 
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reaction at five hours (unpublished results). However, these are preliminary results and 
the analyses shows only the inhibitory potency of compounds for other substrates than 
used in the assays for SIRT2 activity described in Chapter 4.4.  
  
 
Figure 9.1. Compounds 1, 2, 3, 4, and 5.  
 
 
Figure 9.2. Western plot analyses of compounds 1, 2, 3, 4, and 5. 
 
Since the exact binding site of the SIRT2 inhibitors is not fully characterized and the 
binding mode analyses did not provide new information to continue with the studied 
inhibitor backbones, a new approach using the peptide sequences from the substrate 
peptides for designing SIRT2 inhibitors was examined. The binding site of the 
substrates (the active site) offers more exact information about the interaction properties 
between the substrate and the enzyme. Fatkins et al. (2006) showed that an 18-mer 
peptide based on the p53 protein sequence containing Nε-thioacetyl-lysine inhibited 
146 
 
SIRT1 on a low micromolar level. The result can be considered as a starting point for 
the development of substrate-based SIRT2 and SIRT1 inhibitors.   
Both p53 and α-tubulin based sequences were studied (Chapter 8). Not only new 
synthetic methods of inhibitors using a peptide synthesizer and solid phase chemistry, 
but also the encouraging results from the in vitro tests, brought new enthusiasm to the 
project. The first time ever published potent tri-, tetra-, and pentapeptides provide a 
promising starting point for the development of small peptidomimetic SIRT1 and 
SIRT2 inhibitors. In addition, the found selectivity for SIRT1 over SIRT2 was 
extremely interesting.   
The amount of open questions and disbelief in reaching a nanomolar inhibitory 
activity for SIRT2 reflect the challenges that exist in the research of SIRT2 inhibitors. 
However, the research is team work and it is a privilege to work with scientists with 
expertise in different fields and reach the results that take the research of SIRT2 
inhibitors forward. 
 
9.2 Conclusions 
The present study describes the design, synthesis, characterization and in vitro 
evaluation of novel SIRT2 inhibitors. The following conclusions can be made from the 
present study.   
 
1. The new different backbones of SIRT2 inhibitors were used to synthesize new 
series of SIRT2 inhibitors, which overcame many of the problems associated 
with the first known SIRT2 inhibitors.  
 
2. The modified new compounds indicated the value of the backbones for the 
design of SIRT2 inhibitors. Several potent new SIRT2 inhibitors were 
synthesized and tested in vitro for SIRT2. The new compounds revealed the 
structure-activity relationships and gave important information for molecular 
modelling studies. 
 
3. The short peptide sequences indicated the value of the known SIRT2 
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substrates for design of SIRT2 and SIRT1 substrate-based inhibitors. A series 
of tri-, tetra-, and pentapeptides were the shortest sequences and among the 
most potent SIRT2 and SIRT1 inhibitors published so far.  
 
4. Weak SIRT2 selectivity over SIRT1 was shown with the most potent 
compounds of N-(3-(4-hydroxyphenyl)-propenoyl)-amino acid tryptamides. 
Clear SIRT1 selectivity over SIRT2 was shown with two of the p53 based tri- 
and tetrapeptides, which were more selective than well-known selective 
SIRT1 inhibitor EX-527. 
 
In summary, this doctoral dissertation has introduced several new SIRT2 inhibitor 
backbones that interact with different binding sites of the enzyme. The novel SIRT2 
inhibitors have already been used in co-operation with molecular modellers and cell 
biologists for improving the knowledge of the function and the meaning of SIRT2.  
 
9.3 Future perspectives 
The biggest barrier in the research of SIRT2 inhibitors is the lack of the SIRT2 crystal 
structure which would be complexed with the NAD+, a substrate and/ or a potent 
inhibitor. Despite the intensive efforts, the work has not succeeded yet. An increased 
structural diversity of SIRT2 inhibitors will also provide more information for the 
molecular modellers in their studies of the binding sites.  
The substrate-based inhibitors are the most promising lead structures at the moment. 
The binding site of these inhibitors should be easier to study as they are likely to bind to 
the substrate binding site of the enzyme. The design of peptidomimetics will be a major 
objective for the further development of these inhibitors. In addition, it is challenging to 
study the selectivity between SIRT1 and SIRT2 and what interaction properties are 
important for the selectivity. The different cell culture studies and the in vivo data would 
provide important biological information of the inhibitors. The collaboration with 
scientists in different fields will exploit the dynamic screening systems and test assays 
the best and give the long-term results for the SIRT research.    
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